

CITATION REPORT

List of articles citing

Hallmarks of cancer: the next generation

DOI: 10.1016/j.cell.2011.02.013
Cell, 2011, 144, 646-74.

Source: <https://exaly.com/paper-pdf/51199093/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2217	References. 501-518		
2216	Iron Oxide Nanoparticle-Induced Neoplastic-Like Cell Transformation in Vitro Is Reduced with a Protective Amorphous Silica Coating.		
2215	BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro. 2012 , 6, 285		1
2214	Tumor-infiltrating granulocytic cells promote cancer cell dissemination. 2012 , 6, 241		1
2213	Theoretical Analysis of Gas Breakdown Characteristic through a Narrow Discharge Tube. 1995 , 34, 3671-3674	5	
2212	Lymph nodes, bone marrow, and immunodeficiencies. 2000 , 228-274		1
2211	Essential roles of the bHLH transcription factor Hrt2 in repression of atrial gene expression and maintenance of postnatal cardiac function. 2007 , 104, 7975-80		92
2210	Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). 2017 , 6, 159-168		24
2209	BINARY STARS WITH COMPONENTS OF SOLAR TYPE: 25 ORBITS AND SYSTEM MASSES. 2009 , 138, 1159-1170	15	
2208	Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. 2010 , 28, 35-42		283
2207	WITHDRAWN: A new chitosan-thymine conjugate: Synthesis, characterization and biological activity. 2011 ,		
2206	Fast repair of DNA radicals in the earliest stage of carcinogenesis suppresses hallmarks of cancer. 2011 , 1, 1610		4
2205	Future medical applications of single-cell sequencing in cancer. 2011 , 3, 31		155
2204	Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer. 2011 , 13,		78
2203	Molecular classification of triple-negative tumors. 2011 , 13,		78
2202	Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?. 2011 , 13,		78
2201	Epithelial-mesenchymal transition as a mechanism for the progression of breast carcinoma. 2011 , 13,		1

2200	Epigenetics of breast cancer. 2011, 13,	78
2199	Immunity and autoimmunity in breast cancer. 2011, 13,	78
2198	Insulin resistance in breast cancer: relevance and clinical implications. 2011, 13,	1
2197	The phosphatidylinositol-3 kinase/mTOR pathway: new agents. 2011, 13,	1
2196	DNA repair and breast cancer: therapeutic opportunities. 2011, 13,	78
2195	NoncodingRNAs: from bench to bedside. 2011, 13,	78
2194	Targeting HER2 in breast cancer: beyond trastuzumab. 2011, 13,	78
2193	Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer. 2011, 13,	78
2192	Molecular heterogeneity of luminal breast cancer. 2011, 13,	78
2191	Translational breast cancer research in luminal breast cancer. 2011, 13,	78
2190	Interpretation and molecular validation of biomarker studies. 2011, 13,	1
2189	Clinical features and prognosis of tubular breast cancer. 2011, 13,	78
2188	Abstract withdrawn. 2011, 13,	78
2187	Nestin and collagen triple helix repeat containing 1 in breast cancer progression. 2011, 13,	78
2186	Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy. 2011, 13,	78
2185	Oestrogen receptor status predicts for local recurrence following wide local excision for breast tumours. 2011, 13,	1
2184	Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value. 2011, 13,	78
2183	Lobular carcinoma of the breast: outcome of 205 patients. 2011, 13,	78

2182	BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients. 2011 , 13,	1
2181	Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin. 2011 , 13,	1
2180	microRNA and protein expression in breast cancer formalin-fixed paraffin-embedded samples. 2011 , 13,	78
2179	Quantitative proteomics reveals novel proteins and central pathways associated with endocrine resistance in breast cancer. 2011 , 13,	78
2178	The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. 2011 , 13,	78
2177	MicroRNA, nutrition, and cancer prevention. 2011 , 2, 472-85	96
2176	The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. 2011 , 103, 1403-22	26
2175	Fibroblast growth factors and their receptors in cancer. 2011 , 437, 199-213	404
2174	Role of telomere dysfunction in genetic intratumor diversity. 2011 , 112, 11-41	13
2173	The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. 2011 , 2, 1139-45	84
2172	Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. 2011 , 22, 2048-59	121
2171	Leptin and cancer: from cancer stem cells to metastasis. 2011 , 18, C25-9	52
2170	Cibler aussi le méothéome pleural malin et le cancer bronchique ¶petites cellules ?. 2011 , 3, 428-434	
2169	Transforming growth factor-¶in the gastrointestinal and hepatic tumor microenvironment. 2011 , 141, 1167-78	141
2168	Novel cancer drugs based on epigenetics, miRNAs and their interactions. 2011 , 3, 675-8	3
2167	Chromatin: a key player in complex gene regulation and future cancer therapeutics. 2011 , 3, 395-9	20
2166	Molecular biology of lung cancer: clinical implications. 2011 , 32, 703-40	156
2165	Clinical implications of cancer self-seeding. 2011 , 8, 369-77	213

2164	Interfering with pH regulation in tumours as a therapeutic strategy. 2011 , 10, 767-77	1146
2163	Exploring anti-TGF- β therapies in cancer and fibrosis. 2011 , 29, 140-52	122
2162	Noise-assisted interactions of tumor and immune cells. 2011 , 84, 021927	13
2161	Nanoscale delivery systems for multiple drug combinations in cancer. 2011 , 7, 1347-57	11
2160	Cancer: beyond speciation. 2011 , 112, 283-350	52
2159	Conserved features of cancer cells define their sensitivity to HAMLET-induced death; c-Myc and glycolysis. 2011 , 30, 4765-79	31
2158	Encyclopedia of Cancer. 2011 , 697-697	
2157	Oncolytic viruses: a step into cancer immunotherapy. 2011 , 1	2
2156	Spatial structure increases the waiting time for cancer. 2011 , 13,	63
2155	Hypoxia-induced invadopodia formation involves activation of NHE-1 by the p90 ribosomal S6 kinase (p90RSK). 2011 , 6, e28851	65
2154	Tumor invasion and metastasis in Drosophila: a bold past, a bright future. 2011 , 38, 431-8	25
2153	Deciphering tumor-suppressor signaling in flies: genetic link between Scribble/Dlg/Lgl and the Hippo pathways. 2011 , 38, 461-70	38
2152	DNA damage response, genetic instability and cancer: from mechanistic insights to personalized treatment. 2011 , 5, 303-7	17
2151	Molecular-targeted nanotherapies in cancer: enabling treatment specificity. 2011 , 5, 492-503	38
2150	Macrophages in cancer and infectious diseases: the 'good' and the 'bad'. 2011 , 3, 1185-202	22
2149	Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. 2011 , 334, 1573-7	939
2148	Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. 2011 , 16, 4567-98	464
2147	DNA-damage response and repair activities at uncapped telomeres depend on RNF8. 2011 , 13, 1139-45	63

2146 Encyclopedia of Cancer. **2011**, 796-796

2145 Resultats des stratègies ciblées des cancers bronchiques non petites cellules en 2011. **2011**, 3, 423-427

2144 Advances in Personalized Cancer Management. **2011**,

2143 Cancer genome sequencing and functional genomics: from translational to clinical medicine. **2011**, 12, 1371-4

0

2142 The social aspects of EMT-MET plasticity. **2011**, 17, 1048-9

63

2141 Tumour biology: Skin-cancer stem cells outwitted. **2011**, 478, 329-30

7

2140 DNA-templated assembly of droplet-derived PEG microtissues. **2011**, 11, 2967-75

56

2139 Bright solitary waves in malignant gliomas. **2011**, 84, 021921

34

2138 Osteopontin: a potentially important therapeutic target in cancer. **2011**, 15, 1113-26

54

2137 Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. **2011**, 474, 318-26

347

2136 Encyclopedia of Cancer. **2011**, 885-885

2135 Paracrine and endocrine effects of adipose tissue on cancer development and progression. **2011**, 32, 550-70

224

2134 Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in mice. **2011**, 13, 1143-51

26

2133 EGFR expression stratifies oligodendroglioma behavior. **2011**, 179, 1638-44

21

2132 Principles and strategies for developing network models in cancer. *Cell*, **2011**, 144, 864-73

56.2 149

2131 Genetic interactions in cancer progression and treatment. *Cell*, **2011**, 145, 30-8

56.2 304

2130 SnapShot: The epithelial-mesenchymal transition. *Cell*, **2011**, 145, 162.e1

56.2 80

2129 SnapShot: mouse primitive streak. *Cell*, **2011**, 146, 488-488.e2

56.2 25

2128	Cancer invasion and the microenvironment: plasticity and reciprocity. <i>Cell</i> , 2011 , 147, 992-1009	56.2	1348
2127	Microbiome and malignancy. 2011 , 10, 324-35		313
2126	Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. 2011 , 14, 91-103		101
2125	Metabolic flux and the regulation of mammalian cell growth. 2011 , 14, 443-51		295
2124	Serine metabolism: some tumors take the road less traveled. 2011 , 14, 285-6		73
2123	FKBP51 regulation of AKT/protein kinase B phosphorylation. 2011 , 11, 360-4		36
2122	Organotypic spheroid cultures to study tumorstroma interaction during cancer development. 2011 , 8, 113-119		14
2121	Taking a developmental perspective on systems biology. 2011 , 21, 27-8		2
2120	Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. 2011 , 21, 193-215		1657
2119	Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. 2011 , 43, 1812-21		19
2118	Chemoprevention--history and general principles. 2011 , 25, 445-59		35
2117	Inhibition of tumor cell migration and metastasis by the proton-sensing GPR4 receptor. 2011 , 312, 197-208		61
2116	Quantum dots-based double-color imaging of HER2 positive breast cancer invasion. 2011 , 409, 577-82		39
2115	Protein kinase C β activates NF- κ B in response to camptothecin-induced DNA damage. 2011 , 412, 313-7		13
2114	Concanavalin A: a potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics. 2011 , 414, 282-6		74
2113	Cell death pathology: the war against cancer. 2011 , 414, 445-50		30
2112	Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. 2011 , 76, 369-74		79
2111	The dynamic nature of autophagy in cancer. 2011 , 25, 1999-2010		440

2110	Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. 2011 , 10, 945-63	429
2109	Novel oncologic drugs: what they do and how they affect images. 2011 , 31, 2059-91	62
2108	Metal-based antitumour drugs in the post-genomic era: what comes next?. 2011 , 40, 9069-75	203
2107	The neutrophil in vascular inflammation. 2011 , 17, 1381-90	484
2106	A possible role for long non-coding RNA in modulating signaling pathways. 2011 , 77, 962-5	11
2105	Revival of "unsuccessful" chemotherapeutics for highly glycolytic cancers?. 2011 , 77, 1150	4
2104	VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. 2011 , 17, 347-62	334
2103	Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. 2011 , 32, 71-87	79
2102	Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic?. 2011 , 3, 2858-69	21
2101	The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. 2011 , 3, 257-67	60
2100	Epigenetics, nervous system tumors, and cancer stem cells. 2011 , 3, 3525-56	5
2099	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. 2011 , 14, 206-18	23
2098	Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. 2011 , 25, 1716-33	132
2097	Quasispecies as a matter of fact: viruses and beyond. 2011 , 162, 203-15	61
2096	Assessing the safety of stem cell therapeutics. 2011 , 8, 618-28	175
2095	DNA double-strand break repair pathways, chromosomal rearrangements and cancer. 2011 , 22, 886-97	87
2094	Translational genomics in breast cancer. 2011 , 47 Suppl 3, S381-2	1
2093	Inflammation meets cancer, with NF- κ B as the matchmaker. 2011 , 12, 715-23	1086

2092	The role of inflammation in the pathogenesis of lung cancer. 2011 , 15, 1127-37	87
2091	Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine. 2011 , 11, 567-77	6
2090	Cancer: final act of senescence. 2011 , 479, 481-2	18
2089	Anticancer effects of imatinib via immunostimulation. 2011 , 17, 1050-1	21
2088	The potential role of CD133 in immune surveillance and apoptosis: a mitochondrial connection?. 2011 , 15, 2989-3002	7
2087	Enzymatic methods for glyco(diversification/randomization) of drugs and small molecules. 2011 , 28, 1811-53	190
2086	Cell biology. The TASC of secretion. 2011 , 332, 923-5	10
2085	The three M's: melanoma, microphthalmia-associated transcription factor and microRNA. 2011 , 24, 1088-106	52
2084	The drug-induced degradation of oncoproteins: an unexpected Achilles' heel of cancer cells?. 2011 , 1, 117-27	38
2083	The microenvironment in breast cancer progression: biology and implications for treatment. 2011 , 13, 227	246
2082	Rats: gnawing through the barriers to understanding genetic susceptibility and breast cancer. 2011 , 13, 112	1
2081	Clinical relevance and biology of circulating tumor cells. 2011 , 13, 228	113
2080	Encyclopedia of Cancer. 2011 , 591-595	
2079	Nuclear remodeling as a mechanism for genomic instability in cancer. 2011 , 112, 77-126	20
2078	AMPK regulates metabolism and survival in response to ionizing radiation. 2011 , 99, 293-9	48
2077	Molecular Staging and Prognosis in Lung Cancer. 2011 , 47, 539-540	
2076	Cell invasion through basement membrane: the anchor cell breaches the barrier. 2011 , 23, 589-96	65
2075	Therapeutic Targeting of Osteopontin in Breast Cancer Cells. 2011 ,	

2074	Cross-Talk of Breast Cancer Cells with the Immune System. 2011,	2
2073	Proteomic Analysis of Potential Breast Cancer Biomarkers. 2011,	1
2072	Significance, Mechanisms, and Progress of Anticancer Drugs Targeting HGF-Met. 2011,	
2071	Metabolic alterations in cancer cells and therapeutic implications. 2011, 30, 508-25	63
2070	Targeting Cas Family Proteins as a Novel Treatment for Breast Cancer. 2011,	3
2069	Leukemic cells modulate induction of COX-2 in human stromal fibroblasts. 2011, 58, 525-31	
2068	The impact of hypoxia on oncolytic virotherapy. 2011, 71	4
2067	Pulse Power Ablation of Melanoma with Nanosecond Pulsed Electric Fields. 2011,	1
2066	Molecular Pathology of Gastritis. 2011,	
2065	Phytochemicals and Cancer Chemoprevention: Epigenetic Friends or Foe?. 2011,	1
2064	DNA Damage, Repair and Misrepair in Cancer and in Cancer Therapy. 2011,	1
2063	Replication of damaged genomes. 2011, 21, 323-36	17
2062	Apoptotic pathway manipulation. 2011, 6, S1818-9	1
2061	Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. 2011, 26, 209-15	64
2060	Receptor-tyrosine-kinase-targeted therapies for head and neck cancer. 2011, 2011, 982879	17
2059	[Preclinical models in oncology]. 2011, 98, 1355-61	0
2058	Challenges in cancer molecular targets and therapeutics. 2011, 1, 4	2
2057	Protease addiction and synthetic lethality in cancer. 2011, 1, 25	15

2056	A journey under the sea: the quest for marine anti-cancer alkaloids. 2011 , 16, 9665-96	59
2055	Le Hanahan-Weinberg nouveau est arriv�. 2011 , 98, 356	
2054	Bladder cancer and cancer stem cells: basic science and implications for therapy. 2011 , 11, 1187-94	17
2053	Novel Oncology Drug Development Strategies in the Era of Personalised Medicine. 2011 ,	
2052	Epithelial-mesenchymal transition in breast cancer progression and metastasis. 2011 , 30, 603-11	135
2051	MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. 2011 , 11, 135-54	231
2050	High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. 2011 , 6, e24433	35
2049	Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. 2011 , 6, e21573	104
2048	Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events. 2011 , 6, e22570	61
2047	Human tumour immune evasion via TGF-� blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. 2011 , 6, e22842	106
2046	A quantitative theory of solid tumor growth, metabolic rate and vascularization. 2011 , 6, e22973	58
2045	Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis. 2011 , 6, e25139	23
2044	Human cancer long non-coding RNA transcriptomes. 2011 , 6, e25915	292
2043	Membrane-type-3 matrix metalloproteinase (MT3-MMP) functions as a matrix composition-dependent effector of melanoma cell invasion. 2011 , 6, e28325	32
2042	Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis. 2011 , 6, e28844	33
2041	Targeting the Hedgehog and Notch signaling pathways. 2011 , 6, S1820-1	
2040	Advances in pancreatic cancer. 2011 , 27, 460-6	25
2039	Current world literature. 2011 , 21, 440-5	

2038	Vaccines and other immunological approaches for cancer immunoprevention. 2011 , 12, 1957-73	28
2037	Role of TGF- β and the tumor microenvironment during mammary tumorigenesis. 2011 , 15, 117-32	69
2036	High magnification cystoscopy in the primary diagnosis of bladder tumors. 2011 , 21, 398-402	9
2035	NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. 2011 , 118, 6247-57	206
2034	PGE2 promotes angiogenesis through EP4 and PKA C β pathway. 2011 , 118, 5355-64	91
2033	Next-generation leukemia immunotherapy. 2011 , 118, 2951-9	53
2032	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. 2011 , 118, 4421-30	28
2031	The kiss of death in FL. 2011 , 118, 5365-6	3
2030	Cancer Biology. 2011 , 47-73	
2029	A novel potent tumour promoter aberrantly overexpressed in most human cancers. 2011 , 1, 15	13
2028	Magnesium and cancer: a dangerous liason. 2011 , 24, S92-100	76
2027	Personalized management for breast cancer. 2011 , 42-57	
2026	Ups and downs of guided vessel sprouting: the role of polarity. 2011 , 26, 326-33	29
2025	Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. 2011 , 43, 525-35	33
2024	Paratumoral gene expression profiles: promising markers of malignancy in melanocytic lesions. 2011 , 165, 702-3	3
2023	Human cancers express mutator phenotypes: origin, consequences and targeting. 2011 , 11, 450-7	291
2022	Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. 2011 , 11, 523-32	154
2021	Cyclin D as a therapeutic target in cancer. 2011 , 11, 558-72	969

2020	RAS oncogenes: weaving a tumorigenic web. 2011 , 11, 761-74	1174
2019	Dysregulated pH: a perfect storm for cancer progression. 2011 , 11, 671-7	1283
2018	O-GlcNAc signalling: implications for cancer cell biology. 2011 , 11, 678-84	311
2017	RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. 2011 , 11, 629-43	275
2016	Unravelling the complexity of metastasis - molecular understanding and targeted therapies. 2011 , 11, 735-48	277
2015	Cancer research: past, present and future. 2011 , 11, 749-54	119
2014	Parkinson's disease and cancer: two wars, one front. 2011 , 11, 812-23	119
2013	Choline metabolism in malignant transformation. 2011 , 11, 835-48	503
2012	Neutrophils in the activation and regulation of innate and adaptive immunity. 2011 , 11, 519-31	1761
2011	Protective and pathogenic functions of macrophage subsets. 2011 , 11, 723-37	3114
2010	Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. 2011 , 12, 439-52	324
2009	Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. 2011 , 30, 4707-20	154
2008	Biology of cancer. 2011 , 39, 689-692	7
2007	Targeted drug delivery to tumors: myths, reality and possibility. 2011 , 153, 198-205	1347
2006	Why systems biology and cancer?. 2011 , 21, 147-9	3
2005	Cellular senescence: a link between cancer and age-related degenerative disease?. 2011 , 21, 354-9	277
2004	Autophagy in cancer: having your cake and eating it. 2011 , 21, 397-404	34
2003	Regulation of inflammation in cancer by eicosanoids. 2011 , 96, 27-36	217

2002	COX-2 and PGE2-dependent immunomodulation in breast cancer. 2011 , 96, 14-20	71
2001	PARP inhibitors--current status and the walk towards early breast cancer. 2011 , 20 Suppl 3, S12-9	30
2000	Immunity and autoimmunity: revising the concepts of response to breast cancer. 2011 , 20 Suppl 3, S71-4	16
1999	MicroRNA regulation in angiogenesis. 2011 , 55, 79-86	129
1998	"ApoptomiRs" in vascular cells: their role in physiological and pathological angiogenesis. 2011 , 55, 87-91	15
1997	SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer. 2011 , 11, 518	94
1996	Identification and manipulation of tumor associated macrophages in human cancers. 2011 , 9, 216	323
1995	FISH as an effective diagnostic tool for the management of challenging melanocytic lesions. 2011 , 6, 76	30
1994	Clinical trials in the era of personalized oncology. 2011 , 61, 365-81	43
1993	Training the oncologists of the future. 2011 , 23, 565-8	1
1992	Nucleotide excision repair in chromatin: damage removal at the drop of a HAT. 2011 , 10, 734-42	24
1991	N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. 2011 , 46, 5398-407	54
1990	[Molecular staging and prognosis in lung cancer]. 2011 , 47, 539-40	1
1989	The hallmarks of CDKN1C (p57, KIP2) in cancer. 2011 , 1816, 50-6	55
1988	SIRT3 and cancer: tumor promoter or suppressor?. 2011 , 1816, 80-8	85
1987	The multiple roles of amphiregulin in human cancer. 2011 , 1816, 119-31	118
1986	Ubiquitin-independent proteasomal degradation during oncogenic viral infections. 2011 , 1816, 147-57	30
1985	Autophagy as a mediator of chemotherapy-induced cell death in cancer. 2011 , 82, 427-34	141

1984	Intracellular ATP levels determine cell death fate of cancer cells exposed to both standard and redox chemotherapeutic agents. 2011 , 82, 1540-8	37
1983	Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL. 2011 , 21, 4951-5	3
1982	Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5. 2011 , 21, 7331-6	24
1981	The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. 2011 , 19, 429-31	189
1980	Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. 2011 , 19, 701-14	144
1979	A lipid kinase cousin cooperates to promote cancer. 2011 , 19, 693-5	11
1978	Proinvasion metastasis drivers in early-stage melanoma are oncogenes. 2011 , 20, 92-103	116
1977	The Two Faces of NF- κ B Signaling in Cancer Development and Therapy. 2011 , 20, 556-8	21
1976	Power cut: inhibiting mitochondrial translation to target leukemia. 2011 , 20, 555-6	28
1975	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. 2011 , 20, 810-7	510
1974	Cell communication networks in cancer invasion. 2011 , 23, 621-9	61
1973	mTOR signaling in disease. 2011 , 23, 744-55	354
1972	Roles of VRK1 as a new player in the control of biological processes required for cell division. 2011 , 23, 1267-72	55
1971	The evolution of endothelial regulatory paradigms in cancer biology and vascular repair. 2011 , 71, 7339-44	21
1970	Proteomics revisits the cancer metabolome. 2011 , 8, 505-33	10
1969	The death of the cancer cell. 2011 , 71, 4334-7	43
1968	Targeting regulatory T cells in cancer. 2011 , 71, 6915-20	158
1967	Circulation of progenitor cells in obese and lean colorectal cancer patients. 2011 , 20, 2461-8	58

1966	Antimutator variants of DNA polymerases. 2011 , 46, 548-70	19
1965	PI3K inhibitors in cancer: rationale and serendipity merge in the clinic. 2011 , 1, 562-72	117
1964	Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 2011 , 17, 5822-32	73
1963	Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. 2011 , 331, 1565-70	3816
1962	Metabolism, LXR/LXR ligands, and tumor immune escape. 2011 , 90, 673-9	19
1961	Biology and signal transduction pathways of the Lymphotoxin- β /LT β R system. 2011 , 22, 301-10	51
1960	Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. 2011 , 10, 1553-68	69
1959	Normalization of the vasculature for treatment of cancer and other diseases. 2011 , 91, 1071-121	1040
1958	Dissecting the role of peroxisome proliferator-activated receptor- γ (PPAR γ) in colon, breast, and lung carcinogenesis. 2011 , 30, 619-40	46
1957	Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. 2011 , 30, 363-85	61
1956	Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. 2011 , 28, 793-802	40
1955	Gastrointestinal stem cells in self-renewal and cancer. 2011 , 46, 1039-55	37
1954	Angiogenesis in triple-negative adenoid cystic carcinomas of the breast. 2011 , 459, 377-82	8
1953	Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. 2011 , 137, 1151-73	138
1952	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. 2011 , 137, 1397-408	13
1951	Deep sequencing und prädiktive Modellierung als Konzept therapeutischer Entscheidungsfindungen in der Onkologie. 2011 , 17, 477-486	2
1950	Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. 2011 , 14, 467-79	67
1949	Non-redox-active lipoate derivatives disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. 2011 , 89, 1137-48	114

1948	From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. 2011 , 89, 1089-101	40
1947	The transcription factor PU.1 is a critical regulator of cellular communication in the immune system. 2011 , 59, 431-40	50
1946	Advances in tenascin-C biology. 2011 , 68, 3175-99	224
1945	Chromatin remodeling system, cancer stem-like attractors, and cellular reprogramming. 2011 , 68, 3557-71	7
1944	The biomechanical properties of 3d extracellular matrices and embedded cells regulate the invasiveness of cancer cells. 2011 , 61, 217-36	25
1943	How cancer shapes evolution, and how evolution shapes cancer. 2011 , 4, 624-634	46
1942	Mesenchymal niches of bone marrow in cancer. 2011 , 13, 611-6	12
1941	MET and VEGF: synergistic targets in castration-resistant prostate cancer. 2011 , 13, 703-9	34
1940	The therapeutic potential of TRAIL receptor signalling in cancer cells. 2011 , 13, 839-47	35
1939	Real-time intravital imaging of cancer models. 2011 , 13, 848-54	13
1938	Biological aspects of angiogenesis in multiple myeloma. 2011 , 94, 505-18	23
1937	Necroptosis: biochemical, physiological and pathological aspects. 2011 , 17, 791-800	48
1936	Recent advances in colorectal cancer research: the microenvironment impact. 2011 , 4, 127-31	12
1935	The PCa Tumor Microenvironment. 2011 , 4, 283-97	21
1934	New developments in the pathology of malignant lymphoma. A review of the literature published from February 2011 to August 2011. 2011 , 4, 135-144	
1933	MicroRNA-mediated drug resistance in breast cancer. 2011 , 2, 171-185	127
1932	Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia. 2011 , 2, 419-23	17
1931	Sepiapterin regulates cell proliferation and migration: its association with integrin $\beta 1$ and p53 in human lung cancer cells. 2011 , 33, 577-582	8

1930 Mammakarzinom. **2011**, 6, 95-110

1929 The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?. **2011**, 13, 479-87 29

1928 Microplate-based platform for combined chromatin and DNA methylation immunoprecipitation assays. **2011**, 12, 49 21

1927 Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. **2011**, 11, 500 56

1926 The breast cancer genome--a key for better oncology. **2011**, 11, 501 6

1925 Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. **2011**, 11, 529 86

1924 Homeobox gene Dlx-2 is implicated in metabolic stress-induced necrosis. **2011**, 10, 113 25

1923 mRNA expression levels and genetic status of genes involved in the EGFR and NF- κ B pathways in metastatic non-small-cell lung cancer patients. **2011**, 9, 163 22

1922 Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles. **2011**, 8, 36 23

1921 Hypothalamic inflammation is reversed by endurance training in anorectic-cachectic rats. **2011**, 8, 60 29

1920 Is there a role for carbohydrate restriction in the treatment and prevention of cancer?. **2011**, 8, 75 126

1919 Proteomic patterns of cervical cancer cell lines, a network perspective. **2011**, 5, 96 46

1918 Astrocyte elevated gene 1: biological functions and molecular mechanism in cancer and beyond. **2011**, 1, 36 30

1917 Partners in crime: the TGF β and MAPK pathways in cancer progression. **2011**, 1, 42 62

1916 Involvement of lipid rafts in adhesion-induced activation of Met and EGFR. **2011**, 18, 78 7

1915 Lessons from the deep study of rare tumours. **2011**, 224, 306-8 5

1914 Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer. **2011**, 224, 517-28 26

1913 Mutant p53 gain of function is interwoven into the hallmarks of cancer. **2011**, 225, 475-8 44

1912	GABA (̢-aminobutyric acid), a non-protein amino acid counters the ̢-adrenergic cascade-activated oncogenic signaling in pancreatic cancer: a review of experimental evidence. 2011 , 55, 1745-58	24
1911	c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. 2011 , 54, 879-89	148
1910	Apoptosis: a barrier against cancer no more?. 2011 , 54, 1121-4	7
1909	Cancer Immunotherapy Trials Network launches effort to generate new research: focus on agents that improve cancer patients' immune systems. 2011 , 117, 3287-8	
1908	Innate origins of multiple sclerosis pathogenesis: Implications for computer-assisted design of disease-modifying therapies. 2011 , 72, 674-688	1
1907	Analysis of pathway mutation profiles highlights collaboration between cancer-associated superpathways. 2011 , 32, 1028-35	9
1906	Liver development and cancer formation in zebrafish. 2011 , 93, 157-72	24
1905	Tetraspanins in the immune response against cancer. 2011 , 138, 129-36	33
1904	Molecular mechanisms of tumor angiogenesis. 2011 , 2, 1085-96	132
1903	Just in the "Bik" of time. 2011 , 183, 1447-8	0
1902	Changes in glucose uptake rate and in the energy status of PC-12 cells acutely exposed to hexavalent chromium, an established human carcinogen. 2011 , 93, 1202-1211	5
1901	The combination of tephrosin with 2-deoxy-D-glucose enhances the cytotoxicity via accelerating ATP depletion and blunting autophagy in human cancer cells. 2011 , 12, 989-96	16
1900	Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond. 2011 , 10, 3274-83	20
1899	Ras and Rho GTPases on the move: The RasGRF connection. 2011 , 1, 200-204	5
1898	Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. 2011 , 7, 1025-9	7
1897	Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. 2012 , 5, 397-402	44
1896	TSLP1: a new piece in the puzzle of tumor-associated Th2-type inflammation. 2011 , 3, 713-7	0
1895	Genotyping techniques to address diversity in tumors. 2011 , 112, 151-82	9

1894	The tumor microenvironment: part 1. 2011 , 3, 1367-84	18
1893	Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. 2011 , 32, 1724-33	61
1892	SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds. 2011 , 2, e146	23
1891	Hepatocellular carcinoma therapy: combination is the future. 2011 , 74-82	
1890	Tumor-associated macrophages in cancer-related inflammation. 2011 , 3, 21-22	4
1889	New target therapies for patients with neuroendocrine tumors of the pancreas. 2011 , 5, 563-6	2
1888	Ovarian cancer screening and peritoneal carcinomatosis: standards, 'omics' and miRNAs for personalized management. 2011 , 11, 465-7	5
1887	RUNX1 and its understudied role in breast cancer. 2011 , 10, 3461-5	48
1886	Losing control: cancer's catastrophic transition. 2011 , 2, 249-52	5
1885	Pharmacogenomics for tailoring cardiovascular and anticancer drugs: from genotyping to whole-genome sequencing. 2011 , 12, 1081-5	2
1884	An intravenous stimulus package for oncolytic virotherapy. 2011 , 19, 1930-2	4
1883	[Synthetic lethality as a new concept for the treatment of cancer]. 2011 , 136, 1526-30	1
1882	DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer. 2011 , 184, 948-56	30
1881	The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. 2011 , 7, 1223-35	74
1880	Effects of BCR-ABL inhibitors on anti-tumor immunity. 2011 , 18, 5174-84	15
1879	Neuroendokrine Neoplasien des gastroenteropankreatischen Systems. 2011 , 7, 313-342	
1878	[Gastrointestinal neuroendocrine neoplasias: novel individualized therapeutic strategies]. 2011 , 136, 1801-6	3
1877	Protein kinase B/AKT and focal adhesion kinase: two close signaling partners in cancer. 2011 , 11, 993-1002	19

1876	Ion channels and transporters in cancer. 3. Ion channels in the tumor cell-microenvironment cross talk. 2011 , 301, C762-71	49
1875	SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. 2011 , 10, 3153-8	113
1874	Expression of the embryological morphogen Nodal in stage III/IV melanoma. 2011 , 21, 491-501	8
1873	Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. 2011 , 3, 108ra113	456
1872	Targeted therapies for lung cancer: clinical experience and novel agents. 2011 , 17, 512-27	80
1871	Prognostic determinants in prostate cancer. 2011 , 17, 429-37	35
1870	Epithelial delamination and migration: lessons from Drosophila. 2011 , 5, 366-72	19
1869	Quiescence: early evolutionary origins and universality do not imply uniformity. 2011 , 366, 3498-507	48
1868	Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. 2011 , 32, 1441-9	36
1867	Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis. 2011 , 6, e26957	42
1866	Expanding our therapeutic options: Beta blockers for breast cancer?. 2011 , 29, 2612-6	24
1865	Targeting the phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer. 2011 , 6, S1805-7	3
1864	Cancer interception. 2011 , 4, 787-92	61
1863	Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. 2011 , 124, 278-90	55
1862	Is Co-option a prevailing mechanism during cancer progression?. 2011 , 71, 6572-5	11
1861	Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. 2011 , 103, 1859-70	80
1860	Five-dimensional teleparallel theory equivalent to general relativity, the axially symmetric solution, energy and spatial momentum. 2011 , 20, 110402	
1859	A 2D nonlinear inversion of well-seismic data. 2011 , 27, 055005	5

1858	Kinase suppressor of ras 1 (KSR1) regulates PGC1 β and estrogen-related receptor β to promote oncogenic Ras-dependent anchorage-independent growth. 2011 , 31, 2453-61	32
1857	Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins. 2011 , 195, 1123-40	71
1856	Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. 2011 , 9, 1165-74	53
1855	Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. 2011 , 10, 2394-404	46
1854	Mutational inactivation of STAG2 causes aneuploidy in human cancer. 2011 , 333, 1039-43	329
1853	Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. 2011 , 12, 239-51	36
1852	On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. 2011 , 2, 421-438	49
1851	Handbook of Metastatic Breast Cancer. 2011 ,	
1850	ENTPD5, an endoplasmic reticulum UDPase, alleviates ER stress induced by protein overloading in AKT-activated cancer cells. 2011 , 76, 217-23	13
1849	Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. 2011 , 2011, 174149	18
1848	Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy. 2011 , 3, 3610-31	18
1847	Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma?. 2011 , 2011, 521947	4
1846	Toll-like receptor 4 activation in cancer progression and therapy. 2011 , 2011, 609579	101
1845	Anti-MET targeted therapy has come of age: the first durable complete response with MetMAB in metastatic gastric cancer. 2011 , 1, 550-4	17
1844	Defining the molecular basis of tumor metabolism: a continuing challenge since Warburg's discovery. 2011 , 28, 771-92	24
1843	Nanosecond pulsed electric field ablation of hepatocellular carcinoma. 2011 , 2011, 6861-5	10
1842	Recapitulating cancer cell invasion in vitro. 2011 , 108, 6693-4	9
1841	Human BRCA1-associated breast cancer: no increase in numerical chromosomal instability compared to sporadic tumors. 2011 , 135, 84-92	4

1840	Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. 2011 , 34, 499-500	
1839	Targeting tumour cells at the entrance. 2011 , 439, e1-2	4
1838	Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents. 2011 , 10, 2883-93	21
1837	Src family kinases and paclitaxel sensitivity. 2011 , 12, 260-9	66
1836	Therapeutic oligonucleotides: the road not taken. 2011 , 17, 6369-72	11
1835	Treatment with 5-azacytidine accelerates acute promyelocytic leukemia leukemogenesis in a transgenic mouse model. 2011 , 2, 160-5	2
1834	Size matters: sequential mutations in tumorigenesis may reflect the stochastic effect of mutagen target sizes. 2011 , 2, 927-31	15
1833	Modeling tumor invasion and metastasis in Drosophila. 2011 , 4, 753-61	78
1832	Analysis of a Drosophila amplicon in follicle cells highlights the diversity of metazoan replication origins. 2011 , 108, 16681-6	15
1831	Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. 2011 , 187, 118-25	62
1830	GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. 2011 , 286, 43123-33	32
1829	Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. 2011 , 25, 1510-27	276
1828	Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms. 2011 , 108, 18814-9	83
1827	The secret life of Ectenin: moonlighting in morphogenesis. 2011 , 195, 543-52	82
1826	Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. 2011 , 71, 7502-12	101
1825	Linking metabolism and cell cycle progression via the APC/CCdh1 and SCF ^{TrCP} ubiquitin ligases. 2011 , 108, 20857-8	8
1824	High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis. 2011 , 31, 2605-17	40
1823	Sweet DREAMs for Hippo. 2011 , 25, 889-94	7

1822	Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. 2011 , 31, 4938-50	146
1821	Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. 2011 , 71, 5512-21	48
1820	Dietary factors and epigenetic regulation for prostate cancer prevention. 2011 , 2, 497-510	87
1819	It takes two to tango: a new couple in the family of ubiquitin-editing complexes. 2011 , 12, 1133-5	2
1818	Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy. 2011 , 6, 1645-54	4
1817	Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions. 2011 , 3, 528-34	5
1816	Novel ways to target brain tumour metabolism. 2011 , 15, 1227-39	12
1815	Proteome profiling for the identification of lung cancer signatures. 2011 , 8, 689-92	2
1814	Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression. 2011 , 32, 1749-57	35
1813	Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. 2011 , 10, 3598-607	26
1812	Inflammation-induced loss of Pdc4 is mediated by phosphorylation-dependent degradation. 2011 , 32, 1427-33	31
1811	Tumor cell metabolism: an integral view. 2011 , 12, 939-48	120
1810	Personalized management for non-small-cell lung cancer. 2011 , 58-67	
1809	Natural and Induced Humoral Responses to MUC1. 2011 , 3, 3073-103	25
1808	Transcription inhibition as a therapeutic target for cancer. 2011 , 3, 4170-90	27
1807	The tumor suppressor adenomatous polyposis coli controls the direction in which a cell extrudes from an epithelium. 2011 , 22, 3962-70	66
1806	Kaposi's sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis. 2011 , 7, e1002405	92
1805	Tyrosine phosphorylation enhances RAD52-mediated annealing by modulating its DNA binding. 2011 , 30, 3368-82	47

1804	Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. 2011 , 12, 7424-37	96
1803	Extracellular matrix regulation of metabolism and implications for tumorigenesis. 2011 , 76, 313-24	49
1802	Lysophosphatidic acid 5 receptor induces activation of Na(+)/H(+) exchanger 3 via apical epidermal growth factor receptor in intestinal epithelial cells. 2011 , 301, C1008-16	35
1801	Ion channels and transporters in cancer. 5. Ion channels in control of cancer and cell apoptosis. 2011 , 301, C1281-9	63
1800	Physiology, reductionism, and translational medicine: the right mix. 2011 , 301, L389-90	2
1799	Forty years of translational cancer research. 2011 , 1, 383-90	9
1798	New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology. 2011 , 28, 539-55	8
1797	Gene expression analysis of in vitro cocultures to study interactions between breast epithelium and stroma. 2011 , 2011, 520987	27
1796	Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. 2011 , 43, 884-9	29
1795	Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives. 2011 , 3, 2478-500	39
1794	NF-kappaB in lung tumorigenesis. 2011 , 3, 4258-68	27
1793	Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. 2011 , 3, 3225-41	16
1792	Epigenetics in prostate cancer. 2011 , 2011, 580318	46
1791	Evolution of Tumor Metabolism might Reflect Carcinogenesis as a Reverse Evolution process (Dismantling of Multicellularity). 2011 , 3, 3002-17	42
1790	TRAF4, at the Crossroad between Morphogenesis and Cancer. 2011 , 3, 2734-49	14
1789	Cancer genome sequencing and its implications for personalized cancer vaccines. 2011 , 3, 4191-211	17
1788	Angiogenesis: a target in solid tumors, also in leukemia?. 2011 , 2011, 1-8	55
1787	Somatic genetics empowers the mouse for modeling and interrogating developmental and disease processes. 2011 , 7, e1002110	6

1786	Better late than early: FDG-PET imaging in metastatic renal cell carcinoma. 2011 , 17, 5841-3	8
1785	Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. 2012 , 14, 160-74	20
1784	Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples. 2012 , 86, 854-64	113
1783	Karyotypic determinants of chromosome instability in aneuploid budding yeast. 2012 , 8, e1002719	102
1782	Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution. 2012 , 8, e1003027	18
1781	Pancreatic stellate cells: a starring role in normal and diseased pancreas. 2012 , 3, 344	198
1780	Crosstalk and signaling switches in mitogen-activated protein kinase cascades. 2012 , 3, 355	110
1779	An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity. 2012 , 6, 236-48	29
1778	The reactive stroma microenvironment and prostate cancer progression. 2012 , 19, R187-204	204
1777	Roadmap to personalized medicine. 2012 , 53, 294-7	12
1776	VDAC1: from structure to cancer therapy. 2012 , 2, 164	137
1775	The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. 2012 , 3, 270	52
1774	Tumor-promoting circuits that regulate a cancer-related chemokine cluster: dominance of inflammatory mediators over oncogenic alterations. 2012 , 4, 55-76	4
1773	Radical decisions in cancer: redox control of cell growth and death. 2012 , 4, 442-74	52
1772	STAT3 signaling in pulmonary arterial hypertension. 2012 , 1, 223-33	50
1771	General aspects of colorectal cancer. 2012 , 2012, 139268	32
1770	Differential control of growth, apoptotic activity, and gene expression in human breast cancer cells by extracts derived from medicinal herbs Zingiber officinale. 2012 , 2012, 614356	44
1769	Lymphangioliomyomatosis - a wolf in sheep's clothing. 2012 , 122, 3807-16	205

1768	Nutraceuticals and Cancer. 2012,	5
1767	Cancer, inflammation, and insights from ayurveda. 2012, 2012, 306346	27
1766	Rhus verniciflua stokes against advanced cancer: a perspective from the Korean Integrative Cancer Center. 2012, 2012, 874276	35
1765	Combating angiogenesis early: potential of targeting tumor-recruited neutrophils in cancer therapy. 2012, 8, 5-8	13
1764	Deciphering Phosphotyrosine-Dependent Signaling Networks in Cancer by SH2 Profiling. 2012, 3, 353-61	14
1763	The miR-290-295 cluster suppresses autophagic cell death of melanoma cells. 2012, 2, 808	52
1762	Cancer, Autoimmunity, and Psychosocial Stress. 2012, 179-210	
1761	Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells. 2012, 33, 2362-8	29
1760	Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era. 2012, 8, 1373-6	1
1759	Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation. 2012, 2012, 173029	27
1758	Modulation of immunity by antiangiogenic molecules in cancer. 2012, 2012, 492920	81
1757	Urine telomerase for diagnosis and surveillance of bladder cancer. 2012, 2012, 693631	13
1756	Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. 2012, 2012, 762825	199
1755	Salinomycin as a drug for targeting human cancer stem cells. 2012, 2012, 950658	224
1754	Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3. 2012, 72, 5119-29	58
1753	In silico experimentation of glioma microenvironment development and anti-tumor therapy. 2012, 8, e1002355	23
1752	PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. 2012, 19, 1549-60	59
1751	Implications of therapy-induced selective autophagy on tumor metabolism and survival. 2012, 2012, 872091	11

1750	How many diseases are colorectal cancer?. 2012 , 2012, 564741	20
1749	Even stressed cells are individuals: second messengers of free radicals in pathophysiology of cancer. 2012 , 53, 304-9	31
1748	The Key to Unlocking the Chemotherapeutic Potential of PPAR α Ligands: Having the Right Combination. 2012 , 2012, 946943	15
1747	Akt and mTOR in B Cell Activation and Differentiation. 2012 , 3, 228	127
1746	microRNA regulation of cancer-endothelial interactions: vesicular microRNAs on the move 2012 , 31, 3509-10	3
1745	Rab25 in cancer: a brief update. 2012 , 40, 1404-8	50
1744	Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo. 2012 , 14, 561-73	15
1743	Synergistic modulation of cellular contractility by mixed extracellular matrices. 2012 , 2012, 471591	5
1742	Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. 2012 , 2012, 528690	44
1741	The molecular biology of soft-tissue sarcomas and current trends in therapy. 2012 , 2012, 849456	33
1740	Oestrogen-dependent regulation of miRNA biogenesis: many ways to skin the cat. 2012 , 40, 752-8	24
1739	EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. 2012 , 8, e1002723	139
1738	Ccdc94 protects cells from ionizing radiation by inhibiting the expression of p53. 2012 , 8, e1002922	18
1737	MiRNAs and LincRNAs: Could they be considered as biomarkers in colorectal cancer?. 2012 , 13, 840-65	27
1736	Inflammation amplification by Versican: the first mediator. 2012 , 13, 6873-82	37
1735	The role of vascular endothelial growth factor a polymorphisms in breast cancer. 2012 , 13, 14845-64	28
1734	Estradiol, tamoxifen, and flaxseed alter IL-1 α and IL-1Ra levels in normal human breast tissue in vivo. 2012 , 97, E2044-54	25
1733	Generation of functional blood vessels from a single c-kit ⁺ adult vascular endothelial stem cell. 2012 , 10, e1001407	120

1732	Acquisition order of Ras and p53 gene alterations defines distinct adrenocortical tumor phenotypes. 2012 , 8, e1002700	11
1731	Bufalin induces lung cancer cell apoptosis via the inhibition of PI3K/Akt pathway. 2012 , 13, 2025-35	67
1730	Initiation of genome instability and preneoplastic processes through loss of Fhit expression. 2012 , 8, e1003077	74
1729	Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. 2012 , 13, 1951-2011	106
1728	Mitochondrial adaptations to oxidative stress confer resistance to apoptosis in lymphoma cells. 2012 , 13, 10212-28	8
1727	The role of forkhead box Q1 transcription factor in ovarian epithelial carcinomas. 2012 , 13, 13881-93	21
1726	Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. 2012 , 23 Suppl 10, x219-27	46
1725	A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. 2012 , 22, 2302-14	128
1724	Intravascular targets for molecular contrast-enhanced ultrasound imaging. 2012 , 13, 6679-97	21
1723	Shikonin directly targets mitochondria and causes mitochondrial dysfunction in cancer cells. 2012 , 2012, 726025	62
1722	The pharmacological NF- κ B inhibitor BAY11-7082 induces cell apoptosis and inhibits the migration of human uveal melanoma cells. 2012 , 13, 15653-67	21
1721	SCaMC-1 promotes cancer cell survival by desensitizing mitochondrial permeability transition via ATP/ADP-mediated matrix Ca(2+) buffering. 2012 , 19, 650-60	79
1720	Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. 2012 , 28, 423-5	576
1719	Nonheritable cellular variability accelerates the evolutionary processes of cancer. 2012 , 10, e1001296	49
1718	S phase-coupled E2f1 destruction ensures homeostasis in proliferating tissues. 2012 , 8, e1002831	11
1717	Tumor Microenvironment Varies under Different TCM ZHENG Models and Correlates with Treatment Response to Herbal Medicine. 2012 , 2012, 635702	22
1716	Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells. 2012 , 72, 6036-50	67
1715	Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis. 2012 , 19, 36-8	19

1714	Medulloblastoma-biology and microenvironment: a review. 2012 , 29, 495-506	10
1713	Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis. 2012 , 33, 1617-28	26
1712	Role of T lymphocytes in tumor response to radiotherapy. 2012 , 2, 95	112
1711	Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. 2012 , 93, 2529-2545	131
1710	Alterations in Cell-Extracellular Matrix Interactions during Progression of Cancers. 2012 , 2012, 219196	53
1709	Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer. 2012 , 18, 5427-37	95
1708	STAT1 and STAT3 in tumorigenesis: A matter of balance. 2012 , 1, 65-72	146
1707	Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling. 2012 , 3, 362	21
1706	Interactions between epigenetics and metabolism in cancers. 2012 , 2, 163	59
1705	Proteomic technologies for the study of osteosarcoma. 2012 , 2012, 169416	2
1704	Mitochondrial dynamics in cancer and neurodegenerative and neuroinflammatory diseases. 2012 , 2012, 729290	48
1703	Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma. 2012 , 13, 9741-53	10
1702	Differential network entropy reveals cancer system hallmarks. 2012 , 2, 802	111
1701	Vasoactive peptides with angiogenesis-regulating activity predict cancer risk in males. 2012 , 21, 513-22	14
1700	Promises from trametinib in RAF active tumors. 2012 , 367, 171-2	7
1699	Deciphering the signature of selective constraints on cancerous mitochondrial genome. 2012 , 29, 1255-61	27
1698	Characterization of the intronic portion of cadherin superfamily members, common cancer orchestrators. 2012 , 20, 878-83	5
1697	Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. 2012 , 132, 1247-52	48

1696	RNAi-mediated gene silencing in cancer therapy. 2012 , 12, 1495-504	24
1695	In vivo photoacoustic tomography of total blood flow and potential imaging of cancer angiogenesis and hypermetabolism. 2012 , 11, 301-7	28
1694	Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. 2012 , 11, 422-34	69
1693	A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma. 2012 , 32, 4674-83	36
1692	Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. 2012 , 30, 3540-4	83
1691	Hurdles in anticancer drug development from a regulatory perspective. 2012 , 9, 236-43	26
1690	Key concepts in glioblastoma therapy. 2012 , 83, 753-60	59
1689	Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apicoxib. 2012 , 33, 1639-46	18
1688	Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feed-forward loops identifies regulators in human cancers. 2012 , 40, e135	68
1687	Alternative polyadenylation: new insights from global analyses. 2012 , 18, 2105-17	155
1686	Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF- α -independent apoptosis. 2012 , 72, 2645-56	34
1685	c-Myc and cancer metabolism. 2012 , 18, 5546-53	466
1684	A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. 2012 , 72, 154-64	49
1683	Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. 2012 , 30, 3884-92	150
1682	Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. 2012 , 109, E388-97	80
1681	Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. 2012 , 72, 4417-28	36
1680	Thymic stromal lymphopoietin: Next research hotspot of carcinogenesis?. 2012 , 03, 665-668	1
1679	How fibrosis influences imaging and surgical decisions in pancreatic cancer. 2012 , 3, 389	35

1678	Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. 2012 , 18, 3293-304	35
1677	Borrowing strength: a likelihood ratio test for related sparse signals. 2012 , 28, 1980-9	2
1676	IGDB.NSCLC: integrated genomic database of non-small cell lung cancer. 2012 , 40, D972-7	20
1675	Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis. 2012 , 44, 80-91	23
1674	Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present). 2012 , 22, 1263-87	15
1673	Discovering the hidden sub-network component in a ranked list of genes or proteins derived from genomic experiments. 2012 , 40, e158	21
1672	Elimination of avoidable blindness due to cataract: where do we prioritize and how should we monitor this decade?. 2012 , 60, 438-45	26
1671	LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. 2012 , 72, 2980-9	34
1670	Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. 2012 , 72, 2533-42	150
1669	Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment. 2012 , 18, 100-6	46
1668	Here, there be dragons: charting autophagy-related alterations in human tumors. 2012 , 18, 1214-26	30
1667	Next-generation sequencing in breast cancer: first take home messages. 2012 , 24, 597-604	62
1666	An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. 2012 , 41, 1001-7	50
1665	CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. 2012 , 18, 5650-61	67
1664	Loss of Scribble causes cell competition in mammalian cells. 2012 , 125, 59-66	118
1663	Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor β activation pathway in gastric cancer. 2012 , 287, 38028-40	106
1662	Caspase levels and execution efficiencies determine the apoptotic potential of the cell. 2012 , 196, 513-27	94
1661	A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy. 2012 , 2, 624-37	37

1660	Combining Game Theory and Graph Theory to Model Interactions between Cells in the Tumor Microenvironment. 2012 , 3-18	2
1659	Genomic analysis and selected molecular pathways in rare cancers. 2012 , 9, 065004	7
1658	Analgesics for Cancer Pain. 2012 ,	
1657	Systems analysis of cancer cell heterogeneity in caspase-dependent apoptosis subsequent to mitochondrial outer membrane permeabilization. 2012 , 287, 41546-59	23
1656	[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors]. 2012 , 99, 865-74	3
1655	Hypoxia and miscoupling between reduced energy efficiency and signaling to cell proliferation drive cancer to grow increasingly faster. 2012 , 4, 174-6	16
1654	Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data. 2012 , 57, 6079-101	10
1653	Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target. 2012 , 3, 133	35
1652	Role of the tripartite motif protein 27 in cancer development. 2012 , 104, 941-52	26
1651	Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasia. 2012 , 86, 8461-71	12
1650	Efficient sampling for Bayesian inference of conjunctive Bayesian networks. 2012 , 28, 2318-24	16
1649	Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells. 2012 , 7, 999-1013	56
1648	The emergence of phox-ER stress induced immunogenic apoptosis. 2012 , 1, 786-788	77
1647	Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. 2012 , 72, 2565-77	49
1646	Gold nanoshells for imaging and photothermal ablation of cancer. 2012 , 326-355	
1645	Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. 2012 , 26, 1926-44	275
1644	CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. 2012 , 18, 5352-63	57
1643	Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. 2012 , 109, 1637-42	94

1642	Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. 2012 , 18, 4877-82	87
1641	SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. 2012 , 72, 4597-608	190
1640	Targeting olfactomedin-like 3 inhibits tumor growth by impairing angiogenesis and pericyte coverage. 2012 , 11, 2588-99	29
1639	SIRT1, metabolism and cancer. 2012 , 24, 68-75	70
1638	Power from the garden: plant compounds as inhibitors of the hallmarks of cancer. 2012 , 19, 2061-87	45
1637	Cardiotonic steroids-mediated targeting of the Na(+)/K(+)-ATPase to combat chemoresistant cancers. 2012 , 19, 627-46	62
1636	The interplay between inflammation and oxidative stress in carcinogenesis. 2012 , 12, 672-80	35
1635	Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors. 2012 , 12, 303-15	14
1634	Minireview: the year in obesity and cancer. 2012 , 26, 1961-6	15
1633	Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. 2012 , 19, 1751-64	103
1632	Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. 2012 , 18, 1345-71	103
1631	Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. 2012 , 20, 1821-30	51
1630	Conceptual framework for cutting the pancreatic cancer fuel supply. 2012 , 18, 4285-90	48
1629	Molecular link mechanisms between inflammation and cancer. 2012 , 18, 3831-52	291
1628	The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. 2012 , 12, 288-303	61
1627	How can chemoimmunotherapy best be used for the treatment of colon cancer?. 2012 , 4, 1787-90	2
1626	Potential avenues for immunotherapy of colitis-associated neoplasia. 2012 , 4, 397-405	5
1625	NF- κ B as a target for modulating inflammatory responses. 2012 , 18, 5735-45	149

1624	The tumor suppressor gene ARF as a sensor of oxidative stress. 2012 , 12, 704-15	18
1623	Promises and challenges of exhausting pediatric neural cancer stem cells. 2012 , 71, 523-8	4
1622	Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. 2012 , 72, 5744-56	75
1621	The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions?. 2012 , 19, 1771-9	22
1620	Honokiol: a novel natural agent for cancer prevention and therapy. 2012 , 12, 1244-52	159
1619	Role of the microenvironment in the tumorigenesis of microsatellite unstable and MUTYH-associated polyposis colorectal cancers. 2012 , 27, 247-53	8
1618	Computational modeling and simulation of the Bcl-2 family: paving the way for rational drug design. 2012 , 19, 6081-94	5
1617	Dynamic activation of the key pathways: linking colitis to colorectal cancer in a mouse model. 2012 , 33, 1375-83	42
1616	Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. 2012 , 30, 2280-2	11
1615	Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation. 2012 , 33, 2293-300	8
1614	Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. 2012 , 113, 263-72	83
1613	The Herculean task of killing cancer cells: suppression of FOXO3A in acute leukemia involves a hydra of multiple survival kinases. 2012 , 11, 2589	4
1612	Protein phosphatase PP4: role in dephosphorylation of KAP1 and DNA strand break repair. 2012 , 11, 2590-1	7
1611	p53-dependent growth arrest and induction of p21: a critical role for PCAF-mediated histone acetylation. 2012 , 11, 2591-2	14
1610	CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis. 2012 , 11, 2592-3	4
1609	Differential involvement of RalA and RalB in colorectal cancer. 2012 , 3, 126-30	23
1608	Rap1 and its regulatory proteins: the tumor suppressor, oncogene, tumor suppressor gene axis in head and neck cancer. 2012 , 3, 192-7	12
1607	K-Ras and mitochondria: dangerous liaisons. 2012 , 22, 285-7	14

1606	A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. 2012 , 72, 6279-89	50
1605	The thymidine phosphorylase inhibitor 5'-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist. 2012 , 11, 817-29	19
1604	Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer. 2012 , 11, 984-93	31
1603	Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. 2012 , 185, 260-6	122
1602	Protecting the genome from mdm2 and mdmx. 2012 , 3, 283-90	14
1601	Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton. 2012 , 3, 371-81	29
1600	Src, p130Cas, and Mechanotransduction in Cancer Cells. 2012 , 3, 394-401	24
1599	Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. 2012 , 8, 1185-96	43
1598	SRC points the way to biomarkers and chemotherapeutic targets. 2012 , 3, 426-35	18
1597	Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. 2012 , 97, E1506-14	35
1596	New secrets behind bone metastasis. 2012 , 22, 1309-11	2
1595	Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. 2012 , 25, 627-36	74
1594	AMPK α Suppresses Murine Embryonic Fibroblast Transformation and Tumorigenesis. 2012 , 3, 51-62	38
1593	Expression of Yes-associated protein in gastric adenocarcinoma and inhibitory effects of its knockdown on gastric cancer cell proliferation and metastasis. 2012 , 25, 583-90	34
1592	[What we do not take as (sufficiently) true]. 2012 , 35 Suppl 5, 12-20	3
1591	Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?. 2012 , 1, 137-48	5
1590	COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature. 2012 , 8, 1031-40	44
1589	Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. 2012 , 1, 271-278	33

1588	Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy. 2012 , 12, 899-924	25
1587	Cellular and molecular evidence for malignancy-inhibitory functions of p15RS. 2012 , 11, 1988-98	9
1586	Are the large pharmaceutical and biotechnology companies driving the discovery, research and development of targeted cancer therapies?. 2012 , 4, 13-7	0
1585	Fusing telomeres with RNF8. 2012 , 3, 143-9	11
1584	Stem-like cells and therapy resistance in squamous cell carcinomas. 2012 , 65, 235-65	26
1583	Automating tumor classification with pixel-by-pixel contrast-enhanced ultrasound perfusion kinetics. 2012 , 30, 2C103	9
1582	Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. 2012 , 72, 5198-208	145
1581	Angiogenic activity of hepatitis B and C viruses. 2012 , 22, 159-70	23
1580	MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. 2012 , 25, 871-81	64
1579	A transgenic zebrafish liver tumor model with inducible Myc expression reveals conserved Myc signatures with mammalian liver tumors. 2013 , 6, 414-23	59
1578	PDGF in gliomas: more than just a growth factor?. 2012 , 117, 92-8	17
1577	Blood vessels as targets in tumor therapy. 2012 , 117, 178-86	29
1576	MicroRNA-mediated posttranscriptional mechanisms of gene expression in proliferating and quiescent cancer cells. 2012 , 9, 871-80	10
1575	Synthetische Letalitals Therapiekonzept fdie Behandlung maligner Neoplasien. 2012 , 33, 284-289	
1574	YES-associated protein 1 promotes adenocarcinoma growth and metastasis through activation of the receptor tyrosine kinase Axl. 2012 , 25, 989-1001	38
1573	The Pasteurella multocida toxin: a new paradigm for the link between bacterial infection and cancer. 2012 , 361, 131-44	12
1572	Histological and genetic evidence for a variant of superficial spreading melanoma composed predominantly of large nests. 2012 , 25, 838-45	31
1571	The endothelin axis as therapeutic target in human malignancies: present and future. 2012 , 18, 2720-33	5

1570	MicroRNAs: small molecules with a potentially role in oral squamous cell carcinoma. 2013 , 19, 1285-91	21
1569	[Hepatocellular carcinoma - from immunobiology to immunotherapy]. 2012 , 50, 47-56	9
1568	Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic?. 2012 , 9, 349-53	14
1567	Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. 2012 , 12, 1245-8	8
1566	Low serum MMP-1 in breast cancer: a negative prognostic factor?. 2012 , 17, 416-21	7
1565	The actin cytoskeleton as a sensor and mediator of apoptosis. 2012 , 2, 75-87	152
1564	Crossroads of integrins and cadherins in epithelia and stroma remodeling. 2012 , 6, 261-73	14
1563	Inhibiting mitochondrial-dependent proteolysis of Mcl-1 promotes resistance to DNA damage. 2012 , 11, 88-98	3
1562	Posttranslational control of telomere maintenance and the telomere damage response. 2012 , 11, 1524-34	21
1561	Too much or too little: harnessing senescence to control oncogene-driven cancer. 2012 , 11, 3147-8	4
1560	p53-Aurora A mitotic feedback loop regulates cell cycle progression and genomic stability. 2012 , 11, 3719-20	5
1559	Cisplatin-induced apoptosis and development of resistance are transcriptionally distinct processes. 2012 , 11, 3723	2
1558	Cell-autonomous circadian DNA damage response: is the case closed?. 2012 , 11, 3720-1	2
1557	Transcriptional profiling of apoptosis: cell death classification moves toward the systems era. 2012 , 11, 3721-2	2
1556	Wee1-Hsp90 inhibitor combination treatment: molecular therapy with potentially broad applicability. 2012 , 11, 3722-3	2
1555	Downregulation of Cdc6 and pre-replication complexes in response to methionine stress in breast cancer cells. 2012 , 11, 4414-23	19
1554	Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. 2012 , 7, 1249-57	55
1553	Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. 2012 , 1, 48-55	121

1552	CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker?. 2012 , 1, 364-365	33
1551	Rage mediated DAMP signaling in intestinal tumorigenesis. 2012 , 1, 1165-1166	3
1550	Emerging roles of the tumor-associated stroma in promoting tumor metastasis. 2012 , 6, 193-202	44
1549	Autophagy and tumor cell invasion. 2012 , 11, 3718-9	10
1548	CD73 promotes tumor growth and metastasis. 2012 , 1, 67-70	63
1547	Chronic liver inflammation dominated by interferon- γ can prevent hepatocarcinogenesis. 2012 , 1, 222-223	3
1546	Characterization of T-cell responses against IB in cancer patients. 2012 , 1, 1290-1296	4
1545	Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy. 2012 , 12, 966-81	17
1544	Survivin as a prognostic/predictive marker and molecular target in cancer therapy. 2012 , 19, 3679-88	72
1543	Activation of multiple cancer pathways and tumor maintenance function of the 3q amplified oncogene FNDC3B. 2012 , 11, 1773-81	54
1542	Trial watch: Peptide vaccines in cancer therapy. 2012 , 1, 1557-1576	73
1541	New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. 2012 , 64, 4-22	52
1540	MET signaling regulates glioblastoma stem cells. 2012 , 72, 3828-38	130
1539	NMR-based diffusion pore imaging. 2012 , 86, 021906	35
1538	Linking abnormal mitosis to the acquisition of DNA damage. 2012 , 199, 871-81	144
1537	A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. 2012 , 31, 1985-98	249
1536	p27(Kip1) V109G polymorphism and cancer risk: a systematic review and meta-analysis. 2012 , 27, 665-71	16
1535	HMGB1 promotes drug resistance in osteosarcoma. 2012 , 72, 230-8	210

1534	Targeting NKG2D in tumor surveillance. 2012 , 16, 587-99	17
1533	Tumour Formation: Number of Mutations Required. 2012 ,	
1532	The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. 2012 , 8, 596	85
1531	miR-1 and miR-206 regulate angiogenesis by modulating VegfA expression in zebrafish. 2012 , 139, 4356-64	86
1530	Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling. 2012 , 135, 1055-69	56
1529	Searching a multicellular model to tame tumor-induced angiogenesis. 2012 ,	
1528	Oncolytic viruses: smart therapeutics for smart cancers. 2012 , 8, 1-4	16
1527	Proton irradiation suppresses angiogenic genes and impairs cell invasion and tumor growth. 2012 , 178, 33-45	68
1526	mTOR-dependent cell survival mechanisms. 2012 , 4,	109
1525	A hybrid cellular automaton model of solid tumor growth and bioreductive drug transport. 2012 , 9, 1595-606	11
1524	STOCHASTIC PROPERTIES OF TUMOR GROWTH DRIVEN BY WHITE L�Y NOISE. 2012 , 26, 1250149	7
1523	LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. 2012 , 72, 4060-73	73
1522	Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. 2012 , 18, 3868-79	93
1521	The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. 2012 , 107, 864-73	99
1520	Overlapping functions of microRNAs in control of apoptosis during Drosophila embryogenesis. 2012 , 19, 839-46	35
1519	A predictive role for noncancerous prostate cells: low connexin-26 expression in radical prostatectomy tissues predicts metastasis. 2012 , 107, 1963-8	10
1518	Good neighbours in the tumour stroma reduce oxidative stress. 2012 , 14, 235-6	9
1517	Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance. 2012 , 107, 1714-21	35

1516	ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. 2012 , 3, e432	36
1515	Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. 2012 , 3, e449	25
1514	Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia. 2012 , 106, 1089-94	36
1513	Chemotherapeutic induction of mitochondrial oxidative stress activates GSK-3 β and Bax, leading to permeability transition pore opening and tumor cell death. 2012 , 3, e444	54
1512	Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides. 2012 , 18, 824-8	42
1511	miR-200b restoration and DNA methyltransferase inhibitor block lung metastasis of mesenchymal-phenotype hepatocellular carcinoma. 2012 , 1, e15	27
1510	Endothelial cell dysfunction and cytoskeletal changes associated with repression of p16(INK4a) during immortalization. 2012 , 31, 4815-27	13
1509	Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior. 2012 , 31, 2919-30	26
1508	Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. 2012 , 3, e275	225
1507	The retinoblastoma protein (Rb) as an anti-apoptotic factor: expression of Rb is required for the anti-apoptotic function of BAG-1 protein in colorectal tumour cells. 2012 , 3, e408	28
1506	Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. 2012 , 26, 360-71	126
1505	Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. 2012 , 11, 453-66	53
1504	Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. 2012 , 13, 204-15	94
1503	GPR56 in cancer progression: current status and future perspective. 2012 , 8, 431-40	21
1502	MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis. 2012 , 31, 480-93	49
1501	Preclinical imaging of the cellular and molecular events in the multistep process of bone metastasis. 2012 , 8, 415-30	11
1500	Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. 2012 , 15, 195-201	56
1499	Rapid engraftment of human ALL in NOD/SCID mice involves deficient apoptosis signaling. 2012 , 3, e364	18

1498	A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. 2012 , 107, 695-9	290
1497	The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. 2012 , 106, 702-10	36
1496	Proliferation and tissue remodeling in cancer: the hallmarks revisited. 2012 , 3, e397	46
1495	Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. 2012 , 106, 279-83	60
1494	Selection of a highly invasive neuroblastoma cell population through long-term human cytomegalovirus infection. 2012 , 1, e10	4
1493	Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. 2012 , 106, 883-8	7
1492	PP2A inactivation is a crucial step in triggering apoptin-induced tumor-selective cell killing. 2012 , 3, e291	26
1491	The SNF2-like helicase HELLS mediates E2F3-dependent transcription and cellular transformation. 2012 , 31, 972-85	60
1490	Translational genomics: the challenge of developing cancer biomarkers. 2012 , 22, 183-7	70
1489	Ligand-dependent corepressor (LCoR) recruitment by Kruppel-like factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene. 2012 , 287, 8662-74	35
1488	Expression of mitochondrial non-coding RNAs (ncRNAs) is modulated by high risk human papillomavirus (HPV) oncogenes. 2012 , 287, 21303-15	33
1487	Ubiquitination of retinoblastoma family protein 1 potentiates gene-specific repression function. 2012 , 287, 41835-43	8
1486	Wnt/ β -catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. 2012 , 287, 11730-9	192
1485	The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells. 2012 , 10, 143-55	54
1484	Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. 2012 , 18, 6284-95	44
1483	Changing the tumor microenvironment: new strategies for immunotherapy. 2012 , 72, 5159-64	22
1482	MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. 2012 , 18, 2828-37	226
1481	Tips, stalks, tubes: notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesis. 2012 , 2, a006601	83

1480	Nampt/Visfatin/PBEF: a functionally multi-faceted protein with a pivotal role in malignant tumors. 2012 , 18, 6123-32	38
1479	Context-specific roles for paracrine IL-6 in lymphomagenesis. 2012 , 26, 1758-68	24
1478	The RASSF3 candidate tumor suppressor induces apoptosis and G1-S cell-cycle arrest via p53. 2012 , 72, 2901-11	36
1477	Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. 2012 , 109, 8155-60	69
1476	Differential transcriptomic analysis of spontaneous lung tumors in B6C3F1 mice: comparison to human non-small cell lung cancer. 2012 , 40, 1141-59	20
1475	Revisiting the complexity of the ovarian cancer microenvironment--clinical implications for treatment strategies. 2012 , 10, 1254-64	38
1474	Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint. 2012 , 32, 348-64	18
1473	Calcium channels and pumps in cancer: changes and consequences. 2012 , 287, 31666-73	259
1472	Protein kinase casein kinase 2-mediated upregulation of N-cadherin confers anoikis resistance on esophageal carcinoma cells. 2012 , 10, 1032-8	31
1471	Head and neck cancer stem cells. 2012 , 91, 334-40	71
1470	Targeted therapy: overcoming drug resistance with clinical cancer genome. 2012 , 12, 861-4	3
1469	Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. 2012 , 8, 589	132
1468	Cancer cell-derived supernatants that support the carcinogenic process: a future cancer therapy target?. 2012 , 8, 767-9	2
1467	HECT and RING finger families of E3 ubiquitin ligases at a glance. 2012 , 125, 531-7	403
1466	From Nucleic Acids Sequences to Molecular Medicine. 2012 ,	2
1465	Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. 2012 , 18, 1611-8	476
1464	Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. 2012 , 15, 213-21	38
1463	Nanomedicine on the move: from monotherapeutic regimens to combination therapies. 2012 , 5, 105-8	1

1462	The role of cadmium and nickel in estrogen receptor signaling and breast cancer: metalloestrogens or not?. 2012 , 30, 189-224	66
1461	DRAM-1 encodes multiple isoforms that regulate autophagy. 2012 , 8, 18-28	51
1460	Core module network construction for breast cancer metastasis. 2012 ,	
1459	Molecular pathogenesis of malignant mesothelioma. 2012 , 14, e12	27
1458	Aberrant promoter methylation and expression of UTF1 during cervical carcinogenesis. 2012 , 7, e42704	19
1457	A Mathematical Model of Cancer Stem Cell Lineage Population Dynamics with Mutation Accumulation and Telomere Length Hierarchies. 2012 , 7, 136-165	12
1456	Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. 2012 , 18, 2943-53	75
1455	Glucose oxidation modulates anoikis and tumor metastasis. 2012 , 32, 1893-907	146
1454	Necrosis is not induced by gadolinium neutron capture in glioblastoma multiforme cells. 2012 , 88, 980-90	7
1453	SNP array profiling of childhood adrenocortical tumors reveals distinct pathways of tumorigenesis and highlights candidate driver genes. 2012 , 97, E1284-93	33
1452	Actin-bundling proteins in cancer progression at a glance. 2012 , 125, 1073-9	111
1451	Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. 2012 , 72, 304-14	246
1450	Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. 2012 , 72, 726-35	239
1449	Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations. 2012 , 18, 3743-9	64
1448	A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ as a compatible prognostic marker in human solid tumors. 2012 , 18, 2695-703	167
1447	Selective targeting of interferon β to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth. 2012 , 11, 2419-28	39
1446	Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. 2012 , 10, 1403-18	357
1445	Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription. 2012 , 30, 596-608	11

1444	Tumor suppressor PDCD4 represses internal ribosome entry site-mediated translation of antiapoptotic proteins and is regulated by S6 kinase 2. 2012 , 32, 1818-29	72
1443	Double edge: CDK2AP1 in cell-cycle regulation and epigenetic regulation. 2012 , 91, 235-41	15
1442	Guidance for life, cell death, and colorectal neoplasia by netrin dependence receptors. 2012 , 114, 87-186	3
1441	Functional impact bias reveals cancer drivers. 2012 , 40, e169	238
1440	Cancer epigenomics: moving slowly, but at a steady pace from laboratory bench to clinical practice. 2012 , 50, 1699-701	5
1439	Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. 2012 , 2, 168	34
1438	Vandetanib for the treatment of metastatic medullary thyroid cancer. 2012 , 6, 243-52	24
1437	Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma. 2012 , 2012, 395952	6
1436	MAP17, a ROS-dependent oncogene. 2012 , 2, 112	13
1435	The actin cross-linker Filamin/Cheerio mediates tumor malignancy downstream of JNK signaling. 2013 , 126, 927-38	42
1434	Lessons from cancer immunoediting in cutaneous melanoma. 2012 , 2012, 192719	17
1433	A microRNA Link to Glioblastoma Heterogeneity. 2012 , 4, 846-72	14
1432	Expression of thyroid-stimulating hormone receptor, octamer-binding transcription factor 4, and intracisternal A particle-promoted polypeptide in human breast cancer tissues. 2012 , 9, 173-8	7
1431	Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. 2012 , 19, 57-68	55
1430	Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer. 2012 , 19, L31-6	20
1429	Keeping an open mind: highlights and controversies of the breast cancer stem cell theory. 2012 , 4, 155-66	15
1428	Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy. 2012 , 2012, 139-154	18
1427	The anticancer activity of dichloromethane crude extract obtained from <i>Calea pinnatifida</i> . 2012 , 4, 157-62	11

1426	RKIP Suppresses Breast Cancer Metastasis to the Bone by Regulating Stroma-Associated Genes. 2012 , 2012, 124704	14
1425	Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin. 2012 , 2012, 268681	17
1424	Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy. 2012 , 2012, 319287	18
1423	RASSF1 Polymorphisms in Cancer. 2012 , 2012, 365213	10
1422	MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions. 2012 , 2012, 404810	48
1421	Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. 2012 , 2012, 509348	101
1420	Murine models of B-cell lymphomas: promising tools for designing cancer therapies. 2012 , 2012, 701704	50
1419	The Microenvironmental Effect in the Progression, Metastasis, and Dormancy of Breast Cancer: A Model System within Bone Marrow. 2012 , 2012, 721659	29
1418	Implications of the Use of Eukaryotic Translation Initiation Factor 5A (eIF5A) for Prognosis and Treatment of Hepatocellular Carcinoma. 2012 , 2012, 760928	22
1417	Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. 2012 , 2012, 890178	41
1416	In vivo imaging of drug-induced mitochondrial outer membrane permeabilization at single-cell resolution. 2012 , 72, 2949-56	17
1415	Peroxisome proliferator-activated receptor γ cross talks with E2F and attenuates mitosis in HRAS-expressing cells. 2012 , 32, 2065-82	13
1414	The stroma-a key regulator in prostate function and malignancy. 2012 , 4, 531-48	45
1413	The emerging role of fumarate as an oncometabolite. 2012 , 2, 85	108
1412	Oncolytic virotherapy for ovarian cancer. 2012 , 1, 1-21	11
1411	Shifting the balance of mitochondrial apoptosis: therapeutic perspectives. 2012 , 2, 121	17
1410	The spatial distribution of LGR5+ cells correlates with gastric cancer progression. 2012 , 7, e35486	86
1409	Integrative Nutrition and Nutrition/Herbal Supplements. 2012 , 109-124	

1408	New Challenges for Cancer Systems Biomedicine. 2012,	6
1407	Preface. 2012, 7, 1-2	
1406	mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. 2012, 7, e49144	101
1405	Natural diterpenoid compound elevates expression of Bim protein, which interacts with antiapoptotic protein Bcl-2, converting it to proapoptotic Bax-like molecule. 2012, 287, 1054-65	23
1404	Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells. 2012, 287, 28598-608	53
1403	PTPN14 is required for the density-dependent control of YAP1. 2012, 26, 1959-71	133
1402	Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. 2012, 26, 1247-62	75
1401	Mutual exclusivity analysis identifies oncogenic network modules. 2012, 22, 398-406	452
1400	Lysophospholipid acyltransferases: 1-acylglycerol-3-phosphate O-acyltransferases. From discovery to disease. 2012, 23, 290-302	37
1399	Selective induction of apoptosis and autophagy through treatment with dandelion root extract in human pancreatic cancer cells. 2012, 41, 1039-47	39
1398	New therapeutic targets in soft tissue sarcoma. 2012, 19, 170-80	43
1397	PET of signal transduction pathways in cancer. 2012, 53, 1333-6	18
1396	Antioxidant Role of p53 and of Its Target TP53INP1. 2012,	2
1395	Attenuation of cell mechanosensitivity in colon cancer cells during in vitro metastasis. 2012, 7, e50443	18
1394	ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo. 2012, 40, 1251-64	13
1393	Multiple roles of COUP-TFII in cancer initiation and progression. 2012, 49, R135-48	33
1392	Identification of genes potentially involved in bone metastasis by genome-wide gene expression profile analysis of non-small cell lung cancer in mice. 2012, 40, 1455-69	11
1391	High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer. 2012, 28, 1231-6	23

1390	Tracking transcriptional activities with high-content epifluorescent imaging. 2012 , 17, 046008	25
1389	Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression. 2012 , 1, 550-551	37
1388	Monitoring the process of pulmonary melanoma metastasis using large area and label-free nonlinear optical microscopy. 2012 , 17, 066002	3
1387	TGF-beta: a master switch in tumor immunity. 2012 , 18, 4126-34	33
1386	TGF- β in epithelial to mesenchymal transition and metastasis of liver carcinoma. 2012 , 18, 4135-47	83
1385	Heat shock protein 90 inhibitors as therapeutic agents. 2012 , 7, 313-36	15
1384	Targeting the HER2 receptor in metastatic breast cancer. 2012 , 5, 127-37	22
1383	Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo. 2012 , 27, 1511-9	22
1382	S100A8 and S100A9: new insights into their roles in malignancy. 2012 , 4, 31-40	156
1381	Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway. 2012 , 41, 1809-19	39
1380	A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. 2012 , 72, 2228-38	57
1379	miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. 2012 , 18, 6702-13	70
1378	Nuclear receptors as modulators of the tumor microenvironment. 2012 , 5, 3-10	22
1377	The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. 2012 , 11, M111.014647	596
1376	sizzled function and secreted factor network dynamics. 2012 , 1, 286-94	
1375	Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. 2012 , 12, 316-28	23
1374	Polysialyltransferase: a new target in metastatic cancer. 2012 , 12, 925-39	68
1373	A novel mechanism for cancer cells to evade immune attack by NK cells: The interaction between NKp44 and proliferating cell nuclear antigen. 2012 , 1, 572-574	17

1372	Integration in action. 2012 , 13, 769-71	14
1371	Enhancement of apoptotic and autophagic induction by a novel synthetic C-1 analogue of 7-deoxypancratistatin in human breast adenocarcinoma and neuroblastoma cells with tamoxifen. 2012 ,	4
1370	12.1 Continuum Models of Avascular Tumor Growth.	2
1369	anti-tumor effect of AlkB homolog 3 knockdown in hormone- independent prostate cancer cells. 2012 , 12, 847-56	30
1368	Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. 2012 , 19, 3748-62	83
1367	Secondary radiation-induced bone tumours demonstrate a high degree of genomic instability predictive of a poor prognosis. 2012 , 13, 433-7	5
1366	HSF1, a versatile factor in tumorigenesis. 2012 , 12, 1102-7	27
1365	Seek and destroy: the use of natural compounds for targeting the molecular roots of cancer. 2012 , 13, 1072-82	12
1364	A systems pharmacokinetic and pharmacodynamic approach to identify opportunities and pitfalls in energy stress-mediated chemoprevention: the use of metformin and other biguanides. 2012 , 13, 1876-84	3
1363	Tissue biomarkers for prostate cancer radiation therapy. 2012 , 12, 772-87	14
1362	Fibroblast activation protein in remodeling tissues. 2012 , 12, 1220-43	92
1361	YB-1 Protein and Multidrug Resistance of Tumor Cells. 2012 , 7, 237-246	7
1360	Molecular and cellular mechanisms of hexavalent chromium-induced lung cancer: an updated perspective. 2012 , 13, 284-305	41
1359	Making the most of pathological specimens: molecular diagnosis in formalin-fixed, paraffin embedded tissue. 2012 , 13, 1475-87	30
1358	Image-guided nanosystems for targeted delivery in cancer therapy. 2012 , 19, 3230-40	39
1357	Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules. 2012 , 12, 1143-55	13
1356	Synthetic small peptides acting on B7H1 enhance apoptosis in pancreatic cancer cells. 2012 , 6, 553-7	4
1355	Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. 2012 , 27, 1865-72	45

1354	Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation. 2012 , 71, 146-56	72
1353	DIMming ovarian cancer growth. 2012 , 13, 1869-75	13
1352	Chromatin organizer SATB1 as a novel molecular target for cancer therapy. 2012 , 13, 1603-15	26
1351	Identification of disease-relevant genes for molecularly-targeted drug discovery. 2012 , 12, 1-13	9
1350	Antitumor effect of FP3 in a patient-derived tumor tissue xenograft model of gastric carcinoma through an antiangiogenic mechanism. 2012 , 3, 1052-1058	7
1349	The cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway. 2012 , 28, 1693-700	19
1348	Psychoneuroimmunology and Cancer: Biobehavioral Influences on Tumor Progression. 2012 ,	
1347	Imaging glioma initiation in vivo through a polished and reinforced thin-skull cranial window. 2012 ,	9
1346	Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). 2012 , 41, 393-406	44
1345	SREBPs: regulators of cholesterol/lipids as therapeutic targets in metabolic disorders, cancers and viral diseases. 2012 , 7, 27-36	15
1344	High-grade sarcomatous overgrowth in solitary fibrous tumors: a clinicopathologic study of 10 cases. 2012 , 36, 1202-15	71
1343	Discovery and mechanism of natural products as modulators of histone acetylation. 2012 , 13, 1029-47	20
1342	Inhibition of human topoisomerase I and activation of caspase-3 by aza-angucyclinones and arylaminopyrimido[4,5-c]isoquinoline-7,10-quinones. 2012 , 30, 151-6	5
1341	The Warburg effect in 2012. 2012 , 24, 62-7	145
1340	TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. 2012 , 35, 502-12	38
1339	Cancer immunoediting in malignant glioma. 2012 , 71, 201-22; discussion 222-3	62
1338	Tumor necrosis is a prognostic factor in thick cutaneous melanoma. 2012 , 36, 1477-82	15
1337	Current world literature. 2012 , 24, 109-14	

1336 Current world literature. **2012**, 24, 197-202

1335 Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. **2012**, 24, 150-4 50

1334 Myeloid-derived suppressor cells in cancer patients: a clinical perspective. **2012**, 35, 107-15 176

1333 microRNA-based cancer cell reprogramming technology. **2012**, 4, 8-14 7

1332 Human disease: cancer as a result of aberrant proteins. 74-91

1331 Tropism between hepatic and pulmonary metastases in colorectal cancers. **2012**, 28, 459-64 3

1330 Expression of hypoxia-inducible factor-1 β , vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas. **2012**, 3, 1268-1274 25

1329 Autophagy and cancer. **2012**, 1, 520-34 41

1328 Unraveling the Mystery of Cancer by Secretory microRNA: Horizontal microRNA Transfer between Living Cells. **2011**, 2, 97 39

1327 Next-generation sequencing: application in liver cancer-past, present and future?. **2012**, 1, 383-94 15

1326 New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. **2012**, 3, 140 76

1325 Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. **2012**, 8, 1363-74 75

1324 Towards Cancer Hybrid Automata. **2012**, 92, 137-151 1

1323 Effects of Scrophularia extracts on tumor cell proliferation, death and intravasation through lymphoendothelial cell barriers. **2012**, 40, 2063-74 19

1322 Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. **2012**, 4, 231-236 21

1321 Absence of TGF- β RII predicts bone and lung metastasis and is associated with poor prognosis in stage III breast tumors. **2012**, 11, 209-17 10

1320 Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic significance. **2012**, 4, 647-657 8

1319 Growth Regulation of Nervous System Tumours: Models for Assessment of Angiogenesis in Brain Tumours. **2012**, 181-200

1318	Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. 2012 , 41, 1271-7	14
1317	Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. 2012 , 3, 807-815	14
1316	Association of stem cell marker expression pattern and survival in human biliary tract cancer. 2012 , 41, 511-22	11
1315	Hallmarks of Cancer: The Next Generation. 2012 , 2012, 13	10
1314	Is There a Connection between Inammation and Oxidative Stress?. 2012 , 170-183	2
1313	Quantification of antiangiogenic and antivascular drug activity by kinetic analysis of DCE-MRI data. 2012 , 92, 118-24	14
1312	Therapeutic potential of c-MET inhibitors: background and clinical data. 2012 , 2, 301-315	0
1311	Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis. 2012 , 41, 849-54	44
1310	Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. 2012 , 40, 73-8	20
1309	Clues for Cancer from Ocean-Derived Molecules and Role of In Silico Techniques in Anticancer Drug Discovery. 2012 , 393-408	1
1308	Mammalian Hippo signalling: a kinase network regulated by protein-protein interactions. 2012 , 40, 124-8	63
1307	Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. 2012 , 119, 1018-28	5
1306	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. 2012 , 120, 1412-21	264
1305	Mast cells play a protumorigenic role in primary cutaneous lymphoma. 2012 , 120, 2042-54	98
1304	Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome. 2012 , 120, 2475-83	28
1303	Improving Research on Biomarkers for Early Detection and Screening of Cancers. 2012 , 1-22	
1302	Towards the biomarker-guided rational use of antiangiogenic agents in the treatment of metastatic colorectal cancer. 2012 , 1, 149-161	6
1301	The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells. 2012 , 41, 2285-95	15

1300	Prostate Tissue Stem Cells and Prostate Cancer Progression. 2012,	
1299	Transcriptional silencing of the inhibin- β gene in human gastric carcinoma cells. 2012, 41, 690-700	3
1298	Anti-MET-targeted therapy for NSCLC: has it come of age?. 2012, 2, 1053-1056	
1297	Pharmacodynamic end points in early-phase oncology trials. 2012, 2, 679-687	
1296	A novel monomethoxy polyethylene glycol-poly(lactic acid) polymeric micelles with higher loading capacity for docetaxel and well-reconstitution characteristics and its anti-metastasis study. 2012, 60, 1146-54	9
1295	Loss of E-cadherin promotes prostate cancer metastasis via upregulation of metastasis-associated gene 1 expression. 2012, 4, 1225-1233	38
1294	Management of HCC. 2012, 56 Suppl 1, S75-87	438
1293	Gaussian process models of dynamic PET for functional volume definition in radiation oncology. 2012, 31, 1542-56	8
1292	Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway. 2012, 11, 3997-4008	30
1291	Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 2012, 106, 1648-59	34
1290	DNA repair dysregulation from cancer driver to therapeutic target. 2012, 12, 801-17	680
1289	Immunogenic cell death and DAMPs in cancer therapy. 2012, 12, 860-75	1165
1288	Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. 2012, 18, 5585-94	310
1287	PTEN: an intercellular peacekeeper?. 2012, 5, pe50	9
1286	Surgical margins in the genomic era: The Hayes Martin Lecture, 2012. 2012, 138, 1001-13	9
1285	A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, <i>Drosophila</i> , and humans. 2012, 337, 96-100	514
1284	Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. 2012, 38, 698-707	342
1283	integIRTy: a method to identify genes altered in cancer by accounting for multiple mechanisms of regulation using item response theory. 2012, 28, 2861-9	5

1282	Oncolytic viruses in the treatment of cancer: a review of current strategies. 2012 , 18, 771-81	38
1281	Targeting tumor cell metabolism with statins. 2012 , 31, 4967-78	156
1280	The SLC16A family of monocarboxylate transporters (MCTs)--physiology and function in cellular metabolism, pH homeostasis, and fluid transport. 2012 , 70, 275-311	53
1279	Rac2-MRC-cll-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. 2012 , 119, 4253-63	110
1278	Telomerase directly regulates NF- κ B-dependent transcription. 2012 , 14, 1270-81	241
1277	Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. 2012 , 72, 5712-20	98
1276	Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. 2012 , 109, 20071-6	70
1275	Multiscale imaging and computational modeling of blood flow in the tumor vasculature. 2012 , 40, 2425-41	40
1274	Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling. 2012 , 18, 5572-84	77
1273	Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. 2012 , 249, 176-94	73
1272	Intravital microscopy through an abdominal imaging window reveals a pre-micrometastasis stage during liver metastasis. 2012 , 4, 158ra145	147
1271	Genetically-defined metabolic reprogramming in cancer. 2012 , 23, 552-9	60
1270	Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. 2012 , 287, 37732-44	101
1269	NADPH oxidases as regulators of tumor angiogenesis: current and emerging concepts. 2012 , 16, 1229-47	78
1268	Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. 2012 , 30, 4026-34	162
1267	Disrupting the networks of cancer. 2012 , 18, 2801-8	30
1266	Targeted therapies in breast cancer. 2012 , 142, w13550	9
1265	The paradigm of personalized therapy in oncology. 2012 , 16 Suppl 1, S7-16	16

1264	Cancer in light of experimental evolution. 2012 , 22, R762-71	89
1263	ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. 2012 , 341, 859-72	36
1262	Future directions in cancer prevention. 2012 , 12, 835-48	164
1261	Malignant pleural effusion: tumor-host interactions unleashed. 2012 , 186, 487-92	108
1260	Emerging roles of angiotensin-like 4 in human cancer. 2012 , 10, 677-88	114
1259	ScFv anti-heparan sulfate antibodies unexpectedly activate endothelial and cancer cells through p38 MAPK: implications for antibody-based targeting of heparan sulfate proteoglycans in cancer. 2012 , 7, e49092	9
1258	The expanding scope of DNA sequencing. 2012 , 30, 1084-94	237
1257	Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. 2012 , 11, 2314-26	33
1256	Imaging in oncology--over a century of advances. 2012 , 9, 728-37	18
1255	Cell-to-cell miRNA transfer: from body homeostasis to therapy. 2012 , 136, 169-74	130
1254	Model of translational cancer research in multiple myeloma. 2012 , 103, 1907-12	4
1253	Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. 2012 , 17, 1048-59	69
1252	Glutamine depletion and glucose depletion trigger growth inhibition via distinctive gene expression reprogramming. 2012 , 11, 3679-90	31
1251	The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer. 2012 , 19, 67	52
1250	Nerve-cancer interactions in the stromal biology of pancreatic cancer. 2012 , 3, 97	76
1249	ERK5: structure, regulation and function. 2012 , 24, 2187-96	144
1248	Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. 2012 , 52, 549-73	82
1247	Glucose--a sweet way to die: metabolic switching modulates tumor cell death. 2012 , 11, 3919-25	22

1246	Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy. 2012 , 185-203	3
1245	Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy. 2012 , 12, 1427-47	1
1244	Demand-adapted regulation of early hematopoiesis in infection and inflammation. 2012 , 119, 2991-3002	271
1243	The mesenchyme in malignancy: a partner in the initiation, progression and dissemination of cancer. 2012 , 136, 131-41	15
1242	Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor. 2012 , 39, 517-31	13
1241	Reciprocal repression between P53 and TCTP. 2011 , 18, 91-9	151
1240	Epigenetic and genetic alterations-based molecular classification of head and neck cancer. 2012 , 12, 279-90	15
1239	Transforming the microenvironment: a trick of the metastatic cancer cell. 2012 , 22, 279-80	10
1238	The NAD ⁺ -dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca ²⁺ responses. 2012 , 287, 40924-37	129
1237	10 Kallikrein-related Peptidases as Biomarkers in Personalized Cancer Medicine.	2
1236	Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. 2012 , 65, 565-76	187
1235	Mutations arising during repair of chromosome breaks. 2012 , 46, 455-73	97
1234	Epigenetic deregulation of the COX pathway in cancer. 2012 , 51, 301-13	34
1233	Prognostic histopathological and molecular markers in feline mammary neoplasia. 2012 , 194, 19-26	40
1232	MSCs, macrophages, and cancer: a dangerous ménage-à-trois. 2012 , 11, 730-2	27
1231	Chemokine to the rescue: interleukin-8 mediates resistance to PI3K-pathway-targeted therapy in breast cancer. 2012 , 22, 703-5	16
1230	PIM1 kinase as a target for cancer therapy. 2012 , 21, 425-36	87
1229	Epigenetics: Erase for a new start. 2012 , 492, 363-4	4

1228	Cancer: Metabolism in 'the driver's seat. 2012 , 492, 362-3		12
1227	Initiation of Human Tumourigenesis: Upregulation of FOXM1 Transcription Factor. 2012 , 149-154		1
1226	Pyridostatin analogues promote telomere dysfunction and long-term growth inhibition in human cancer cells. 2012 , 10, 6537-46		83
1225	Hybrid ligand-alkylating agents targeting telomeric G-quadruplex structures. 2012 , 10, 2798-806		85
1224	Deciphering the message broadcast by tumor-infiltrating dendritic cells. 2012 , 181, 733-42		48
1223	Non-Clinical Drug Development. 2012 , 517-529		1
1222	Evidence-based Materia Medica for Cancer Chemoprevention. 2012 , 315-351		
1221	TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. <i>Cell</i> , 2012 , 150, 481-94	56.2	213
1220	Glycolysis inhibitor screening identifies the bis-geranylacylphloroglucinol protonophore moronone from <i>Moronobea coccinea</i> . 2012 , 75, 2216-22		11
1219	Targeting the metabolic microenvironment of tumors. 2012 , 65, 63-107		109
1218	Oncogenes in cell survival and cell death. 2012 , 4,		79
1217	Aneuploidy-induced delaminating cells drive tumorigenesis in <i>Drosophila</i> epithelia. 2012 , 109, 20549-54		78
1216	Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. <i>Cell</i> , 2012 , 151, 1068-82	56.2	258
1215	Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization. 2012 , 72, 1953-63		27
1214	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. 2012 , 76, 19-25		136
1213	Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. 2012 , 4, 124ra27		393
1212	The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. <i>Cell</i> , 2012 , 151, 1185-99	56.2	476
1211	Elevated expression of Rad18 regulates melanoma cell proliferation. 2012 , 25, 213-8		19

1210	Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. 2012 , 25, 384-94	50
1209	CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κ B: implications for bidirectional tumor-stromal interactions. 2012 , 287, 39115-24	92
1208	Improving the description of metabolic networks: the TCA cycle as example. 2012 , 26, 3625-36	21
1207	Differentiation-associated microRNAs antagonize the Rb-E2F pathway to restrict proliferation. 2012 , 199, 77-95	36
1206	Inhibition of Telomerase with Imetelstat Causes Depletion of Cancer Stem Cells. 2012 , 13-24	
1205	The DNA damage response and cancer therapy. 2012 , 481, 287-94	1118
1204	Embryonic stem cell miRNAs and their roles in development and disease. 2012 , 22, 428-36	21
1203	A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. 2012 , 30, 1958-61	6
1202	Breast-cancer stem cells-beyond semantics. 2012 , 13, e43-8	117
1201	Potential for statins in the chemoprevention and management of hepatocellular carcinoma. 2012 , 27, 1654-64	50
1200	The interaction between ER and NF κ B in resistance to endocrine therapy. 2012 , 14, 212	76
1199	Lack of transforming growth factor- β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk. 2012 , 14, R98	55
1198	Is breast cancer a part of Lynch syndrome?. 2012 , 14, 110	8
1197	High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. 2012 , 14, R123	31
1196	p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells. 2012 , 14, R137	21
1195	Isolation of mammary epithelial cells from three-dimensional mixed-cell spheroid co-culture. 2012 ,	11
1194	Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. 2012 , 72, 4920-30	404
1193	Cancer prevention by targeting angiogenesis. 2012 , 9, 498-509	220

1192	Oncolytic virotherapy. 2012 , 30, 658-70	947
1191	Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. 2012 , 109, 15894-9	160
1190	Lymphotoxin, NF- κ B, and cancer: the dark side of cytokines. 2012 , 30, 453-68	46
1189	Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma. 2012 , 19, 822-7	6
1188	Selective RNA Versus DNA G-Quadruplex Targeting by In Situ Click Chemistry. 2012 , 124, 11235-11240	28
1187	Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion. 2012 , 51, 8740-3	73
1186	Selective RNA versus DNA G-quadruplex targeting by in situ click chemistry. 2012 , 51, 11073-8	120
1185	Expanding the concepts and tools of metabolic engineering to elucidate cancer metabolism. 2012 , 28, 1409-18	15
1184	Systemic targeted therapy beyond sorafenib. 2012 , 1, 212-216	6
1183	A complex of β integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. 2012 , 4, 1156-75	37
1182	Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. 2012 , 56, 1817-27	117
1181	Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy. 2012 , 56, 2231-41	304
1180	The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. 2012 , 60, 391-9	48
1179	[Biological effect and tumor risk of diagnostic x-rays. The "war of the theories"]. 2012 , 52, 892-7	5
1178	Die orale Bürstenabstrichmethode zur Bestimmung von humanen Papillomavirus (HPV)-Infektionen. 2012 , 109, 35-39	4
1177	A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer. 2012 , 34, 523-9	16
1176	Metabolic shifts: a fitness perspective for microbial cell factories. 2012 , 34, 2147-60	51
1175	Cancer cells and adaptive explanations. 2012 , 27, 785-810	22

1174	Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. 2012 , 134, 943-55	126
1173	Imaging mitochondrial redox potential and its possible link to tumor metastatic potential. 2012 , 44, 645-53	25
1172	A methodological approach to unravel organ-specific breast cancer metastasis. 2012 , 17, 135-45	13
1171	Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. 2012 , 17, 217-28	33
1170	Targeting insulin and insulin-like growth factor signaling in breast cancer. 2012 , 17, 251-61	66
1169	In vivo pH imaging with (99m)Tc-pHLIP. 2012 , 14, 725-34	52
1168	New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions. 2012 , 14, 653-66	33
1167	Tristetraprolin: roles in cancer and senescence. 2012 , 11, 473-84	53
1166	Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. 2012 , 22, 479-93	95
1165	Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. 2012 , 22, 494-505	85
1164	Trespassing cancer cells: 'fingerprinting' invasive protrusions reveals metastatic culprits. 2012 , 24, 662-9	34
1163	Transcriptional amplification in tumor cells with elevated c-Myc. <i>Cell</i> , 2012 , 151, 56-67	56.2 996
1162	Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. <i>Cell</i> , 2012 , 150, 1107-20	1304
1161	Prognostic impact of vitamin B6 metabolism in lung cancer. 2012 , 2, 257-69	100
1160	The secret of MIM: a novel, MCL-1-specific small molecule. 2012 , 19, 1082-3	8
1159	The Junctional Adhesion Molecule-B regulates JAM-C-dependent melanoma cell metastasis. 2012 , 586, 4046-51	25
1158	T63, a new 4-arylidene curcumin analogue, induces cell cycle arrest and apoptosis through activation of the reactive oxygen species-FOXO3a pathway in lung cancer cells. 2012 , 53, 2204-17	35
1157	Global profiling of protein kinase activities in cancer cells by mass spectrometry. 2012 , 77, 492-503	11

1156	Avascular tumour growth dynamics and the constraints of protein binding for drug transportation. 2012 , 313, 142-52	13
1155	Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. 2012 , 144, 1185-91	25
1154	Overexpression of lumican affects the migration of human colon cancer cells through up-regulation of gelsolin and filamentous actin reorganization. 2012 , 318, 2312-23	41
1153	Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance. 2012 , 93, 315-8	3
1152	Methods for analysis of the cancer microenvironment and their potential for disease prediction, monitoring and personalized treatments. 2012 , 3, 7	4
1151	Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer. 2012 , 33, 897-910	28
1150	RHBDD2: a 5-fluorouracil responsive gene overexpressed in the advanced stages of colorectal cancer. 2012 , 33, 2393-9	17
1149	Novel PET Radiotracers for Potential Use in Management of Lymphoma. 2012 , 7, 83-117	6
1148	Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. 2012 , 114, 1-20	41
1147	Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma. 2012 , 34, 465-9	16
1146	The adaptive immune response to colorectal cancer: from the laboratory to clinical practice. 2012 , 38, 889-96	12
1145	ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity. 2012 , 181, 1056-68	58
1144	An RNA-seq-based gene expression profiling of radiation-induced tumorigenic mammary epithelial cells. 2012 , 10, 326-35	9
1143	Matrix metalloproteinases: potential therapy to prevent the development of second malignancies after breast radiotherapy. 2012 , 21, e143-51	55
1142	Molecular and functional ultrasound imaging of breast tumors. 2012 , 81 Suppl 1, S11-2	7
1141	Mechanisms regulating the secretion of the promalignancy chemokine CCL5 by breast tumor cells: CCL5's 40s loop and intracellular glycosaminoglycans. 2012 , 14, 1-19	15
1140	IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. 2012 , 14, 1223-35	41
1139	Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. 2012 , 14, 656-65	36

1138	hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. 2012 , 5, 105-12	38
1137	Decorin: a guardian from the matrix. 2012 , 181, 380-7	207
1136	Selected telomere length changes and aberrant three-dimensional nuclear telomere organization during fast-onset mouse plasmacytomas. 2012 , 14, 344-51	9
1135	The P2X7 receptor is a key modulator of aerobic glycolysis. 2012 , 3, e370	86
1134	SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. 2012 , 338, 1069-72	147
1133	Obesity-associated dysregulation of calpastatin and MMP-15 in adipose-derived stromal cells results in their enhanced invasion. 2012 , 30, 2774-83	30
1132	Therapeutic application of monoclonal antibodies in cancer: advances and challenges. 2012 , 104, 41-59	52
1131	Carcinogenesis as the Sum of Its Parts. 2012 , 1, 110-115	5
1130	Cross-analysis of gene and miRNA genome-wide expression profiles in human fibroblasts at different stages of transformation. 2012 , 16, 24-36	11
1129	Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. 2012 , 18, 771-82	129
1128	Trypsin-2 enhances carcinoma invasion by processing tight junctions and activating ProMT1-MMP. 2012 , 30, 583-92	14
1127	Carbon monoxide mediates the anti-apoptotic effects of heme oxygenase-1 in medulloblastoma DAOY cells via K ⁺ channel inhibition. 2012 , 287, 24754-64	50
1126	Identifying mutated core modules in glioblastoma by integrative network analysis. 2012 ,	
1125	The ubiquitin-proteasome system meets angiogenesis. 2012 , 11, 538-48	54
1124	Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. 2012 , 10, 995-1009	122
1123	Migration dynamics of breast cancer cells in a tunable 3D interstitial flow chamber. 2012 , 4, 401-9	132
1122	Extensive up-regulation of gene expression in cancer: the normalised use of microarray data. 2012 , 8, 818-27	23
1121	Treating colon cancer with a suicide gene delivered by self-assembled cationic MPEG-PCL micelles. 2012 , 4, 2400-7	31

1120	Soft nanomaterial-based targeting polymersomes for near-infrared fluorescence multispectral in vivo imaging. 2012 , 4, 7097-105	15
1119	High-fat-diet-induced obesity causes an inflammatory and tumor-promoting microenvironment in the rat kidney. 2012 , 5, 627-35	43
1118	Biotechnological, genomics and systems-synthetic biology revolution: redesigning genetic code for a pragmatic systems medicine. 2012 , 9, 97-101	11
1117	Cancer develops, progresses and responds to therapies through restricted perturbation of the protein-protein interaction network. 2012 , 4, 1038-48	8
1116	Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications. 2012 , 53, 1709-13	11
1115	Biomarkers of therapeutic response to BCL2 antagonists in cancer. 2012 , 16, 347-56	11
1114	Melanoma: new insights and new therapies. 2012 , 132, 854-63	121
1113	Fulfilling the metabolic requirements for cell proliferation. 2012 , 446, 1-7	54
1112	The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist. 2012 , 3, e443	41
1111	ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas. 2012 , 31, 4778-88	36
1110	The extracellular matrix: a dynamic niche in cancer progression. 2012 , 196, 395-406	1999
1109	Consensus on the role of human cytomegalovirus in glioblastoma. 2012 , 14, 246-55	205
1108	Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. 2012 , 14, 257-65	101
1107	Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. 2012 , 72, 5130-40	359
1106	Nature-inspired particles as carriers for multimodal molecular imaging applications. 2012 ,	
1105	Chemotherapy and targeted agents for thymic malignancies. 2012 , 12, 685-95	38
1104	Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes. 2012 , 31, 641-51	20
1103	Plasticity of disseminating cancer cells in patients with epithelial malignancies. 2012 , 31, 673-87	167

1102	The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. 2012 , 31, 823-42	56
1101	Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. 2012 , 29, 729-36	30
1100	Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. 2012 , 9, 2339-49	55
1099	Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody. 2012 , 9, 645-53	36
1098	Nrf2: friend and foe in preventing cigarette smoking-dependent lung disease. 2012 , 25, 1805-24	60
1097	Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody. 2012 , 9, 1441-8	32
1096	Novel promising IAP antagonist on the horizon for clinical translation. 2012 , 55, 4099-100	6
1095	Cigarette smoke-induced failure of apoptosis resulting in enhanced neoplastic transformation in human bronchial epithelial cells. 2012 , 75, 707-20	18
1094	Development of a Grp94 inhibitor. 2012 , 134, 9796-804	92
1093	Pre-clinical experiment of pH-weighted magnetic resonance imaging in human brain tumor at 1.5 tesla. 2012 ,	
1092	Differential effects of procaspase-3 activating compounds in the induction of cancer cell death. 2012 , 9, 1425-34	29
1091	Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. 2012 , 61, 855-64	56
1090	Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers. 2012 , 11, 2508-20	45
1089	Enhanced radiosensitivity of head and neck squamous cell carcinoma cells by $\alpha 1$ integrin inhibition. 2012 , 104, 235-42	27
1088	The diverse role of the PPAR γ coactivator 1 family of transcriptional coactivators in cancer. 2012 , 23, 381-8	45
1087	New aspects of the Warburg effect in cancer cell biology. 2012 , 23, 352-61	228
1086	The <i>Xenopus</i> oocyte: a model for studying the metabolic regulation of cancer cell death. 2012 , 23, 412-8	17
1085	Mechanisms of age-related macular degeneration. 2012 , 75, 26-39	556

1084	Biologically targeted therapeutics in pediatric brain tumors. 2012 , 46, 203-11	19
1083	A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. 2012 , 10, 183-97	171
1082	In vitro malignant transformation of human bronchial epithelial cells induced by benzo(a)pyrene. 2012 , 26, 362-8	12
1081	Gene expression profiles induced by E6 from non-European HPV18 variants reveals a differential activation on cellular processes driving to carcinogenesis. 2012 , 432, 81-90	20
1080	Sirtuins, metabolism, and cancer. 2012 , 3, 22	55
1079	Unraveling the complex regulatory relationships between metabolism and signal transduction in cancer. 2012 , 736, 179-89	8
1078	The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy. 2012 , 18, 1561-7	59
1077	Cancer biomarkers: selecting the right drug for the right patient. 2012 , 11, 201-14	202
1076	The rebel angel: mutant p53 as the driving oncogene in breast cancer. 2012 , 33, 2007-17	199
1075	DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. 2012 , 18, 2360-73	73
1074	Targeting the Hedgehog signaling pathway for cancer therapy. 2012 , 16, 49-66	61
1073	Recurrent hemizygous deletions in cancers may optimize proliferative potential. 2012 , 337, 104-9	148
1072	Targeting the tumor mutanome for personalized vaccination therapy. 2012 , 1, 768-769	49
1071	Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers. 2012 , 461, 231-43	41
1070	Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. 2012 , 11, 865-70	31
1069	A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis. 2012 , 166, 737-48	27
1068	Can immuno-oncology offer a truly pan-tumour approach to therapy?. 2012 , 23 Suppl 8, viii53-7	10
1067	Competitive interactions of cancer cells and normal cells via secretory microRNAs. 2012 , 287, 1397-405	208

1066	Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. 2012 , 13, 9545-71	182
1065	Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(β -D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells. 2012 , 55, 3058-65	34
1064	Mechanisms of cell death in heart disease. 2012 , 32, 1552-62	251
1063	Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. 2012 , 18, 2048-55	43
1062	Mutant p53: one name, many proteins. 2012 , 26, 1268-86	781
1061	Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells. 2012 , 237, 1007-17	34
1060	Magnesium and its transporters in cancer: a novel paradigm in tumour development. 2012 , 123, 417-27	43
1059	RNA-binding protein nucleolin in disease. 2012 , 9, 799-808	165
1058	What are we learning from the cancer genome?. 2012 , 9, 621-30	43
1057	Recapitulating tumour microenvironment in chitosan-gelatin three-dimensional scaffolds: an improved in vitro tumour model. 2012 , 9, 3288-302	38
1056	MicroRNAs in autophagy and their emerging roles in crosstalk with apoptosis. 2012 , 8, 873-82	105
1055	CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. 2012 , 186, 1025-36	114
1054	The bright and the dark sides of activin in wound healing and cancer. 2012 , 125, 3929-37	72
1053	Chromothripsis and cancer: causes and consequences of chromosome shattering. 2012 , 12, 663-70	268
1052	Genetic variation and alterations of genes involved in NFB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. 2012 , 33, 2126-34	92
1051	Navigating cancer network attractors for tumor-specific therapy. 2012 , 30, 842-8	115
1050	Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. 2012 , 87, 701-30	94
1049	Aiding and abetting roles of NOX oxidases in cellular transformation. 2012 , 12, 627-37	214

1048	The secret ally: immunostimulation by anticancer drugs. 2012 , 11, 215-33	494
1047	MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. 2012 , 11, 1273-81	94
1046	ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. 2012 , 61, 1560-7	139
1045	Progress in circulating tumor cell capture and analysis: implications for cancer management. 2012 , 12, 303-12	42
1044	Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. 2012 , 31, 2839-51	162
1043	Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. 2012 , 30, 3525-32	175
1042	Molecular regulation of lymphangiogenesis in development and tumor microenvironment. 2012 , 5, 249-60	14
1041	Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. 2012 , 72, 3290-301	177
1040	Molecular pathways: tumor cells Co-opt the brain-specific metabolism gene CPT1C to promote survival. 2012 , 18, 5850-5	36
1039	Non-glucose metabolism in cancer cells--is it all in the fat?. 2012 , 31, 689-98	56
1038	Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. 2012 , 72, 3725-34	91
1037	Cancer cell metabolism: one hallmark, many faces. 2012 , 2, 881-98	609
1036	Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients. 2012 , 106, 2004-9	18
1035	Targeting the Fas/FasL signaling pathway in cancer therapy. 2012 , 16, 85-101	111
1034	Differentiation-promoting culture of competent and noncompetent keratinocytes identifies biomarkers for head and neck cancer. 2012 , 180, 457-72	22
1033	Claudin-4 as therapeutic target in cancer. 2012 , 524, 64-70	35
1032	Polysialylation of the neural cell adhesion molecule: interfering with polysialylation and migration in neuroblastoma cells. 2012 , 524, 56-63	19
1031	Regulation of adherens junctions by Rho GTPases and p120-catenin. 2012 , 524, 48-55	50

1030	Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. 2012 , 56, 267-75	133
1029	A dual role for hypoxia inducible factor-1 β in the hepatitis C virus lifecycle and hepatoma migration. 2012 , 56, 803-9	65
1028	At the cancer steering wheel: defining key genomic drivers of liver cancer with next generation sequencing. 2012 , 56, 1412-4	
1027	Bak deficiency inhibits liver carcinogenesis: a causal link between apoptosis and carcinogenesis. 2012 , 57, 92-100	45
1026	M6P/IGF2R modulates the invasiveness of liver cells via its capacity to bind mannose 6-phosphate residues. 2012 , 57, 337-43	20
1025	Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. 2012 , 57, 577-83	39
1024	Molecular functions of syndecan-1 in disease. 2012 , 31, 3-16	223
1023	Les outils de médecine nucléaire pour le développement de la médecine personnalisée dans le cancer du sein. 2012 , 36, 233-236	
1022	Chromosomally-integrated human herpesvirus 6 in familial glioma etiology. 2012 , 79, 193-6	8
1021	The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response. 2012 , 45, 731-42	167
1020	Lifting the threshold between life and death: SUMO and HDAC fine-tune HIPK2 to sense redox status. 2012 , 46, 382-3	1
1019	Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. 2012 , 18, 13-26	118
1018	Cancer research, a field on the verge of a paradigm shift?. 2012 , 18, 299-303	13
1017	Prediction in the face of uncertainty: a Monte Carlo-based approach for systems biology of cancer treatment. 2012 , 746, 163-70	26
1016	A new chitosan-thymine conjugate: synthesis, characterization and biological activity. 2012 , 50, 493-502	64
1015	Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. 2012 , 13, 425-37	67
1014	Biomedical applications of the ESRF synchrotron-based microspectroscopy platform. 2012 , 177, 248-58	74
1013	Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease. 2012 , 1820, 1366-72	21

1012	The importance of being supercoiled: how DNA mechanics regulate dynamic processes. 2012 , 1819, 632-8	66
1011	Genome-wide studies of the transcriptional regulation by p53. 2012 , 1819, 684-7	6
1010	The dual lives of bidirectional promoters. 2012 , 1819, 688-93	44
1009	Opposing roles of connexin43 in glioma progression. 2012 , 1818, 2058-67	82
1008	Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment. 2012 , 1824, 123-32	22
1007	Cysteine cathepsins: from structure, function and regulation to new frontiers. 2012 , 1824, 68-88	775
1006	Lipid metabolism enzyme 5-LOX and its metabolite LTB4 are capable of activating transcription factor NF- κ B in hepatoma cells. 2012 , 418, 647-51	19
1005	Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. 2012 , 423, 26-31	78
1004	Reduction of DNA hydroxymethylation in the mouse kidney insulted by ischemia reperfusion. 2012 , 422, 697-702	51
1003	Tumor cells can evade dependence on autophagy through adaptation. 2012 , 425, 684-8	9
1002	Chemoprevention of liver cancer by plant polyphenols. 2012 , 50, 2155-70	119
1001	Protective effects of yacon (<i>Smallanthus sonchifolius</i>) intake on experimental colon carcinogenesis. 2012 , 50, 2902-10	47
1000	Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. 2012 , 44, 1276-89	36
999	Cancer cell migration within 3D layer-by-layer microfabricated photocrosslinked PEG scaffolds with tunable stiffness. 2012 , 33, 7064-70	94
998	Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. 2012 , 316, 11-22	49
997	SUMOylation in carcinogenesis. 2012 , 316, 113-25	116
996	Vitamin K(3) and K(5) are inhibitors of tumor pyruvate kinase M2. 2012 , 316, 204-10	35
995	The Na ⁺ /H ⁺ exchanger NHE1, but not the Na ⁺ , HCO ₃ ⁻ cotransporter NBCn1, regulates motility of MCF7 breast cancer cells expressing constitutively active ErbB2. 2012 , 317, 172-83	83

994	Reduced 4-aminobiphenyl-induced liver tumorigenicity but not DNA damage in arylamine N-acetyltransferase null mice. 2012 , 318, 206-13		17
993	Circadian rhythms and tumor growth. 2012 , 318, 115-23		65
992	CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. 2012 , 319, 154-163		26
991	Bcl-2 family members: essential players in skin cancer. 2012 , 320, 1-13		22
990	Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?. 2012 , 323, 115-27		105
989	Extracellular matrix secreted by reactive stroma is a main inducer of pro-tumorigenic features on LNCaP prostate cancer cells. 2012 , 321, 55-64		21
988	Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. 2012 , 321, 18-26		20
987	New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. 2012 , 38, 303-10		24
986	Epithelial immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. 2012 , 83, 293-8		19
985	EMT and dissemination precede pancreatic tumor formation. <i>Cell</i> , 2012 , 148, 349-61	56.2	1422
984	Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. <i>Cell</i> , 2012 , 148, 259-72	56.2	483
983	The genetic basis for cancer treatment decisions. <i>Cell</i> , 2012 , 148, 409-20	56.2	242
982	Cellular metabolism and disease: what do metabolic outliers teach us?. <i>Cell</i> , 2012 , 148, 1132-44	56.2	509
981	Paternal RLIM/Rnf12 is a survival factor for milk-producing alveolar cells. <i>Cell</i> , 2012 , 149, 630-41	56.2	25
980	Target practice: modeling tumors with stem cells. <i>Cell</i> , 2012 , 149, 1185-7	56.2	4
979	Cancer epigenetics: from mechanism to therapy. <i>Cell</i> , 2012 , 150, 12-27	56.2	1932
978	Adenovirus evasion of interferon-mediated innate immunity by direct antagonism of a cellular histone posttranslational modification. 2012 , 11, 597-606		86
977	Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. 2012 , 15, 827-37		389

976	The CD47-SIRP α pathway in cancer immune evasion and potential therapeutic implications. 2012 , 24, 225-32	362
975	Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. 2012 , 15, 21-38	192
974	Collateral sensitivity as a strategy against cancer multidrug resistance. 2012 , 15, 98-105	215
973	Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. 2012 , 48, 333-9	103
972	Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11. 2012 , 48, 432-40	54
971	Qualification of imaging biomarkers for oncology drug development. 2012 , 48, 409-15	61
970	Basal Ki67 expression measured by digital image analysis is optimal for prognostication in oral squamous cell carcinoma. 2012 , 48, 2166-74	25
969	Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. 2012 , 22, 21-7	22
968	Screens, maps & networks: from genome sequences to personalized medicine. 2012 , 22, 36-44	14
967	Cancer immunoediting by the innate immune system in the absence of adaptive immunity. 2012 , 209, 1869-82	221
966	New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies. 2012 , 12, 457-67	6
965	Evolution of the cancer genome. 2012 , 13, 795-806	424
964	Understanding the genetic basis of gastric cancer: recent advances. 2012 , 6, 335-41	30
963	Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. 2012 , 18, 1323-33	138
962	Metformin reduces endogenous reactive oxygen species and associated DNA damage. 2012 , 5, 536-43	224
961	Molecular and cellular effects of Auger emitters: 2008-2011. 2012 , 88, 864-70	13
960	Introduction and Conclusion: The Rationale for Thresholds for Genotoxic Carcinogens. 2012 , 1-20	1
959	Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells. 2012 , 7, e46571	160

958	Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the niche. 2012 , 2012, 537861	31
957	Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. 2012 , 92, 503-10	69
956	Genetic pathways linking hemostasis and cancer. 2012 , 129 Suppl 1, S22-9	34
955	From drug discovery to biomarker-driven clinical trials in lymphoma. 2012 , 9, 643-53	23
954	Controlling spatial organization of multiple cell types in defined 3D geometries. 2012 , 24, 5543-7, 5542	38
953	Dual-Function CXCR4 Antagonist Polyplexes To Deliver Gene Therapy and Inhibit Cancer Cell Invasion. 2012 , 124, 8870-8873	14
952	The metastatic cancer cell cortex: an adaptation to enhance robust cell division in novel environments?. 2012 , 34, 1017-20	13
951	Molecular crosstalk between cancer cells and tumor microenvironment components suggests potential targets for new therapeutic approaches in mobile tongue cancer. 2012 , 1, 128-40	48
950	The tyrosine kinase Abl is a component of macrophage podosomes and is required for podosome formation and function. 2012 , 42, 2720-6	12
949	IL-23: one cytokine in control of autoimmunity. 2012 , 42, 2263-73	123
948	Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells. 2012 , 113, 3143-52	40
947	Concomitant consumption of lycopene and fish oil inhibits tumor growth and progression in a mouse xenograft model of colon cancer. 2012 , 56, 1520-31	24
946	Core module biomarker identification with network exploration for breast cancer metastasis. 2012 , 13, 12	31
945	Integrating gene expression and protein-protein interaction network to prioritize cancer-associated genes. 2012 , 13, 182	90
944	Network enrichment analysis: extension of gene-set enrichment analysis to gene networks. 2012 , 13, 226	86
943	DNA methylation arrays as surrogate measures of cell mixture distribution. 2012 , 13, 86	1815
942	Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma. 2012 , 13, 160	24
941	Defining new criteria for selection of cell-based intestinal models using publicly available databases. 2012 , 13, 274	41

940	Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study. 2012 , 13, 334	102
939	Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma. 2012 , 12, 332	20
938	The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors. 2012 , 12, 350	12
937	Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. 2012 , 12, 365	25
936	Complement activation in astrocytomas: deposition of C4d and patient outcome. 2012 , 12, 565	8
935	Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. 2012 , 12, 571	92
934	Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. 2012 , 12, 580	21
933	Molecular pathways undergoing dramatic transcriptomic changes during tumor development in the human colon. 2012 , 12, 608	13
932	The clinical features of papillary thyroid cancer in Hashimoto's thyroiditis patients from an area with a high prevalence of Hashimoto's disease. 2012 , 12, 610	64
931	A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. 2012 , 12, 16	35
930	Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors. 2012 , 12, 14	29
929	Is systems biology a promising approach to resolve controversies in cancer research?. 2012 , 12, 12	17
928	Triplex DNA-binding proteins are associated with clinical outcomes revealed by proteomic measurements in patients with colorectal cancer. 2012 , 11, 38	22
927	Importance of glycolysis and oxidative phosphorylation in advanced melanoma. 2012 , 11, 76	108
926	Changes in the expression of proteins associated with aerobic glycolysis and cell migration are involved in tumorigenic ability of two glioma cell lines. 2012 , 10, 53	24
925	Hepatocyte-specific S100a8 and S100a9 transgene expression in mice causes Cxcl1 induction and systemic neutrophil enrichment. 2012 , 10, 40	17
924	TGF- β - an excellent servant but a bad master. 2012 , 10, 183	252
923	Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. 2012 , 10, 247	47

922	The importance of ubiquitination and sumoylation on the transforming activity of HTLV Tax-1 and Tax-2. 2012 , 9, 103	9
921	Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis. 2012 , 9, 114	26
920	The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. 2012 , 9, 74	35
919	Harnessing the complexity of gene expression data from cancer: from single gene to structural pathway methods. 2012 , 7, 44	19
918	Detection of a common chimeric transcript between human chromosomes 7 and 16. 2012 , 7, 49	14
917	RACK1, a clue to the diagnosis of cutaneous melanomas in horses. 2012 , 8, 95	10
916	The ubiquitin-proteasome system in glioma cell cycle control. 2012 , 7, 18	15
915	Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. 2012 , 7, 12	15
914	The effects of MicroRNA transfections on global patterns of gene expression in ovarian cancer cells are functionally coordinated. 2012 , 5, 33	28
913	Relevance of immunohistochemical expression of p57kip2 in epithelial ovarian carcinoma- A systematic literature review. 2012 , 5, 46	0
912	Genistein abrogates G2 arrest induced by curcumin in p53 deficient T47D cells. 2012 , 20, 82	4
911	Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. 2012 , 1, 12	82
910	The immuno-oncology framework: Enabling a new era of cancer therapy. 2012 , 1, 334-339	32
909	A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. 2011 , 481, 190-4	413
908	Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations. 2012 , 65, 315-34	13
907	MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. 2012 , 31, 2499-511	78
906	Nuclear receptor coactivator RAC3 inhibits autophagy. 2012 , 103, 2064-71	10
905	Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. 2012 , 45, 487-98	912

904	Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. 2012 , 77, 918-25	84
903	Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold. 2012 , 55, 4664-82	55
902	Advances in gas chromatographic methods for the identification of biomarkers in cancer. 2012 , 3, 404-20	33
901	Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer. 2012 , 53, 1262-8	43
900	Comparative analysis of algorithms for integration of copy number and expression data. 2012 , 9, 351-5	26
899	Cell polarity as a regulator of cancer cell behavior plasticity. 2012 , 28, 599-625	97
898	Nuclear morphometry, nucleomics and prostate cancer progression. 2012 , 14, 375-84	19
897	A symbiotic view of life: we have never been individuals. 2012 , 87, 325-41	491
896	In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. 2012 , 106, 1967-75	33
895	Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1). 2012 , 14, 44-50	29
894	Inhibition of autophagy impairs tumor cell invasion in an organotypic model. 2012 , 11, 2022-9	94
893	Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples. 2012 , 18, 3261-9	61
892	The ghrelin axis--does it have an appetite for cancer progression?. 2012 , 33, 849-91	64
891	Targeting Axl with an high-affinity inhibitory aptamer. 2012 , 20, 2291-303	121
890	Nanovector delivery of siRNA for cancer therapy. 2012 , 19, 367-73	138
889	Autophagy and cancer. 2012 , 4, a008821	120
888	Cancer. 2012 , 238-251	1
887	CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. 2012 , 167, 1415-30	101

886	Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. 2012 , 16, 1553-62	38
885	Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. 2012 , 60, 2232-6	30
884	Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. 2012 , 25, 732-9	69
883	Mitophagy or how to control the Jekyll and Hyde embedded in mitochondrial metabolism: implications for melanoma progression and drug resistance. 2012 , 25, 721-31	15
882	Modeling prostate cancer in mice: limitations and opportunities. 2012 , 33, 133-44	36
881	A possible role for perforin and granzyme B in resveratrol-enhanced radiosensitivity of prostate cancer. 2012 , 33, 752-60	26
880	Targeting endoplasmic reticulum signaling pathways in cancer. 2012 , 51, 822-30	60
879	Induction of epithelial-mesenchymal transition by transforming growth factor β 2012 , 22, 446-54	106
878	Role of ion channels and transporters in cell migration. 2012 , 92, 1865-913	289
877	The tumor microenvironment at a glance. 2012 , 125, 5591-6	1029
876	Regulation of autophagy by nucleoporin Tpr. 2012 , 2, 878	37
875	Anti-tumor immunity: myeloid leukocytes control the immune landscape. 2012 , 278, 21-6	18
874	Novel targets for VEGF-independent anti-angiogenic drugs. 2012 , 21, 451-72	31
873	^{125}I -radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand of $\alpha_5\beta_1$ Integrin as a molecular imaging probe for angiogenesis. 2012 , 55, 5024-33	24
872	The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules. 2012 , 4, 395-424	4
871	Cdc6: a multi-functional molecular switch with critical role in carcinogenesis. 2012 , 3, 124-9	25
870	Apoptosis-modulating drugs for improved cancer therapy. 2012 , 48, 111-20	63
869	Micro-RNA-632 downregulates DNAJB6 in breast cancer. 2012 , 92, 1310-7	20

868	Breast cancer and protein biomarkers. 2012 , 2, 86-91	23
867	Therapy of human papillomavirus-related disease. 2012 , 30 Suppl 5, F71-82	121
866	Human telomerase reverse transcriptase (hTERT) is a target gene of β -catenin in human colorectal tumors. 2012 , 11, 3331-8	24
865	Functional drug-gene interactions in lung cancer. 2012 , 12, 291-302	5
864	Apoptosis in targeted therapy responses: the role of BIM. 2012 , 65, 519-42	45
863	Confusion Surrounds the Origin of Cancer. 2012 , 15-29	
862	Respiratory Insufficiency, the Retrograde Response, and the Origin of Cancer. 2012 , 177-194	1
861	Abnormalities in Growth Control, Telomerase Activity, Apoptosis, and Angiogenesis Linked to Mitochondrial Dysfunction. 2012 , 207-213	
860	Mitochondrial Respiratory Dysfunction and the Extrachromosomal Origin of Cancer. 2012 , 253-259	1
859	Metabolic Management of Cancer. 2012 , 291-354	1
858	Therapeutic targeting of the p53 pathway in cancer stem cells. 2012 , 16, 1161-74	29
857	Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. 2012 , 11, 974-89	87
856	Targeting the subtypes of breast cancer: rethinking investigational drugs. 2012 , 21, 191-204	1
855	MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. 2012 , 19, 926-36	41
854	Influence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer prevention. 2012 , 60, 5693-708	93
853	Wip1-dependent signaling pathways in health and diseases. 2012 , 106, 307-25	39
852	PTEN—linking metabolism, cell growth, and cancer. 2012 , 367, 1061-3	11
851	Breast cancer intratumor genetic heterogeneity: causes and implications. 2012 , 12, 1021-32	57

850	Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner. 2012 , 53, 1102-9	25
849	Chromosomal instability, aneuploidy and routine high-resolution DNA content analysis in oral cancer risk evaluation. 2012 , 8, 1257-71	24
848	Differential gene expression pattern in early gastric cancer by an integrative systematic approach. 2012 , 41, 1675-82	14
847	EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. 2012 , 69, 3429-56	369
846	A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. 2012 , 1826, 423-33	59
845	Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. 2012 , 7, 723-43	25
844	Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. 2012 , 30, 648-57	85
843	A Review of Mechanisms of Contrast for Diffuse Optical Imaging of Cancer. 2012 , 20, 185-202	6
842	Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. 2013 , 329, 73-132	119
841	Cigarette smoke-induced transgenerational alterations in genome stability in cord blood of human F1 offspring. 2012 , 26, 3946-56	60
840	Integrated inference and analysis of regulatory networks from multi-level measurements. 2012 , 110, 19-56	15
839	Modifying effects of lemongrass essential oil on specific tissue response to the carcinogen N-methyl-N-nitrosurea in female BALB/c mice. 2012 , 15, 161-8	9
838	RETRACTED: Obesity-induced increase in tumor necrosis factor- α leads to development of colon cancer in mice. 2012 , 143, 741-753.e4	65
837	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. 2012 , 10, 20-26	
836	Personalized nanomedicine: paving the way to the practical clinical utility of genomics and nanotechnology advancements. 2012 , 64, 1359-62	21
835	β -Catenin mutations in 2 nested stromal epithelial tumors of the liver--a neoplasia with defective mesenchymal-epithelial transition. 2012 , 43, 1815-27	34
834	Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?. 2012 , 164, 265-75	233
833	Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours. 2012 , 147, 171-6	6

832	Novel involvement of leukotriene B ₂ receptor 2 through ERK activation by PP2A down-regulation in leukotriene B ₂ induced keratin phosphorylation and reorganization of pancreatic cancer cells. 2012 , 1823, 2120-9	22
831	5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells. 2012 , 428, 292-7	3
830	Proteasome inhibitors in mantle cell lymphoma. 2012 , 25, 133-41	22
829	DNA methylation based biomarkers: practical considerations and applications. 2012 , 94, 2314-37	118
828	Effect of homotypic and heterotypic interaction in 3D on the E-selectin mediated adhesive properties of breast cancer cell lines. 2012 , 33, 9037-48	28
827	Cognitive-behavioral stress management reverses anxiety-related leukocyte transcriptional dynamics. 2012 , 71, 366-72	162
826	FTIR spectro-imaging of collagens for characterization and grading of gliomas. 2012 , 30, 1432-46	42
825	Mismatch in mechanical and adhesive properties induces pulsating cancer cell migration in epithelial monolayer. 2012 , 102, 2731-41	66
824	Caspase 9 promoter polymorphisms confer increased susceptibility to breast cancer. 2012 , 205, 508-12	14
823	Long-term effects of systemic cancer treatment on DNA oxidative damage: the potential for targeted therapies. 2012 , 327, 134-41	18
822	Interleukin-1 beta and transforming growth factor-beta 3 cooperate to activate matrix metalloproteinase expression and invasiveness in A549 lung adenocarcinoma cells. 2012 , 325, 220-6	26
821	Integration of cell biology, pharmacological modeling and statistical analysis: part I: cell biology and PK/PD in the Oncology paradigm. 2012 , 83, 153-69	1
820	The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes. 2012 , 38, 737-59	30
819	The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer. 2012 , 38, 943-55	39
818	Evolution of inflammatory diseases. 2012 , 22, R733-40	214
817	Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis. 2012 , 23, 547-59	38
816	Chromothripsis: chromosomes in crisis. 2012 , 23, 908-17	105
815	pH regulators in invadosomal functioning: proton delivery for matrix tasting. 2012 , 91, 847-60	60

814	6-[(1-naphthylmethyl)sulfanyl]-9H-purine induces G2/M phase arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. 2012 , 695, 27-33	7
813	Nuclear factor- κ B, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. 2012 , 37, 317-24	105
812	Cancer heterogeneity: origins and implications for genetic association studies. 2012 , 28, 538-43	20
811	Structural mutations in cancer: mechanistic and functional insights. 2012 , 28, 550-9	54
810	Metronomic therapy for gynecologic cancers. 2012 , 51, 167-78	14
809	Shiga toxins. 2012 , 60, 1085-107	140
808	Columbamine suppresses the proliferation and neovascularization of metastatic osteosarcoma U2OS cells with low cytotoxicity. 2012 , 215, 174-80	42
807	New concepts and best practices for management of pre- and post-transplantation cancer. 2012 , 26, 261-79	70
806	Automated GMP synthesis of [(18)F]ICMT-11 for in vivo imaging of caspase-3 activity. 2012 , 39, 1000-5	32
805	Premetastatic vasculogenesis in oral squamous cell carcinoma xenograft-draining lymph nodes. 2012 , 48, 663-70	7
804	SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification. 2012 , 48, 1106-13	35
803	Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. 2012 , 110, 69-86	45
802	Protein degradation and the stress response. 2012 , 23, 515-22	68
801	Hippo signalling in the G2/M cell cycle phase: lessons learned from the yeast MEN and SIN pathways. 2012 , 23, 794-802	58
800	The biology of human breast epithelial progenitors. 2012 , 23, 606-12	18
799	Regulation of the Hippo pathway by cell architecture and mechanical signals. 2012 , 23, 803-11	100
798	Do Gleason patterns 3 and 4 prostate cancer represent separate disease states?. 2012 , 188, 1667-75	56
797	Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. 2012 , 76, 26-31	36

796	DNA methylation downregulates expression of several apoptosis-associated and tumor suppressor genes in non-small cell lung carcinoma cells. 2012 , 77, S8-S9	
795	Stereotactic body radiotherapy for early stage non-small cell lung cancer. 2012 , 77, S9-S10	
794	Molecular aspects of thymic carcinoma. 2012 , 78, 127-32	20
793	Personalized primary tumor xenograft model established for the pre-clinical trial to guide postoperative chemotherapy. 2012 , 79, 705-8	3
792	Regulation of Yorkie activity in Drosophila imaginal discs by the Hedgehog receptor gene patched. 2012 , 129, 339-49	27
791	Metabolic regulation by SIRT3: implications for tumorigenesis. 2012 , 18, 516-23	89
790	Hallmarks of cancer: of all cancer cells, all the time?. 2012 , 18, 509-15	90
789	Pre-mRNA splicing in disease and therapeutics. 2012 , 18, 472-82	319
788	The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. 2012 , 6, 111-27	118
787	Molecular diagnostics in lymphoma: why, when and how to apply. 2012 , 18, 53-63	6
786	TGF- β -induced epithelial-mesenchymal transition: a link between cancer and inflammation. 2012 , 22, 455-61	153
785	GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. 2012 , 33, 784-811	101
784	Clonal architecture of secondary acute myeloid leukemia. 2012 , 366, 1090-8	582
783	A novel retinoblastoma therapy from genomic and epigenetic analyses. 2012 , 481, 329-34	364
782	Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions. 2012 , 69, 3765-805	119
781	Growth factor signaling in metastasis: current understanding and future opportunities. 2012 , 31, 479-91	23
780	Mitochondrial respiratory uncoupling promotes keratinocyte differentiation and blocks skin carcinogenesis. 2012 , 31, 4725-31	14
779	Targeting the signaling pathways in cancer therapy. 2012 , 16, 1-3	9

778	Angiogenesis-related agents in esophageal cancer. 2012 , 12, 1335-45	8
777	Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. 2012 , 186, 1180-8	137
776	Cytokine-Cytokine Cross Talk and Cell-Death Decisions. 2012 , 163-180	
775	The bed and the bugs: interactions between the tumor microenvironment and cancer stem cells. 2012 , 22, 462-70	39
774	Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. 2012 , 107, 287-90	30
773	Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. 2012 , 53, 2015-23	33
772	In vivo models of primary brain tumors: pitfalls and perspectives. 2012 , 14, 979-93	169
771	HAMLET: functional properties and therapeutic potential. 2012 , 8, 1301-13	21
770	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. 2012 , 1, 1323-1343	173
769	Rbf1 degran dysfunction enhances cellular DNA replication. 2012 , 11, 3731-8	6
768	Inter-cellular signaling network reveals a mechanistic transition in tumor microenvironment. 2012 , 4, 1478-86	13
767	N-terminal truncation of Lats1 causes abnormal cell growth control and chromosomal instability. 2013 , 126, 508-20	31
766	Maspin: molecular mechanisms and therapeutic implications. 2012 , 31, 529-51	77
765	Resting potential, oncogene-induced tumorigenesis, and metastasis: the bioelectric basis of cancer in vivo. 2012 , 9, 065002	104
764	Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors. 2012 , 15, 286-92	3
763	Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. 2012 , 65, 45-61	50
762	On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53. 2012 , 7, e37518	44
761	Modeling Oncogenic Signaling Networks from Gene Expression Dynamics. 2012 , 69-81	

760	Systems Biology of Pancreatic Cancer: The Role of Tumor-Microenvironment Communication in Development, Progression and Therapy Resistance. 2012 , 135-164	
759	Understanding Cancer Progression Using Protein Interaction Networks. 2012 , 167-195	1
758	Pasteurella multocida. 2012 ,	3
757	PAK signaling in cancer. 2012 , 2, 105-116	143
756	LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. 2012 , 11, 5914-23	93
755	DNA confinement in nanochannels: physics and biological applications. 2012 , 75, 106601	260
754	Noncoding RNAs: Identification of Cancer-Associated MicroRNAs. 2012 , 573-587	
753	Mass spectrometry-based phosphoproteomics in cancer research. 2012 , 7, 566-586	0
752	Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. 2012 , 7, 173-81	19
751	Hypoxic cell waves around necrotic cores in glioblastoma: a biomathematical model and its therapeutic implications. 2012 , 74, 2875-96	70
750	Reduction of CAII Expression in Gastric Cancer: Correlation with Invasion and Metastasis. 2012 , 24, 196-200	14
749	Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. 2012 , 8, 994-1010	43
748	Telomeres and tissue engineering: the potential roles of TERT in VEGF-mediated angiogenesis. 2012 , 8, 1275-81	14
747	Identification and chromosomal localizations of signal transduction genes associated with human ovarian cancer metastasis. 2012 , 29, 2932-6	
746	Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation. 2012 , 6, 233-48	26
745	The SGBS cell strain as a model for the in vitro study of obesity and cancer. 2012 , 14, 774-82	26
744	The EMT signaling pathways in endometrial carcinoma. 2012 , 14, 715-20	76
743	Current status of biology, bioengineering, and therapeutic potential of stem cells. 2012 , 35, 193-6	2

742	Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. 2012 , 5, 261-73	126
741	Cancer microenvironment and cancer vaccine. 2012 , 5, 333-44	13
740	Multifaceted tumor stromal fibroblasts. 2012 , 5, 187-93	10
739	Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma. 2012 , 5, 203-9	44
738	Dynamic education of macrophages in different areas of human tumors. 2012 , 5, 195-201	28
737	Role of proprotein convertases in prostate cancer progression. 2012 , 14, 1032-42	41
736	Targeting BRAFV600E in an inducible murine model of melanoma. 2012 , 181, 785-94	42
735	Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor. 2012 , 14, 943-51	29
734	Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. 2012 , 23 Suppl 8, viii6-9	344
733	On a fundamental structure of gene networks in living cells. 2012 , 109, 4702-7	42
732	Deletion(20q) as the sole abnormality in plasma cell myeloma is not associated with plasma cells as identified by clg FISH. 2012 , 205, 644-52	3
731	Regulation of p73 activity by post-translational modifications. 2012 , 3, e285	47
730	Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. 2012 , 12, 363-8	199
729	Natural product-derived antitumor compound phenethyl isothiocyanate inhibits mTORC1 activity via TSC2. 2012 , 75, 1051-7	18
728	Images of Cancer. 2012 , 1-14	
727	Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. 2012 , 14, 1203-11	182
726	KiSS1 and its G-protein-coupled receptor GPR54 in cancer development and metastasis. 2012 , 31, 585-91	26
725	Autophagy and cancer. 2012 , 44, 109-20	214

724	The mTOR signalling pathway in human cancer. 2012 , 13, 1886-918	508
723	[Molecular signaling pathways. Mechanisms and clinical use]. 2012 , 188 Suppl 3, 308-11	9
722	Epigenetik in der Onkologie. 2012 , 15, 10-18	
721	Molekulare Onkologie. 2012 , 18, 1023-1028	0
720	[Mechanisms of cell death. Novel insights and implications for tumor pathology]. 2012 , 33 Suppl 2, 241-5	1
719	[Epithelial-mesenchymal transition in non-small cell lung cancer]. 2012 , 33 Suppl 2, 311-7	18
718	Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer. 2012 , 27, 1369-76	37
717	NK cells are never alone: crosstalk and communication in tumour microenvironments. 2023 , 22,	0
716	The role of redox homeostasis biomarkers in clear cell renal cell carcinoma development and progression. 2022 , 73, 34-39	0
715	Targeting fat mass and obesity-associated protein mitigates human colorectal cancer growth in vitro and in a murine model. 13,	0
714	PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. 2023 , 35, 517-534.e8	0
713	Revisiting the hallmarks of cancer: A new look at long noncoding RNAs in breast cancer. 2023 , 243, 154381	0
712	Cancer immunotherapies: A hope for the incurable?. 3,	0
711	Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. 2023 , 22, 333-342	0
710	New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. 2023 , 24, 4044	0
709	Is the Level of Contrast Enhancement on Contrast-Enhanced Mammography (CEM) Associated with the Presence and Biological Aggressiveness of Breast Cancer?. 2023 , 13, 754	0
708	Antiangiogenic drugs in combination with seaweed fucoidan: A mechanistic in vitro and in vivo study exploring the VEGF receptor and its downstream signaling molecules in hepatic cancer. 14,	0
707	Structure-function relationship and physiological role of apelin and its G protein coupled receptor. 2023 , 15, 127-143	1

- 706 Lactobacillus plantarum Metabolites Elicit Anticancer Effects by Inhibiting Autophagy-Related Responses. **2023**, 28, 1890 ○
- 705 Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies. **2023**, 28, 1897 ○
- 704 Elevated STIL predicts poor prognosis in patients with hepatocellular carcinoma. **2023**, 102, e33004 ○
- 703 Association between systemic immune-inflammation index (SII) and survival outcome in patients with primary glioblastoma. **2023**, 102, e33050 ○
- 702 Modeling Ewing Sarcoma Lung Metastasis. **2023**, 3, ○
- 701 Development of Prognostic Features of Hepatocellular Carcinoma Based on Metabolic Gene Classification and Immune and Oxidative Stress Characteristic Analysis. **2023**, 2023, 1-29 ○
- 700 Optimal clinical protocols for total-body 18F-FDG PET/CT examination under different activity administration plans. **2023**, 10, ○
- 699 Dynamic network biomarker to determine the critical point of breast cancer stage progression. **2023**, 30, 453-465 ○
- 698 Regulation of the Epithelial to Mesenchymal Transition in Osteosarcoma. **2023**, 13, 398 ○
- 697 A Novel Preclinical In Vitro 3D Model of Oral Carcinogenesis for Biomarker Discovery and Drug Testing. **2023**, 24, 4096 ○
- 696 p53 mutation and deletion contribute to tumor immune evasion. 14, ○
- 695 Non-Coding RNA-Dependent Regulation of Mitochondrial Dynamics in Cancer Pathophysiology. **2023**, 9, 16 ○
- 694 Predicting the Clinical Outcome of Triple-Negative Breast Cancer Based on the Gene Expression Characteristics of Necroptosis and Different Molecular Subtypes. **2023**, 2023, 1-16 ○
- 693 Nano-Electrochemical Characterization of a 3D Bioprinted Cervical Tumor Model. **2023**, 15, 1327 ○
- 692 Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis. **2023**, 24, 4148 ○
- 691 DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. **2023**, 15, 1342 ○
- 690 Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer. **2023**, 46, 161-166 ○
- 689 Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives. **2023**, 2, 65-78 ○

- 688 P2RX7 promotes osteosarcoma progression and glucose metabolism by enhancing c-Myc stabilization. **2023**, 21, ○
- 687 TIM-4 orchestrates mitochondrial homeostasis to promote lung cancer progression via ANXA2/PI3K/AKT/OPA1 axis. **2023**, 14, ○
- 686 A non-genetic switch triggers alternative telomere lengthening and cellular immortalization in ATRX deficient cells. **2023**, 14, ○
- 685 Prognostic Significance of Amino Acid Metabolism-Related Genes in Prostate Cancer Retrieved by Machine Learning. **2023**, 15, 1309 ○
- 684 A Simple 3D Cell Culture Method for Studying the Interactions between Human Mesenchymal Stromal/Stem Cells and Patients Derived Glioblastoma. **2023**, 15, 1304 ○
- 683 Circular RNA Ubiquitin-associated Protein 2 Silencing Suppresses Bladder Cancer Progression by Downregulating DNA Topoisomerase 2-alpha Through Sponging miR-496. **2023**, 50, 31-42 ○
- 682 Advances in antibody-based therapy in oncology. **2023**, 4, 165-180 ○
- 681 A timeline of tumour-associated macrophage biology. **2023**, 23, 238-257 ○
- 680 A compilation of bioinformatic approaches to identify novel downstream targets for the detection and prophylaxis of cancer. **2023**, 75-113 ○
- 679 Prognostic Value of Transglutaminase 2 in Patients with Solid Tumors: A Meta-analysis. **2023**, 27, 36-43 ○
- 678 Mono-ADP-ribosylation by PARP10 and PARP14 in genome stability. **2023**, 5, ○
- 677 2-Deoxy-D -glucose simultaneously targets glycolysis and Wnt/ β -catenin signaling to inhibit cervical cancer progression. ○
- 676 The cytidine deaminase APOBEC3A is required for large ribosomal subunit biogenesis. ○
- 675 Hypercholesterolemia Influences the Progression of Cancer by Changing the Biomolecular and Immunological Status of the Tumor Microenvironment. **2023**, 1-30 ○
- 674 The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures. 12, ○
- 673 Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors. ○
- 672 Pericyte stem cells induce Ly6G + cell accumulation and immunotherapy resistance in pancreatic cancer. **2023**, 24, ○
- 671 Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. **2023**, 22, ○

- 670 On the gene expression landscape of cancer. **2023**, 18, e0277786 ○
- 669 Carcinogenic Effects of Areca Nut and Its Metabolites: A Review of the Experimental Evidence. **2023**, 13, 326-346 ○
- 668 Footprints: Stamping hallmarks of lung cancer with patient-derived models, from molecular mechanisms to clinical translation. 11, ○
- 667 MORC2 and MAX contributes to the expression of glycolytic enzymes, breast cancer cell proliferation and migration. **2023**, 40, ○
- 666 Discovery of new deregulated miRNAs in gingivo buccal carcinoma using Group Benjamini Hochberg method: a commentary on [A quest for miRNA bio-marker: a track back approach from gingivo buccal cancer to two different types of precancers](#) ○
- 665 Methylation of nonessential genes in cutaneous melanoma [Rule Out hypothesis](#). Publish Ahead of Print, ○
- 664 Targeting PSAT1 to mitigate metastasis in tumors with p53-72Pro variant. **2023**, 8, ○
- 663 ARHGAP15 promotes metastatic colonization in gastric cancer by suppressing RAC1-ROS pathway. **2023**, 19, e1010640 ○
- 662 PIP5K1C phosphoinositide kinase deficiency distinguishes PIKFYVE-dependent cancer cells from non-malignant cells. 1-21 ○
- 661 Urine-based liquid biopsy in bladder cancer: Opportunities and challenges. **2023**, 3, ○
- 660 The Role of Inflammatory Cell Infiltration in Urogenital Cancers. **2023**, ○
- 659 Prognostic value and clinicopathological status of PD-L1 expression and CD8 + TILs in oral squamous cell cancer patients with or without traditional risk factors. **2023**, 45, 1017-1025 ○
- 658 Exploring Core Genes by Comparative Transcriptomics Analysis for Early Diagnosis, Prognosis, and Therapies of Colorectal Cancer. **2023**, 15, 1369 ○
- 657 Participation of adhesion molecules in changing cell interactions during metastasis development. **2020**, 15, 27-32 ○
- 656 Pediatric Patient-Derived-Xenograft development in MAPPYACTS [International pediatric cancer precision medicine trial in relapsed and refractory tumors](#). ○
- 655 Tailoring therapies to counter the divergent immune landscapes of breast cancer. 11, ○
- 654 USP15 Represses Hepatocellular Carcinoma Progression by Regulation of Pathways of Cell Proliferation and Cell Migration: A System Biology Analysis. **2023**, 15, 1371 ○
- 653 hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer. **2023**, 83, 628-640 ○

- 652 The Correlation between Peripheral Blood Index and Immune Cell Expansion in Vietnamese Elderly Lung Cancer Patients. **2023**, 24, 4284
- 651 A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥ 2 lines) anti-programmed death-1 monotherapy. **2023**, 139, 106336
- 650 Polymorphism and Ligand Binding Modulate Fast Dynamics of Human Telomeric G-Quadruplexes. **2023**, 24, 4280
- 649 The GSTP1/MAPKs/BIM/SMAC modulatory actions of nitazoxanide: Bioinformatics and experimental evidence in subcutaneous solid Ehrlich carcinoma-inoculated mice. **2023**, 319, 121496
- 648 Killer to cure: Expression and production costs calculation of tobacco plant-made cancer-immune checkpoint inhibitors.
- 647 Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance.
- 646 Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients.
- 645 In-silico structural characterization and phylogenetic analysis of Nucleoside diphosphate kinase: A novel antiapoptotic protein of *Porphyromonas gingivalis*. **2023**, 124, 545-556
- 644 Transcriptomic study of gastrointestinal stromal tumors with liver metastasis. 14,
- 643 Matrix Metalloproteinase-2-Induced Morphologic Transformation of Self-Assembled Peptide Nanocarriers Inhibits Tumor Growth and Metastasis. **2023**, 5, 900-908
- 642 Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer. 14,
- 641 Andrographolide suppresses aerobic glycolysis and induces apoptotic cell death by inhibiting pyruvate dehydrogenase kinase 1 expression. **2023**, 49,
- 640 Targeting of Glucose Transport and the NAD Pathway in Neuroendocrine Tumor (NET) Cells Reveals New Treatment Options. **2023**, 15, 1415
- 639 Phenotypic Discovery of Thiocarbohydrazone with Anticancer Properties and Catalytic Inhibition of Human DNA Topoisomerase IIβ **2023**, 16, 341
- 638 Vascular endothelial growth factor and risk of malignant brain tumor: A genetic correlation and two-sample Mendelian randomization study. 13,
- 637 RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation. **2023**, 6,
- 636 The versatile roles of ADAM8 in cancer cell migration, mechanics, and extracellular matrix remodeling. 11,
- 635 MicroRNA in lung cancer—novel potential way for early diagnosis and therapy.

- 634 An angiogenesis-related three-long non-coding ribonucleic acid signature predicts the immune landscape and prognosis in hepatocellular carcinoma. **2023**, 9, e13989 ○
- 633 Positive Correlation between PMS2 Deficiency and PD-L1 Expression in Pancreatic Cancer. **2023**, 14, 74-90 ○
- 632 The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome. ○
- 631 Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism-related genes and their relationships with immune infiltration. **2023**, 13, 736-750 ○
- 630 Changes in the urine proteome in patients with advanced lung cancer after different drug treatments. **2023**, 5, 1-12 ○
- 629 Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer. **2023**, 14, ○
- 628 Genomics-Driven Precision Medicine in Pediatric Solid Tumors. **2023**, 15, 1418 ○
- 627 Radiotherapy, photodynamic therapy, and cryoablation-induced abscopal effect: Challenges and future prospects. ○
- 626 Precision Hydrogels for the Study of Cancer Cell Mechanobiology. ○
- 625 Role of RUNX3 in Restriction Point Regulation. **2023**, 12, 708 ○
- 624 Homologous recombination suppresses transgenerational DNA end resection and chromosomal instability in fission yeast. ○
- 623 Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer. **2023**, 11, 691 ○
- 622 Systemic immune-inflammation index in predicting non-curative resection of endoscopic submucosal dissection in patients with early gastric cancer. **2023**, 35, 376-383 ○
- 621 The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis. **2023**, 171, 83-94 ○
- 620 Cytomegalovirus at the crossroads of immunosenescence and oncogenesis. 17-27 ○
- 619 MiRNAs Action and Impact on Mitochondria Function, Metabolic Reprogramming and Chemoresistance of Cancer Cells: A Systematic Review. **2023**, 11, 693 ○
- 618 A promising new cancer marker: Long noncoding RNA EGFR-AS1. 13, ○
- 617 Integrative radiomics and transcriptomics analyses reveal subtype characterization of non-small cell lung cancer. ○

- 616 A novel preoperative inflammation score system established for postoperative prognosis predicting of intrahepatic cholangiocarcinoma. **2023**, 23, ○
- 615 An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1. ○
- 614 Utility of pre-treatment 18F-fluorodeoxyglucose PET radiomic analysis in assessing nodal involvement in cervical cancer. **2023**, 44, 375-380 ○
- 613 The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases. **2023**, ○
- 612 Shaping of the Clinical Landscape of Immunotherapy by PD-L1 Expression in Breast Cancer. **2023**, 1-20 ○
- 611 PDGF gene expression and p53 alterations contribute to the biology of diffuse astrocytic gliomas. **2023**, 8, ○
- 610 Pro-inflammatory polarization and colorectal cancer modulate alternative and intronic polyadenylation in primary human macrophages. ○
- 609 Risk factors of preoperative myocardial injury in patients with gastrointestinal tumors. **2023**, 23, ○
- 608 Direct cellular targets and anticancer mechanisms of the natural product oridonin. **2023**, 2, ○
- 607 Glutamine metabolism in breast cancer and possible therapeutic targets. **2023**, 210, 115464 ○
- 606 Delineating the tumour-regulatory roles of EYA4. **2023**, 210, 115466 ○
- 605 Molecular modeling study of pyrrolidine derivatives as novel myeloid cell leukemia-1 inhibitors through combined 3D-QSAR, molecular docking, ADME/Tox and MD simulation techniques. 1-17 ○
- 604 Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity. ○
- 603 Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers. **2023**, 24, 4601 ○
- 602 JAG1 is correlated to suppressive immune microenvironment and predicts immunotherapy resistance in lung adenocarcinoma. 13, ○
- 601 Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy. 14, ○
- 600 Expression Dynamics of CA IX Epitope in Cancer Cells under Intermittent Hypoxia Correlates with Extracellular pH Drop and Cell Killing by Ureido-Sulfonamide CA IX Inhibitors. **2023**, 24, 4595 ○
- 599 Introduction on Cancerous Cells and Metastasis. **2023**, 1-24 ○

- 598 Natural Products in Precision Oncology: Plant-Based Small Molecule Inhibitors of Protein Kinases for Cancer Chemoprevention. **2023**, 15, 1192 ○
- 597 Construction of a radiogenomic association map of pancreatic ductal adenocarcinoma. **2023**, 23, ○
- 596 The Two Faces of Immune-Related lncRNAs in Head and Neck Squamous Cell Carcinoma. **2023**, 12, 727 ○
- 595 Impact of dietary carbohydrate restriction on the pathobiology of Hepatocellular Carcinoma: The gut-liver axis and beyond. **2023**, 66, 101736 ○
- 594 Biologically informed NeuralODEs for genome-wide regulatory dynamics. ○
- 593 Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C. **2023**, 34, 609-619 ○
- 592 KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions. **2023**, 12, 749 ○
- 591 Role of alternative splicing in health and diseases. **2023**, 19-36 ○
- 590 The enduring interdependence of shotgun and targeted proteomics in cancer research. **2023**, 241-256 ○
- 589 Carcinogenicity Assessment. **2023**, 125-172 ○
- 588 Nanocarrier of Pin1 inhibitor based on supercritical fluid technology inhibits cancer metastasis by blocking multiple signaling pathways. **2023**, 10, ○
- 587 Identification and validation of a novel anoikis-related prognostic model for prostate cancer. ○
- 586 Targeted Therapies: A Molecular Overview. **2023**, 22, 1-14 ○
- 585 Ultrasound sensitive O₂ microbubbles radiosensitize murine breast cancer but lead to higher metastatic spread. **2023**, 199, 166-176 ○
- 584 Erianin inhibits the growth of uveal melanoma cells by regulating VEGF secretion. ○
- 583 An Introduction to Human Cancers. **2023**, 3-28 ○
- 582 Bufalin-Mediated Regulation of Cell Signaling Pathways in Different Cancers: Spotlight on JAK/STAT, Wnt/ β -Catenin, mTOR, TRAIL/TRAIL-R, and Non-Coding RNAs. **2023**, 28, 2231 ○
- 581 Biomarkers for Monitoring the Immunotherapy Response to Cancer. **2023**, 1-37 ○

- 580 The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non-small cell lung cancer. **2023**, 14, 869-878 ○
- 579 Elevated Levels of Lamin A Promote HR and NHEJ-Mediated Repair Mechanisms in High-Grade Ovarian Serous Carcinoma Cell Line. **2023**, 12, 757 ○
- 578 Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer. **2023**, ○
- 577 Metabolic Barriers to Glioblastoma Immunotherapy. **2023**, 15, 1519 ○
- 576 Neuroendocrine Tumors and Immune System. **2023**, ○
- 575 Bioenergetic Profiling in Glioblastoma Multiforme Patients with Different Clinical Outcomes. **2023**, 13, 362 ○
- 574 Xiaotan Sanjie decoction normalizes tumor permissive microenvironment in gastric cancer (Review). **2023**, 49, ○
- 573 Discovering metabolic vulnerability using spatially resolved metabolomics for antitumor small molecule-drug conjugates development as a precise cancer therapy strategy. **2023**, ○
- 572 Influence of octreotide on apoptosis and metabolome expression in lipopolysaccharide-induced A549 cells. **2023**, 29, ○
- 571 Excitable dynamics in a molecularly-explicit model of cell motility: Mixed-mode oscillations and beyond. **2023**, 564, 111450 ○
- 570 Modeling of senescent cell dynamics predicts a late-life decrease in cancer incidence. **2023**, 16, 609-624 ○
- 569 ER⁺PR⁺ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor. **2023**, 30, 436-452 ○
- 568 Puromycin Prodrug Activation by Thioredoxin Reductase Overcomes Its Promiscuous Cytotoxicity. **2023**, 66, 3250-3261 ○
- 567 Enzyme-catalyzed synthesis of selenium-doped manganese phosphate for synergistic therapy of drug-resistant colorectal cancer. **2023**, 21, ○
- 566 Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer. 13, ○
- 565 Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. **2023**, 30, 235-247.e12 ○
- 564 Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. **2023**, 11, 735 ○
- 563 IN SILICO LIBRARY SCREENING TO FIND NOVEL ANTICANCER AGENT WITH CHEMOSENSITIZING PROPERTIES: FOCUS ON TARGETING ATAXIA TELANGIECTASIA AND Rad3 RELATED KINASE. ○

- 562 Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition. **2023**, 24, 4722 ○
- 561 Cell division cycle-associated 8 is a prognostic biomarker related to immune invasion in hepatocellular carcinoma. ○
- 560 Anti-HER2 scFv-nCyt c -Modified Lipid-Encapsulated Oxygen Nanobubbles Prepared with Bulk Nanobubble Water for Inducing Apoptosis and Improving Photodynamic Therapy. 2206091 ○
- 559 Bleb protrusions help cancer cells to cheat death. **2023**, 615, 402-403 1
- 558 Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner. **2023**, 21, ○
- 557 Effects of epigenetic therapy on natural killer cell function and development in hematologic malignancy. ○
- 556 Regulatory roles of ferroptosis-related non-coding RNAs and their research progress in urological malignancies. 14, ○
- 555 Pan-Cancer Analysis Reveals Functional Similarity of Three lncRNAs across Multiple Tumors. **2023**, 24, 4796 ○
- 554 Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. **2023**, 21, ○
- 553 Deep learning - cancer genetics and application of deep learning to cancer oncology. **2022**, 60, 885-928 ○
- 552 Plant extract from *Caesalpinia spinosa* inhibits cancer-associated fibroblast-like cells generation and function in a tumor microenvironment model. **2023**, 9, e14148 ○
- 551 Molecular predictors of metastasis in patients with prostate cancer. **2023**, 23, 199-215 ○
- 550 Panic at the Bile Duct. **2023**, ○
- 549 Modeling cancer's ecological and evolutionary dynamics. **2023**, 40, ○
- 548 A *Drosophila* chemical screen reveals synergistic effect of MEK and DGK inhibition in Ras-driven cancer. **2023**, 16, ○
- 547 Glycomic, Glycoproteomic, and Proteomic Profiling of Philippine Lung Cancer and Peritumoral Tissues: Case Series Study of Patients Stages I-III. **2023**, 15, 1559 ○
- 546 The Yin and Yang Effect of the Apelinergic System in Oxidative Stress. **2023**, 24, 4745 ○
- 545 Hepatocellular carcinoma subtypes based on metabolic pathways reveals potential therapeutic targets. 13, ○

- 544 Development of a Molecular-Subtype-Associated Immune Prognostic Signature That Can Be Recognized by MRI Radiomics Features in Bladder Cancer. **2023**, 10, 318 ○
- 543 Therapeutic Implications of CDKs in Breast Cancer. **2023**, 233-252 ○
- 542 Prognosis and complications of patients with primary gastrointestinal diffuse large B-cell lymphoma: Development and validation of the systemic inflammation response index-covered score. ○
- 541 Expression of Cav-1, MCT1, and MCT4 in Ductal Carcinoma In Situ of the Breast and Their Associations With Clinicopathologic Features. **2023**, 31, 204-212 ○
- 540 A noncanonical response to replication stress protects genome stability through ROS production, in an adaptive manner. ○
- 539 *Gynostemma pentaphyllum* an immortal herb with promising therapeutic potential: a comprehensive review on its phytochemistry and pharmacological perspective. **2023**, 26, 808-832 1
- 538 T regulatory cells metabolism: The influence on functional properties and treatment potential. 14, ○
- 537 The Hippo signaling pathway: from multiple signals to the hallmarks of cancers. **2023**, ○
- 536 Quantitative proteomics identified a novel invasion biomarker associated with EMT in pituitary adenomas. 14, ○
- 535 Identification of lactylation related model to predict prognostic, tumor infiltrating immunocytes and response of immunotherapy in gastric cancer. 14, ○
- 534 Development of a coupled modeling for tumor growth, angiogenesis, oxygen delivery, and phenotypic heterogeneity. ○
- 533 The differential role of resistin on invasive liver cancer cells. **2022**, ○
- 532 Molecular Pathways Implicated in Radioresistance of Glioblastoma Multiforme: What Is the Role of Extracellular Vesicles?. **2023**, 24, 4883 ○
- 531 Platelets in the tumor microenvironment and their biological effects on cancer hallmarks. 13, ○
- 530 Targeting CDKs with Other Chemotherapeutic Drugs: A Combinatorial Approach. **2023**, 269-289 ○
- 529 Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers. **2023**, 211-232 ○
- 528 RPL11 promotes non-small cell lung cancer cell proliferation by regulating endoplasmic reticulum stress and cell autophagy. **2023**, 24, ○
- 527 MAEL facilitates metabolic reprogramming and breast cancer progression by promoting the degradation of citrate synthase and fumarate hydratase via chaperone-mediated autophagy. ○

- 526 Fluorescence Lifetime Imaging Microscopy (FLIM) reveals spatial-metabolic changes in 3D breast cancer spheroids. **2023**, 13, ○
- 525 HIPK2 in Angiogenesis: A Promising Biomarker in Cancer Progression and in Angiogenic Diseases. **2023**, 15, 1566 ○
- 524 CDK1 Dysregulation in Breast Cancer. **2023**, 195-210 ○
- 523 Digital droplet PCR TERT promoter mutational screening in fine needle aspiration cytology of thyroid lesions: A highly specific technique for pre-operative identification of high-risk cases. ○
- 522 An oncospace for human cancers. **2023**, 45, ○
- 521 Combining atomic force microscopy with complementary techniques for multidimensional single-cell analysis. ○
- 520 Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression. ○
- 519 S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) inhibits lung cancer tumorigenesis by regulating cell plasticity. **2023**, 18, ○
- 518 ALKBH5 -induced circular RNA NRIP1 promotes glycolysis in thyroid cancer cells by targeting PKM2. ○
- 517 Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development. **2023**, 12, ○
- 516 Evaluation of Cytotoxic Activity of Epigenetic Drugs in Oesophageal Squamous Cell Carcinoma. **2023**, 5, 25-36 ○
- 515 Early inflammatory biomarkers and melanoma survival. ○
- 514 Tumor Evasion of the Immune System: Role of Interferon and Tumor Necrosis Factor in Cancer. **2022**, 1-27 ○
- 513 HSV: The scout and assault for digestive system tumors. 10, ○
- 512 The prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia. **2023**, 14, 879-890 ○
- 511 Tumor Metabolism: Challenges and Future Perspectives. **2023**, 1-27 ○
- 510 Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer: A Review of the Literature. **2023**, 13, 987 ○
- 509 Exosomes as crucial emerging tools for intercellular communication with therapeutic potential in ovarian cancer. **2023**, 9, ○

- 508 Emerging Therapies in CLL in the Era of Precision Medicine. **2023**, 15, 1583 ○
- 507 The Importance of the Fifth Nucleotide in DNA: Uracil. ○
- 506 *Helicobacter pylori* infection induces abnormal expression of pro-angiogenic gene ANGPT2 and miR-203a in AGS gastric cell line. ○
- 505 TUBB2B facilitates progression of hepatocellular carcinoma by regulating cholesterol metabolism through targeting HNF4A/CYP27A1. **2023**, 14, ○
- 504 Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins. **2023**, 24, 4961 ○
- 503 Intravoxel incoherent motion imaging used to assess tumor microvascular changes after transarterial chemoembolization in a rabbit VX2 liver tumor model. 13, ○
- 502 An impact of neutrophil extracellular traps to the prothrombotic state and tumor progression in gynecological cancer patients. **2023**, 17, 53-64 ○
- 501 A study of indirect action's impact on simulated neutron-induced DNA damage. **2023**, 68, 075014 ○
- 500 Immune Compartments and Extracellular Matrix Crosstalk Involved in Tumor Dissemination. **2023**, 1-22 ○
- 499 The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. **2023**, 13, ○
- 498 Exploring heterogeneity of tumor immune cells and adrenal cells in aldosterone-producing adenomas using single-cell RNA-seq and investigating differences by sex. **2023**, 9, e14357 ○
- 497 Cancer Biology. **2023**, 1-30 ○
- 496 Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF- α triggers tumorigenic inflammation in neuroblastoma. **2023**, 11, e005478 ○
- 495 Malignant human thyroid neoplasms associated with blood parasitic (haemosporidian) infection. ○
- 494 Zbtb46 coordinates angiogenesis and immunity to control tumor outcome. ○
- 493 Pro-Apoptotic and Anti-Cancer Activity of the *Vernonanthura nudiflora* Hydroethanolic Extract. **2023**, 15, 1627 ○
- 492 TLN1 contains a cancer-associated cassette exon that alters talin-1 mechanosensitivity. **2023**, 222, ○
- 491 Prognostic Value of the Lung Immune Prognostic Index for Metastatic Non-Small Cell Lung Cancer Patients: A Chinese Cohort Study. Volume 16, 881-893 ○

- 490 Ainsliadimer A induces ROS-mediated apoptosis in colorectal cancer cells via directly targeting peroxiredoxin 1 and 2. **2023**, 30, 295-307.e5 ○
- 489 Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer. **2023**, 21, ○
- 488 Verteporfin-induced proteotoxicity impairs cell homeostasis and survival in neuroblastoma subtypes independent of YAP/TAZ expression. **2023**, 13, ○
- 487 Ferredoxin 1, the key regulator of cuproptosis, was associated with prognosis and immune cell infiltration in clear cell renal cell carcinoma. **2023**, 2, ○
- 486 Potential Approaches for Delivery of Surface Decorated Nano-carriers in the Management of Carcinoma. **2023**, 64-105 ○
- 485 ELITE: Expression deconvolution using linear optimization in bulk transcriptomics mixtures. ○
- 484 EGR1 drives cell proliferation by directly stimulating TFEB transcription in response to starvation. **2023**, 21, e3002034 ○
- 483 Key Members of the CmPn as Biomarkers Distinguish Histological and Immune Subtypes of Hepatic Cancers. **2023**, 13, 1012 1
- 482 Atherosclerosis is a smooth muscle cell-driven tumor-like disease. ○
- 481 A Novel Method in Identifying Pyroptosis and Apoptosis Based on the Double Resonator Piezoelectric Cytometry Technology. **2023**, 13, 356 ○
- 480 Strategies to target the cancer driver MYC in tumor cells. 13, ○
- 479 Identification of Genetic Alterations in Rapid Progressive Glioblastoma by Use of Whole Exome Sequencing. **2023**, 13, 1017 ○
- 478 Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. 14, ○
- 477 Correlation between Imaging Markers Derived from PET/MRI and Invasive Acquired Biomarkers in Newly Diagnosed Breast Cancer. **2023**, 15, 1651 ○
- 476 Mapping the Complex Genetic Landscape of Human Neurons. ○
- 475 Relationship between Systemic Inflammatory Markers, GLUT1 Expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-Small Cell Lung Carcinoma and Their Prognostic Significance. **2023**, 13, 1013 ○
- 474 Real-world Efficacy Data on Anti-Angiogenic Drugs in Recurrent Small Cell Cervical Carcinoma: A Retrospective Study. **2023**, 22, 153303382311603 ○
- 473 Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience. **2023**, 559, 216119 ○

- 472 Geographically weighted linear combination test for gene-set analysis of a continuous spatial phenotype as applied to intratumor heterogeneity. 11, ○
- 471 Analysis of context-specific KRAS effector (sub)complexes in Caco-2 cells. **2023**, 6, e202201670 ○
- 470 Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. **2023**, 13, ○
- 469 Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy. 2206211 ○
- 468 BIN1 in cancer: biomarker and therapeutic target. ○
- 467 Effects of β -caryophyllene and oxygen availability on cholesterol and fatty acids in breast cancer cells. **2023**, 18, e0281396 ○
- 466 BrcaDx: Precise identification of breast cancer from expression data using a minimal set of features. ○
- 465 Immunomodulatory function and anti-tumor mechanism of natural polysaccharides: A review. 14, ○
- 464 Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells. **2023**, 24, 5208 ○
- 463 NOTCH Signaling in Osteosarcoma. **2023**, 45, 2266-2283 ○
- 462 A crowdsourcing database for the copy-number variation of the Spanish population. **2023**, 17, ○
- 461 PCGF6/MAX/KDM5D facilitates MAZ/CDK4 axis expression and pRCC progression by hypomethylation of the DNA promoter. **2023**, 16, ○
- 460 Glutamine Starvation Affects Cell Cycle, Oxidative Homeostasis and Metabolism in Colorectal Cancer Cells. **2023**, 12, 683 ○
- 459 Bioconjugation of COL1 protein on liquid-like solid surfaces to study tumor invasion dynamics. **2023**, 18, 021001 ○
- 458 Establishment of a new prognostic risk model of MAPK pathway-related molecules in kidney renal clear cell carcinoma based on genomes and transcriptomes analysis. 13, ○
- 457 Cathepsin H Knockdown Reverses Radioresistance of Hepatocellular Carcinoma via Metabolic Switch Followed by Apoptosis. **2023**, 24, 5257 ○
- 456 MR Elastography in Cancer. Publish Ahead of Print, ○
- 455 Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues. **2023**, 11, 842 ○

- 454 Chemokines and Chemokine Receptors in Cancer: An Update. **2023**, 1-30 ○
- 453 Beneficial insights into postbiotics against colorectal cancer. 10, ○
- 452 Identification and Characterization of Metabolic Subtypes of Endometrial Cancer Using a Systems-Level Approach. **2023**, 13, 409 ○
- 451 Metformin May Alter the Metabolic Reprogramming in Cancer Cells by Disrupting the L-Arginine Metabolism: A Preliminary Computational Study. **2023**, 24, 5316 ○
- 450 Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer. **2023**, 23, ○
- 449 Peptidergic Systems and Cancer: Focus on Tachykinin and Calcitonin/Calcitonin Gene-Related Peptide Families. **2023**, 15, 1694 ○
- 448 BIRC5 Regulates IGFBP-3-Induced Autocrine Loop in Cancer Stem Cells. ○
- 447 Predicting response to neoadjuvant therapy with glucose transporter-1 in breast cancer. **2023**, 69, 440-446 ○
- 446 Cervical cancer immune infiltration microenvironment identification, construction of immune scores, assisting patient prognosis and immunotherapy. 14, ○
- 445 Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients. ○
- 444 Inflammation burden score in multidrug-resistant HIV-1 infection. **2023**, ○
- 443 Silencing LCN2 suppresses oral squamous cell carcinoma progression by reducing EGFR signal activation and recycling. **2023**, 42, ○
- 442 Identification of chemotherapy targets reveals a nucleus-to-mitochondria ROS sensing pathway. ○
- 441 Palmitic acid-induced ferroptosis via CD36 activates ER stress to break calcium-iron balance in colon cancer cells. ○
- 440 Multiplex single-cell chemical genomics reveals the kinase dependence of the response to targeted therapy. ○
- 439 Endothelial-to-mesenchymal transition in tumour progression and its potential roles in tumour therapy. **2023**, 55, 1058-1069 ○
- 438 Pretreatment red blood cell distribution width may be a potential biomarker of prognosis in urologic cancer: a systematic review and meta-analysis. **2022**, 16, 1289-1300 ○
- 437 The Influence of Ambient Temperature on Adipose Tissue Homeostasis, Metabolic Diseases and Cancers. **2023**, 12, 881 ○

- 436 Cancer hallmarks intersect with neuroscience in the tumor microenvironment. **2023**, 41, 573-580 ○
- 435 PML and PML-like exonucleases restrict retrotransposons in jawed vertebrates. ○
- 434 The Role of Genetic, Metabolic, Inflammatory, and Immunologic Mediators in the Progression of Intraductal Papillary Mucinous Neoplasms to Pancreatic Adenocarcinoma. **2023**, 15, 1722 ○
- 433 An Angiogenesis-Related lncRNA Signature Is Associated with Prognosis and Tumor Immune Microenvironment in Breast Cancer. **2023**, 13, 513 ○
- 432 The Chorioallantoic Membrane Xenograft Assay as a Reliable Model for Investigating the Biology of Breast Cancer. **2023**, 15, 1704 ○
- 431 The nature of cancer. ○
- 430 Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal Cancer. **2023**, 15, 1735 ○
- 429 Integrative Analyses Reveal the Anticancer Mechanisms and Sensitivity Markers of the Next-Generation Hypomethylating Agent NTX-301. **2023**, 15, 1737 ○
- 428 Constructing and validating a novel nomogram based on nutritional biomarkers to predict prognosis postresection intrahepatic cholangiocarcinoma cases. ○
- 427 Human Cytomegalovirus Protein Expression Is Correlated with Shorter Overall Survival in Breast Cancer Patients: A Cohort Study. **2023**, 15, 732 ○
- 426 Automated immunohistochemical quantification of hypoxia biomarkers shows correlation with dysplastic epithelial changes. ○
- 425 Evaluation of entropy and fractal dimension as biomarkers for tumor growth and treatment response using cellular automata. **2023**, 564, 111462 ○
- 424 Editorial: Regulatory networks in genome stability pathways. 14, ○
- 423 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor-on-a-Chip. ○
- 422 An In Vitro Pilot Study Investigating the Antineoplastic Effects of GP-2250 on Cutaneous Squamous Cell Carcinoma Cell Lines: Preliminary Results. **2023**, 3, 85-96 ○
- 421 How Does Dietary Intake Relate to Dispositional Optimism and Health-Related Quality of Life in Germline BRCA1/2 Mutation Carriers?. **2023**, 15, 1396 ○
- 420 The New Dimension of the Renin-Angiotensin System in the Hallmarks of Cancer. **2023**, 395-413 ○
- 419 Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy. 13, ○

- 418 Recent Progress in Fluorescent Probes for Real-Time Monitoring of Glioblastoma. ○
- 417 Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes. 14, ○
- 416 Polarity and mixed-mode oscillations may underlie different patterns of cellular migration. **2023**, 13, ○
- 415 Multi-range ERK responses shape the proliferative trajectory of single cells following oncogene induction. **2023**, 42, 112252 ○
- 414 A nomogram based on platelet-to-lymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy. **2023**, 23, ○
- 413 The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. **2023**, 1-32 ○
- 412 Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma. **2023**, 24, 5493 ○
- 411 Free Fatty Acids from Cow Urine DMSO Fraction Induce Cell Death in Breast Cancer Cells without Affecting Normal GMSCs. **2023**, 11, 889 ○
- 410 Association between altered metabolism and genetic mutations in human glioma. ○
- 409 Aspartate β -Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer. **2023**, 24, 5482 ○
- 408 Diagnostic and Prognostic values of systemic inflammatory markers in colorectal cancer. ○
- 407 Machine Learning of Multi-Modal Tumor Imaging Reveals Trajectories of Response to Precision Treatment. **2023**, 15, 1751 ○
- 406 Emerging roles of Aurora-A kinase in cancer therapy resistance. **2023**, ○
- 405 Association of Glycosylation-Related Genes with Different Patterns of Immune Profiles and Prognosis in Cervical Cancer. **2023**, 13, 529 ○
- 404 The Role of Exosomes in Pancreatic Ductal Adenocarcinoma Progression and Their Potential as Biomarkers. **2023**, 15, 1776 ○
- 403 Inflammasomes driven inflammation in lung cancer revisited: a short review. 70-81 ○
- 402 Orpinolide disrupts a leukemic dependency on cholesterol transport by inhibiting the oxysterol-binding protein OSBP. ○
- 401 Telomere Length Changes in Cancer: Insights on Carcinogenesis and Potential for Non-Invasive Diagnostic Strategies. **2023**, 14, 715 ○

- 400 Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy. **2023**, 9, ○
- 399 Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA. ○
- 398 Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with 177 Lu-PSMA-617. A single-center prospective observational study. **2023**, 83, 792-800 ○
- 397 Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region. 13, ○
- 396 Development and validation of machine learning models for predicting prognosis and guiding individualized postoperative chemotherapy: A real-world study of distal cholangiocarcinoma. 13, ○
- 395 SOLID LIPID NANOPARTICLES: A REVIEW ON DIFFERENT TECHNIQUES AND APPROACHES TO TREAT BREAST CANCER. 52-62 ○
- 394 The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients. **2023**, 23, ○
- 393 Low-temperature plasma as magic wand to differentiate between the good and the evil. **2023**, 57, 38-46 ○
- 392 The role of RNA methyltransferase METTL3 in gynecologic cancers: Results and mechanisms. 14, 1
- 391 Exploration of genotype-by-environment interactions affecting gene expression responses in porcine immune cells. 14, ○
- 390 Association of serum metabolome profile with the risk of breast cancer in participants of the HUNT2 study. 13, ○
- 389 Challenges and Opportunities in Antimicrobial Stewardship among Hematopoietic Stem Cell Transplant and Oncology Patients. **2023**, 12, 592 ○
- 388 A synthetic tumour microenvironment. **2023**, 22, 412-413 ○
- 387 The Heparan Sulfate Proteoglycan Syndecan-1 Triggers Breast Cancer Cell-Induced Coagulability by Induced Expression of Tissue Factor. **2023**, 12, 910 ○
- 386 Editorial: Metabolism-based omics integrations, biosensors, and molecular mechanisms in human cancers. 13, ○
- 385 Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma. **2023**, 15, 1794 ○
- 384 NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer. **2023**, 15, 1792 ○
- 383 Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. ○

- 382 Quinolate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPAR β signaling axis. **2023**, 14,
- 381 The Prognostic Significance of FOXD1 Expression in Head and Neck Squamous Cell Carcinoma. **2023**, 13, 530
- 380 The Role of Ferroptosis in Placental-Related Diseases.
- 379 Overexpression of the telomerase holoenzyme induces EMT and tumorigenesis of HPV-immortalized keratinocytes. **2023**, 95,
- 378 Counteracting Colon Cancer by Inhibiting Mitochondrial Respiration and Glycolysis with a Selective PKC δ Activator. **2023**, 24, 5710
- 377 A comprehensive overview of exosome lncRNAs: Emerging biomarkers and potential therapeutics in gynecological cancers. 13,
- 376 Design, Molecular Modelling and Synthesis of Novel Benzothiazole Derivatives as BCL-2 inhibitors.
- 375 Rectum adenocarcinoma metabolic subtypes analysis and a risk prognostic model construction based on fatty acid metabolism genes. **2023**, 102, e33186
- 374 Development of stimuli responsive polymeric nanomedicines modulating tumor microenvironment for improved cancer therapy. **2023**, 3, 4-30
- 373 Therapeutic efficacy of caffeic acid phenethyl ester in cancer therapy: An updated review.
- 372 PLGA-based nanoparticles for enhanced diagnosis and cancer therapy. **2023**, 179-210
- 371 Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing. **2023**, 16, 451
- 370 Recent advances in the role of endogenous hydrogen sulphide in cancer cells.
- 369 Self-adaptive hydrogel for breast cancer therapy via accurate tumor elimination and on-demand adipose tissue regeneration. **2023**, 108343
- 368 Analysis of systemic inflammatory and coagulation biomarkers in advanced cervical cancer: Prognostic and predictive significance. 039361552311635
- 367 Involvement of inflammasomes in tumor microenvironment and tumor therapies. **2023**, 16,
- 366 Identification of immune related molecular subtypes and prognosis model for predicting prognosis, drug resistance in cervical squamous cell carcinoma. 14,
- 365 Neutrophil to lymphocyte ratio can predict overall survival in patients with stage II to III colorectal cancer. **2023**, 102, e33279

- 364 A protein hydroxylase couples epithelial membrane biology to nucleolar ribosome biogenesis. ○
- 363 Targeting TLK2 inhibits the progression of gastric cancer by reprogramming amino acid metabolism through mTOR/ASNS axis. ○
- 362 Secreted protease PRSS35 suppresses hepatocellular carcinoma by disabling CXCL2-mediated neutrophil extracellular traps. **2023**, 14, ○
- 361 The roles of ATP-binding cassette transporter A1 and its substrate cholesterol in head and neck cancers. ○
- 360 THE RIBOREGULATION MECHANISM OF HUMAN SERINE HYDROXYMETHYLTRANSFERASE IS ROOTED IN AN ALLOSTERIC SWITCH. ○
- 359 m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis. **2023**, 83, 1165-1179.e11 ○
- 358 Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests. **2023**, 12, 935 1
- 357 Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer. **2023**, 12, 926 ○
- 356 IDriveGenes: Cancer Driver Genes Prediction Using Machine Learning. **2023**, 11, 28439-28453 ○
- 355 Fate-mapping lymphocyte clones and their progenies from induced antigen-signals identifies temporospatial behaviours of T cells mediating tolerance. ○
- 354 Identification of immunotherapy and chemotherapy-related molecular subtypes in colon cancer by integrated multi-omics data analysis. 14, ○
- 353 Propagated Circulating Tumor Cells Uncover the Potential Role of NF κ B, EMT, and TGF β Signaling Pathways and COP1 in Metastasis. **2023**, 15, 1831 ○
- 352 ????? ? ? ???? ???? ? ????? ? ? ? ? ??. **2023**, 39, 53-64 ○
- 351 The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. 14, ○
- 350 Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer. 14, ○
- 349 Identifying ITGB2 as a Potential Prognostic Biomarker in Ovarian Cancer. **2023**, 13, 1169 ○
- 348 Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells. **2023**, 15, 987 ○
- 347 Mutational processes of tobacco smoking and APOBEC activity generate protein-truncating mutations in cancer genomes. ○

- 346 Therapy drives genomic evolution in metastatic cancer. **2023**, 14, 216-218 ○
- 345 Subcellular Epithelial HMGB1 Expression Is Associated with Colorectal Neoplastic Progression, Male Sex, Mismatch Repair Protein Expression, Lymph Node Positivity, and an "Immune Cold" Phenotype Associated with Poor Survival. **2023**, 15, 1865 ○
- 344 A phase-field model for non-small cell lung cancer under the effects of immunotherapy. ○
- 343 Phthalides Isolated from the Endolichenic *Arthrinium* sp. EL000127 Exhibits Antiangiogenic Activity. **2023**, 8, 12548-12557 ○
- 342 Integration of multi-omics data reveals a novel hybrid breast cancer subtype and its biomarkers. 13, ○
- 341 Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. **2023**, 16, ○
- 340 Integrative Data Mining Pipeline for Identification of a Protein- Based Prognostic Signature in Lung Squamous Cell Carcinoma. ○
- 339 Ironing out fasting-induced persister cancer cells to render chemotherapy effective: is this the solution?. **2023**, 90, 104542 ○
- 338 Editorial: Profiling the tumour microenvironment to unveil biomarkers and develop novel therapeutics for cancer therapy. 10, ○
- 337 Tumour microenvironment in pheochromocytoma and paraganglioma. 14, ○
- 336 Magnetic microrheometry of tumor-relevant stiffness levels and probabilistic quantification of viscoelasticity differences inside 3D cell culture matrices. **2023**, 18, e0282511 ○
- 335 Bayesian kinetic modeling for tracer-based metabolomic data. **2023**, 24, ○
- 334 Data-driven spatio-temporal modelling of glioblastoma. **2023**, 10, ○
- 333 To metabolomics and beyond: a technological portfolio to investigate cancer metabolism. **2023**, 8, ○
- 332 Isolation of Oral Bacteria, Measurement of the C-Reactive Protein, and Blood Clinical Parameters in Dogs with Oral Tumor. **2023**, 2023, 1-18 ○
- 331 ABCB1 and ABCC1 Function during TGF- β -Induced Epithelial-Mesenchymal Transition: Relationship between Multidrug Resistance and Tumor Progression. **2023**, 24, 6046 ○
- 330 Oncogenic signaling pathways in pancreatic ductal adenocarcinoma. **2023**, ○
- 329 Senescent Stromal Cells in the Tumor Microenvironment: Victims or Accomplices?. **2023**, 15, 1927 ○

- 328 Current Applications of Liquid Biopsy in Gastrointestinal Cancer Disease From Early Cancer Detection to Individualized Cancer Treatment. **2023**, 15, 1924 ○
- 327 Downregulation of BUD31 Promotes Prostate Cancer Cell Proliferation and Migration via Activation of p-AKT and Vimentin In Vitro. **2023**, 24, 6055 ○
- 326 A New Frontier of Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. **2023**, 13, 4382-4388 ○
- 325 Phytochemical-based nanodrugs going beyond the state-of-the-art in cancer management Targeting cancer stem cells in the framework of predictive, preventive, personalized medicine. 14, ○
- 324 Is Systemic Inflammatory Response Index (SIRI) a Reliable Tool for Prognosis of Gastric Cancer Patients Without Neoadjuvant Therapy?. **2023**, ○
- 323 Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19. 14, ○
- 322 Amino acids in hematologic malignancies: Current status and future perspective. 10, ○
- 321 Mechanisms and shapes of causal exposure-response functions for asbestos in mesotheliomas and lung cancers. **2023**, 115607 ○
- 320 DHMMF, a natural flavonoid from Resina Draconis, inhibits hepatocellular carcinoma progression via inducing apoptosis and G2/M phase arrest mediated by DNA damage-driven upregulation of p21. **2023**, 211, 115518 ○
- 319 Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer. **2023**, 26, 106484 ○
- 318 Principles of phosphoproteomics and applications in cancer research. **2023**, 480, 403-420 ○
- 317 Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines. **2023**, 37, ○
- 316 Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer. **2023**, 15, 1936 ○
- 315 Metabolomic Signatures of Scarff-Bloom-Richardson (SBR) Grade in Non-Metastatic Breast Cancer. **2023**, 15, 1941 ○
- 314 Latent transcriptional programs reveal histology-encoded tumor features spanning tissue origins. ○
- 313 Breast cancer cell growth arrest and chemopreventive effects of Passiflora edulis Sims (Passifloraceae) ethanolic leaves extract on a rat model of mammary carcinoma. **2023**, 311, 116408 ○
- 312 Mitochondrial transfer in PC-3 cells fingerprinted in ferroptosis sensitivity: a brand new approach targeting cancer metabolism. ○
- 311 Multiagent Intratumoral Immunotherapy Can Be Effective in A20 Lymphoma Clearance and Generation of Systemic T Cell Immunity. **2023**, 15, 1951 ○

- 310 Microparticle Phosphatidylserine Mediates Coagulation: Involvement in Tumor Progression and Metastasis. **2023**, 15, 1957 ○
- 309 Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming. **2023**, 15, 1935 ○
- 308 Shell-Core Bilayer Nanoparticle as Chemotherapeutic Drug Co-Delivery Platforms Render Synchronized Microenvironment Respond and Enhanced Antitumor Effects. Volume 18, 1521-1536 ○
- 307 Chronic Exposure to TDI Induces Cell Migration and Invasion via TGF- β 1 Signal Transduction. **2023**, 24, 6157 ○
- 306 An Immune-Related Gene Signature for Determining Tumor Prognosis Based on Machine Learning. **2023**, 1-18 ○
- 305 The Liver and Glycogen: In Sickness and in Health. **2023**, 24, 6133 ○
- 304 Profiling of immune responses by lactate modulation in cervical cancer reveals key features driving clinical outcome. **2023**, 9, e14896 ○
- 303 Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. **2023**, 22, ○
- 302 Human Microbiome Modulation: A Potential Therapeutic Strategy for Pancreatic Cancer. **2023**, 205-242 ○
- 301 Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-faceted relationship. **2023**, 22, ○
- 300 A comprehensive analysis of PANoptosome to prognosis and immunotherapy response in pan-cancer. **2023**, 13, ○
- 299 Prognostic impact of desmoplastic reaction in esophageal squamous cell carcinoma patients with neoadjuvant therapy. ○
- 298 Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies. **2023**, 12, ○
- 297 Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer. ○
- 296 The Voltage-Gated Hv1 H⁺ Channel Is Expressed in Tumor-Infiltrating Myeloid-Derived Suppressor Cells. **2023**, 24, 6216 ○
- 295 Computational Biology Helps Understand How Polyploid Giant Cancer Cells Drive Tumor Success. **2023**, 14, 801 ○
- 294 Insights into radiation carcinogenesis based on dose-rate effects in tissue stem cells. 1-19 ○
- 293 Current Understanding of Flavonoids in Cancer Therapy and Prevention. **2023**, 13, 481 ○

- 292 Evaluation of the Expression Levels of miR-21-5p and miR-429 Genes in Biopsy Samples from Patients with Oral Squamous Cell Carcinoma. **2023**, 13, 1244 ○
- 291 The role of the SNF1 signaling pathway in the growth of *Saccharomyces cerevisiae* in different carbon and nitrogen sources. ○
- 290 Changes in the Proteome Profile of A549 Cells Following Helichrysetin-Induced Apoptosis Suggest the Involvement of DNA Damage Response and Cell Cycle Arrest-Associated Proteins. ○
- 289 Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation. 14, ○
- 288 Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma. 14, ○
- 287 Antioxidant and chemotherapeutic efficacies of seaweed-derived phlorotannins in cancer treatment: A review regarding novel anticancer drugs. ○
- 286 Association between Posttreatment Serum Platelet-to-Lymphocyte Ratio and Distant Metastases in Patients with Hepatocellular Carcinoma Receiving Curative Radiation Therapy. **2023**, 15, 1978 ○
- 285 An actin filament branching surveillance system regulates cell cycle progression, cytokinesis and primary ciliogenesis. **2023**, 14, ○
- 284 Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis. **2023**, 14, ○
- 283 Galectin-9 in Gastroenterological Cancer. **2023**, 24, 6174 ○
- 282 Cellular senescence-driven transcriptional reprogramming of the MAFB/NOTCH3 axis activates the PI3K/AKT pathway and promotes osteosarcoma progression. **2023**, ○
- 281 p53 isoform expression promotes a stemness phenotype and inhibits doxorubicin sensitivity in breast cancer. ○
- 280 Emerging role of substance and energy metabolism associated with neuroendocrine regulation in tumor cells. 14, ○
- 279 Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model. **2023**, 24, 6196 ○
- 278 Exploration of the Shared Gene Signatures and Molecular Mechanisms Between Breast Cancer and Endometriosis. ○
- 277 The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma. **2023**, 15, 857 ○
- 276 A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence. **2023**, 30, ○
- 275 Systematic pan-cancer analysis identifies transmembrane protein 158 as a potential therapeutic, prognostic and immunological biomarker. **2023**, 23, ○

- 274 Long noncoding RNA SNHG15: A promising target in human cancers. 13, ○
- 273 The p52-ZER6/G6PD axis alters aerobic glycolysis and promotes tumor progression by activating the pentose phosphate pathway. **2023**, 12, ○
- 272 Identification of calcium metabolism related score associated with the poor outcome in papillary thyroid carcinoma. 13, ○
- 271 The involvement of Aurora-A and p53 in oxaliplatin-resistant colon cancer cells. **2023**, 124, 619-632 ○
- 270 Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma. 13, ○
- 269 The ratio of intratumoral CD15+ neutrophils to CD8+ lymphocytes predicts recurrence in gastric cancer patients after resection. ○
- 268 Dual Nanozyme-Driven PtSn Bimetallic Nanoclusters for Metal-Enhanced Tumor Photothermal and Catalytic Therapy. **2023**, 17, 6833-6848 ○
- 267 CAR T Cell Therapy: A Versatile Living Drug. **2023**, 24, 6300 ○
- 266 CDK4/6 Inhibition Induces Senescence and Enhances Radiation Response by Disabling DNA Damage Repair in Oral Cavity Squamous Cell Carcinoma. **2023**, 15, 2005 ○
- 265 Roles of cancer stem cells in cancer immune surveillance. **2023**, 35, ○
- 264 Computational Approaches for Identification of Potential Plant Bioactives as Novel G6PD Inhibitors Using Advanced Tools and Databases. **2023**, 28, 3018 ○
- 263 Transgelin promotes lung cancer progression via activation of cancer-associated fibroblasts with enhanced IL-6 release. **2023**, 12, ○
- 262 High-throughput mechano-cytometry as a method to detect apoptosis, necroptosis, and ferroptosis. ○
- 261 Concurrent treatment of flavonol with chemotherapeutics potentiates or counteracts the therapeutic implications in cervical cancer cells. **2023**, 35, ○
- 260 Breast density and estradiol are associated with distinct different expression patterns of metabolic proteins in normal human breast tissue in vivo. 13, ○
- 259 Minimal Morphoelastic Models of Solid Tumour Spheroids: A Tutorial. **2023**, 85, ○
- 258 A SPONTANEOUS MELANOMA MOUSE MODEL APPLICABLE FOR A LONGITUDINAL CHEMOTHERAPY AND IMMUNOTHERAPY STUDY. **2023**, ○
- 257 Technology, Science and Culture: A Global Vision, Volume IV. ○

- 256 Highly Sensitive Imaging of Tumor Metastasis Based on the Targeting and Polarization of M2-like Macrophages. **2023**, 145, 7941-7951 ○
- 255 Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial. **2023**, 15, 2030 ○
- 254 A novel lysosome-related gene signature coupled with gleason score for prognosis prediction in prostate cancer. 14, ○
- 253 Hyperextended telomeres promote formation of C-circle DNA in telomerase positive human cells. **2023**, 104665 ○
- 252 Maackiain inhibits proliferation and promotes apoptosis of nasopharyngeal carcinoma cells by inhibiting the MAPK/Ras signaling pathway. **2023**, 21, 185-196 ○
- 251 Prognostic and clinicopathological role of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: A meta-analysis. 13, ○
- 250 Mesenchymal Stem/Stromal Cells Derived from Cervical Cancer Promote M2 Macrophage Polarization. **2023**, 12, 1047 ○
- 249 Mitochondrial H₂O₂ release does not directly cause genomic DNA damage. ○
- 248 Prognostic value of miR-219-5p in relation to mortality in patients with small cell lung cancer: a retrospective, observational cohort study in China. **2023**, 13, e064700 ○
- 247 Assessment of the Anticancer Effect of Chlorojanerin Isolated from *Centaurothamnus maximus* on A549 Lung Cancer Cells. **2023**, 28, 3061 ○
- 246 The role of LOXL2 induced by glucose metabolism-activated NF- κ B in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC. ○
- 245 Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. **2023**, 15, 2049 ○
- 244 A Computational Approach to Predict the Role of Genetic Alterations in Methyltransferase Histones Genes With Implications in Liver Cancer. **2023**, 22, 117693512311614 ○
- 243 Integration analysis based on fatty acid metabolism robustly predicts prognosis, dissecting immunity microenvironment and aiding immunotherapy for soft tissue sarcoma. 14, ○
- 242 Untargeted Metabolomic Characterization of Glioblastoma Intra-Tumor Heterogeneity Using OrbiSIMS. **2023**, 95, 5994-6001 ○
- 241 Linking dysbiosis to precancerous stomach through inflammation: Deeper than and beyond imaging. 14, ○
- 240 Construction and validation of a metabolic-associated lncRNA risk index for predicting colorectal cancer prognosis. 13, ○
- 239 Effect of doxorubicin on viability and Bax, Bcl-2, p53, Nanog, Sox-2, Oct-4 gene expressions in MCF-7 stem-like cells. ○

- 238 Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Carcinomatosis: Additional Information Helps to Optimize Patient Selection before Surgery. **2023**, 15, 2089 ○
- 237 Functional consequences of A-to-I editing of miR-379 in prostate cancer cells. ○
- 236 Identification and characterization of novel ETV4 splice variants in prostate cancer. **2023**, 13, ○
- 235 Determining the mechanism of action of the Qishan formula against lung adenocarcinoma by integration of network pharmacology, molecular docking, and proteomics. **2023**, 102, e33384 ○
- 234 Ethyl Acetate Extract of *Halymenia durvillei* Induced Apoptosis, Autophagy, and Cell Cycle Arrest in Colorectal Cancer Cells. **2023**, 28, 69-78 ○
- 233 Oncogene-mediated nuclear accumulation of lactate promotes epigenetic alterations to induce cancer cell proliferation. **2023**, 124, 495-519 ○
- 232 Pan-Cancer Analysis of the COVID-19 Causal Gene SLC6A20. **2023**, 8, 13153-13161 ○
- 231 Mutual induced-fit mechanism drives binding between intrinsically disordered Bim and cryptic binding site of Bcl-xL. **2023**, 6, ○
- 230 Metabolically Active Zones Involving Fatty Acid Elongation Delineated by DESI-MSI Correlate with Pathological and Prognostic Features of Colorectal Cancer. **2023**, 13, 508 ○
- 229 Metabolic reprogramming provides a novel approach to overcome resistance to BH3-mimetics in Malignant Pleural Mesothelioma. ○
- 228 Comprehensive analysis of glycolysis mediated pattern clusters and immune infiltration characterization of tumor microenvironment in triple-negative breast cancer. **2023**, 9, e15175 ○
- 227 A novel inflammation-related signature for predicting prognosis and characterizing the tumor microenvironment in colorectal cancer. **2023**, 15, 2554-2581 1
- 226 A mixed-valence biotinylated Cu(i/ii) complex for tumor-targeted chemodynamic therapy accompanied by GSH depletion. ○
- 225 Utilizing metabolite connectivity and G-CNN to detect gallbladder cancer. **2023**, ○
- 224 A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma. ○
- 223 LncRNA CCAT1 facilitates the progress of gastric cancer via the PTBP1/glycolysis axis. ○
- 222 Contribution of EpsteinBarr Virus Lytic Proteins to Cancer Hallmarks and Implications from Other Oncoviruses. **2023**, 15, 2120 ○
- 221 A new glance at autophagolysosomal-dependent or -independent function of transcriptional factor EB in human cancer. ○

- 220 Multicomponent Reaction-Assisted Drug Discovery: A Time- and Cost-Effective Green Approach Speeding Up Identification and Optimization of Anticancer Drugs. **2023**, 24, 6581 ○
- 219 Targeting multifunctional magnetic nanowires for drug delivery in cancer cell death: an emerging paradigm. ○
- 218 PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation. **2023**, 14, ○
- 217 Use of honokiol in lung cancer therapy: a mini review of its pharmacological mechanism. 1-9 ○
- 216 Integrative bioinformatics approaches to establish potential prognostic immune-related genes signature and drugs in the non-small cell lung cancer microenvironment. 14, ○
- 215 NMR-Metabolomics Reveals a Metabolic Shift after Surgical Resection of Non-Small Cell Lung Cancer. **2023**, 15, 2127 ○
- 214 A genomic instability-associated lncRNA signature for predicting prognosis and biomarkers in lung adenocarcinoma. ○
- 213 Neurodevelopmental disorders, like cancer, are connected to impaired chromatin remodelers, PI3K/mTOR, and PAK1-regulated MAPK. ○
- 212 Phase separation in cancer at a glance. **2023**, 21, ○
- 211 Tumor microenvironment signaling and therapeutics in cancer progression. ○
- 210 Anticancer activity of *Acmella uliginosa* against WiDr colon cancer cell line and T47D breast cancer cell line. **2023**, 640-644 ○
- 209 Immune Landscape of Pheochromocytoma and Paraganglioma: A Potentially Novel Avenue for Prognostic Reclassification?. ○
- 208 CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS. ○
- 207 Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017 Present). **2023**, 16, 534 ○
- 206 RAS-induced transformation of mammary epithelial cells relies on ZEB1-dependent cellular reprogramming via a paracrine process. ○
- 205 Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers. **2023**, 19, ○
- 204 Multiple Actions of Telomerase Reverse Transcriptase in Cell Death Regulation. **2023**, 11, 1091 ○
- 203 Integrated gene network analysis sheds light on understanding the progression of Osteosarcoma. 10, ○

- 202 Dissecting the roles and clinical potential of YY1 in the tumor microenvironment. 13, ○
- 201 Human papillomavirus and Epstein-Barr virus co-infection in oral and oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis. ○
- 200 Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept. **2023**, 59, ○
- 199 FYN/TOPK/HSPB1 axis facilitates the proliferation and metastasis of gastric cancer. **2023**, 42, ○
- 198 The nonlinearity of regulation in biological networks. **2023**, 9, ○
- 197 Exportin XPO7 acts as an oncogenic factor in prostate cancer via upregulation of TCF3. ○
- 196 Small extracellular vesicles promote invadopodia activity in glioblastoma cells in a therapy-dependent manner. ○
- 195 Heavy Particles in Non-small Cell Lung Cancer: Carbon Ions. **2023**, ○
- 194 Ribosomal protein L32 enhances hepatocellular carcinoma progression. ○
- 193 Lipid Metabolic Reprogramming in Embryonal Neoplasms with MYCN Amplification. **2023**, 15, 2144 ○
- 192 Computational screening and structural analysis of Gly201Arg and Gly201Asp missense mutations in human cyclin-dependent kinase 4 protein. **2023**, 57-96 ○
- 191 MicroRNA-29 regulates tumor progression and survival through miR-29a-SIRT1-Wnt/ β -catenin pathway in hepatocellular carcinoma. ○
- 190 Prognostic value of various immune cells and Immunoscore in triple-negative breast cancer. 14, ○
- 189 A novel molecular signature for predicting prognosis and immunotherapy response in osteosarcoma based on tumor-infiltrating cell marker genes. 14, ○
- 188 Pan-cancer analysis of super enhancer-induced PRR7-AS1 as a potential prognostic and immunological biomarker. 14, ○
- 187 DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. ○
- 186 Genomic instability and eye diseases. **2023**, ○
- 185 Identification of the cell cycle characteristics of non-small cell lung cancer and its relationship with tumor immune microenvironment, cell death pathways, and metabolic reprogramming. 14, ○

- 184 Systematic integration of protein-affecting mutations, gene fusions, and copy number alterations into a comprehensive somatic mutational profile. **2023**, 100442 ○
- 183 Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer. ○
- 182 Human Papilloma Virus: An Unraveled Enigma of Universal Burden of Malignancies. **2023**, 12, 564 ○
- 181 Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis. **2023**, ○
- 180 Tumours and Tumour-Like Lesions. **2024**, 842-946 ○
- 179 Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report. 13, ○
- 178 Polypharmacy stewardship: a novel approach to tackle a major public health crisis. **2023**, ○
- 177 Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. 14, ○
- 176 Proline Maintains the Proliferation of Hepatocellular Carcinoma Cells by Decreasing Intracellular Oxidative Stress and Reducing Autophagy During Acute Nutrient Stress. ○
- 175 Identification of MYB gene family and functional analysis of GhMYB4 in cotton (*Gossypium* spp.). ○
- 174 Evaluation of the Effect of Fibroblasts on Melanoma Metastasis Using a Biomimetic Co-Culture Model. ○
- 173 A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes. ○
- 172 Epstein-Barr virus regulates the life cycle and host cell biology by hijacking post-translational modification. ○
- 171 Molecular/Nanomechanical Insights into Electrostimulation-Inhibited Energy Metabolism Mechanisms and Cytoskeleton Damage of Cancer Cells. ○
- 170 RNA-binding proteins in cancer drug discovery. **2023**, 28, 103580 ○
- 169 PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration. **2023**, 14, ○
- 168 Apoptosis. ○
- 167 LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and radioiodine resistance in papillary thyroid cancer. ○

- 166 A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients. ○
- 165 Platinum Engineering on Nanoceria Surface toward High Catalytic Activity for Inducing Tumor Cell Apoptosis and Inhibiting Migration. ○
- 164 Synergistic Target of Intratumoral Microbiome and Tumor by MetronidazoleFluorouridine Nanoparticles. ○
- 163 Regulation of Autophagy via Carbohydrate and Lipid Metabolism in Cancer. **2023**, 15, 2195 ○
- 162 Turning Cold into Hot: New Insights in Cancer Immunotherapy. **2022**, 1-13 ○
- 161 Tumor-Infiltrating CD45RO+ Memory Cells Are Associated with Favorable Prognosis in Oral Squamous Cell Carcinoma Patients. **2023**, 15, 2221 ○
- 160 Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. **2023**, 11, 1073 ○
- 159 Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma. **2023**, 21, ○
- 158 Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy. **2023**, 11, 1130 ○
- 157 Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment Studies. **2023**, 11, 1133 ○
- 156 The RUNX Family of Proteins, DNA Repair, and Cancer. **2023**, 12, 1106 ○
- 155 Hesperetin and Capecitabine Abate 1,2 Dimethylhydrazine-Induced Colon Carcinogenesis in Wistar Rats via Suppressing Oxidative Stress and Enhancing Antioxidant, Anti-Inflammatory and Apoptotic Actions. **2023**, 13, 984 ○
- 154 Rewiring of RNA methylation by the oncometabolite fumarate in renal cell carcinoma. ○
- 153 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 152 On the Role of Glycolysis in Early TumorigenesisPermissive and Executioner Effects. **2023**, 12, 1124 ○
- 151 Gallstones, Cholecystectomy, and Kidney Cancer: Observational and Mendelian Randomization Results Based on Large Cohorts. **2023**, ○
- 150 Hallmarks of an Aging and Malignant Tumor Microenvironment and the Rise of Resilient Cell Subpopulations. **2023**, 113-137 ○
- 149 Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials. ○

- 148 Physical Regulations of Cell Interactions and Metabolism in Tumor Microenvironments. **2023**, 139-157 ○
- 147 Development of Amino Acid Metabolism-Related Prognostic Model and Immune Infiltration Analysis in Patients with Stomach Adenocarcinoma. ○
- 146 A Comprehensive Pan-Cancer Analysis of the Regulation and Prognostic Effect of Coat Complex Subunit Zeta 1. **2023**, 14, 889 ○
- 145 AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. **2023**, 109669 ○
- 144 Microfluidics and Cancer Treatment: Emerging Concept of Biomedical Engineering. **2023**, 523-562 ○
- 143 Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures. 13, ○
- 142 The RNA binding proteins LARP4A and LARP4B promote sarcoma and carcinoma growth and metastasis. ○
- 141 Structure based High-Throughput Virtual Screening, Molecular Docking and Molecular Dynamics Study of anticancer natural compounds against fimbriae (FimA) protein of *Porphyromonas gingivalis* in oral squamous cell carcinoma. ○
- 140 Aurora B Inhibitors as Cancer Therapeutics. **2023**, 28, 3385 ○
- 139 BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair. ○
- 138 Essential oil of lemon myrtle (*Backhousia citriodora*) induces S-phase cell cycle arrest and apoptosis in HepG2 cells. **2023**, 312, 116493 ○
- 137 The RNA interactome in the Hallmarks of Cancer. ○
- 136 Application of Artificial Intelligence in the Diagnosis, Treatment, and Prognostic Evaluation of Mediastinal Malignant Tumors. **2023**, 12, 2818 ○
- 135 Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictive markers in hepatoblastoma. 11, ○
- 134 Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis. **2023**, 24, 7076 ○
- 133 Application of Mendelian randomization to explore the causal role of the human gut microbiome in colorectal cancer. **2023**, 13, ○
- 132 HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia. **2023**, ○
- 131 Proteomics mining of cancer hallmarks on a single-cell resolution. ○

- 130 Humanin activates integrin α -TGF β axis and leads to glioblastoma progression. ○
- 129 Metabolic dependencies and targets in ovarian cancer. **2023**, 245, 108413 ○
- 128 DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis. ○
- 127 Functions of N6-methyladenosine in cancer metabolism: from mechanism to targeted therapy. **2023**, 11, ○
- 126 Hypoxia and the Metastatic Cascade. **2023**, 181-216 ○
- 125 The role of ETFS amino acids on the stability and inhibition of p53-MDM2 complex of anticancer p53-derivatives peptides: Density functional theory and molecular docking studies. **2023**, 122, 108472 ○
- 124 The Role of BTBD7 in Normal Development and Tumor Progression. **2023**, 22, 153303382311677 ○
- 123 OBHS Drives Abnormal Glycometabolis Reprogramming via GLUT1 in Breast Cancer. **2023**, 24, 7136 ○
- 122 Fibroblasts in cancer: Unity in heterogeneity. **2023**, 186, 1580-1609 ○
- 121 Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation. **2023**, 24, 7180 ○
- 120 The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives. **2023**, 28, 3407 ○
- 119 Cancer heterogeneity is defined by normal cellular trade-offs. ○
- 118 Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy. **2023**, 11, 1166 ○
- 117 Hypoxic Tumor Microenvironment: Driver for Cancer Progression. **2023**, 65-88 ○
- 116 Pomiferin targets SERCA, mTOR, and P-gp to induce autophagic cell death in apoptosis-resistant cancer cells, and reverses the MDR phenotype in cisplatin-resistant tumors in vivo. **2023**, 106769 ○
- 115 Multiple regulatory roles of the transfer RNA-derived small RNAs in cancers. **2023**, ○
- 114 MicroRNA Signatures of Tumor Hypoxia. **2023**, 139-159 ○
- 113 Hypoxia and Extracellular Matrix-Major Drivers of Tumor Metastasis. **2023**, 217-244 ○

- 112 Metastasis. **2023**, 186, 1564-1579 ○
- 111 Understanding HAT1: A Comprehensive Review of Noncanonical Roles and Connection with Disease. **2023**, 14, 915 ○
- 110 Lipocalin-2 as a biomarker for diabetic nephropathy. 11, 92-101 ○
- 109 Extracellular Vesicles in Chronic Lymphocytic Leukemia: Tumor Microenvironment Messengers as a Basis for New Targeted Therapies?. **2023**, 15, 2307 ○
- 108 An Overview of the Role of MicroRNAs on Carcinogenesis: A Focus on Cell Cycle, Angiogenesis and Metastasis. **2023**, 24, 7268 ○
- 107 DeepGene Transformer: Transformer for the gene expression-based classification of cancer subtypes. **2023**, 120047 ○
- 106 Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy. **2023**, 12, 1156 ○
- 105 Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non-small cell lung cancer. ○
- 104 Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer. ○
- 103 Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence. **2023**, 13, 560 ○
- 102 Scutebarbatine A induces ROS-mediated DNA damage and apoptosis in breast cancer cells by modulating MAPK and EGFR/Akt signaling pathway. **2023**, 378, 110487 ○
- 101 PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma. **2023**, 570, 111931 ○
- 100 Glycolytic Genes Predict Immune Status and Prognosis Non-Small-Cell Lung Cancer Patients with Radiotherapy and Chemotherapy. **2023**, 2023, 1-24 ○
- 99 TERT promoter mutations in head and neck squamous cell carcinoma: A systematic review and meta-analysis on prevalence and prognostic significance. **2023**, 140, 106398 ○
- 98 Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. **2023**, 14, ○
- 97 Potential mechanisms of osthole against bladder cancer cells based on network pharmacology, molecular docking, and experimental validation. **2023**, 23, ○
- 96 Effects of the interactions between platelets with other cells in tumor growth and progression. 14, ○
- 95 The RSK2-RPS6 axis promotes axonal regeneration in the peripheral and central nervous systems. **2023**, 21, e3002044 ○

- 94 Restoring Balance: A Physical Activity Intervention for Native American Cancer Survivors and Their Familial Support Persons. **2023**, 1, ○
- 93 Noncanonical Roles of RAD51. **2023**, 12, 1169 ○
- 92 Integrated bioinformatic analysis of mitochondrial metabolism-related genes in acute myeloid leukemia. 14, ○
- 91 Oncogenes, Signal Transduction and the Hallmarks of Cancer. **2023**, 423-433 ○
- 90 3D dynamic cultures of HGSOc organoids to model innovative and standard therapies. 11, ○
- 89 Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities. **2023**, 15, 2354 ○
- 88 Bibliometric analysis and mini-review of global research on pyroptosis in the field of cancer. ○
- 87 Comprehensive Interactome Mapping of the DNA Repair Scaffold SLX4 Using Proximity Labeling and Affinity Purification. ○
- 86 Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy. **2023**, ○
- 85 Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. ○
- 84 Agent-Based Model for Studying the Effects of Solid Stress and Nutrient Supply on Tumor Growth. **2023**, 11, 1900 ○
- 83 Structural and functional insight into a new emerging target IP3R in cancer. 1-27 ○
- 82 A functional genetic screen for metabolic proteins unveils GART and the de novo purine biosynthetic pathway as novel targets for the treatment of luminal A ER⁺ expressing primary and metastatic invasive ductal carcinoma. 14, ○
- 81 The metabolic cross-talk between cancer and T cells. **2023**, ○
- 80 Novel mRNA-based Immunological Biomarker for Early Detection of Resectable Pancreatic Cancer. ○
- 79 Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. **2023**, 11, e006267 ○
- 78 Crosstalk between Metabolite Production and Signaling Activity in Breast Cancer. **2023**, 24, 7450 ○
- 77 Implications of the Organ-Specific Immune Environment for Immune Priming Effect of Radiotherapy in Metastatic Setting. **2023**, 13, 689 ○

- 76 Lysosome directed red light photodynamic therapy using glycosylated iron(III) conjugates of boron-dipyrromethene. **2023**, 112226 ○
- 75 Integrating Multi-Omics Data to Construct Reliable Interconnected Models of Signaling, Gene Regulatory, and Metabolic Pathways. **2023**, 139-151 ○
- 74 PARP Inhibitors in Breast and Ovarian Cancer. **2023**, 15, 2357 ○
- 73 Pan-Cancer Study of the Prognostic Value of Selenium Phosphate Synthase 1. **2023**, 30, 107327482311704 ○
- 72 The Unique Spectrum of MUTYH Germline Mutations in Colombian Patients with Extracolonic Carcinomas. Volume 16, 53-62 ○
- 71 Research progress on the interaction between oxidative stress and platelets: Another avenue for cancer?. **2023**, 106777 ○
- 70 Role of ER-Mitochondria interface in the regulation of Glioma Stem Cells. ○
- 69 Common genetic variations in telomere length genes and lung cancer: a Mendelian randomisation study and its novel application in lung tumour transcriptome. 12, ○
- 68 LncRNA modulates Hippo-YAP signaling to reprogram iron metabolism. **2023**, 14, ○
- 67 Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future. **2023**, 103988 ○
- 66 Elevated Nuclear PHGDH Synergistically Functions with cMyc to Reshape the Immune Microenvironment of Liver Cancer. ○
- 65 Six-Transmembrane Epithelial Antigen of Prostate 4: An Indicator of Prognosis and Tumor Immunity in Hepatocellular Carcinoma. Volume 10, 643-658 ○
- 64 Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer. **2023**, ○
- 63 Basic Pathogenic Mechanisms and Epigenetic Players Promoted by Extracellular Vesicles in Vascular Damage. **2023**, 24, 7509 ○
- 62 The role of lipid metabolism in cancer radioresistance. ○
- 61 Identification and validation of a novel cuproptosis-related gene signature in multiple myeloma. 11, ○
- 60 Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach. ○
- 59 Role of voltage-gated proton channel (Hv1) in cancer biology. 14, ○

- 58 Cooperation between Prostaglandin E2 and Epidermal Growth Factor Receptor in Cancer Progression: A Dual Target for Cancer Therapy. **2023**, 15, 2374 ○
- 57 Role and research progress of hematological markers in laryngeal squamous cell carcinoma. **2023**, 18, ○
- 56 Massively recruited sTLR9+ neutrophils in rapidly formed nodules at the site of tumor cell inoculation and their contribution to a pro-tumor microenvironment. ○
- 55 Tumor Evolution Models of Phase-Field Type with Nonlocal Effects and Angiogenesis. **2023**, 85, ○
- 54 Ovarian Cancer and Parkinson Disease: A Bidirectional Mendelian Randomization Study. **2023**, 12, 2961 ○
- 53 A novel 25-ferroptosis-related gene signature for the prognosis of gliomas. 13, ○
- 52 The Enhanced Expression of ZWILCH Predicts Poor Survival of Adrenocortical Carcinoma Patients. **2023**, 11, 1233 ○
- 51 Machine Learning Predicts the Oxidative Stress Subtypes Provide an Innovative Insight into Colorectal Cancer. **2023**, 2023, 1-12 ○
- 50 Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis. 14, ○
- 49 Natural compound-based scaffold to design in vitro disease systems. **2023**, 373-389 ○
- 48 Inducible nitric oxide synthase 2 (NOS2) and antitumor T cells. **2023**, 151-172 ○
- 47 Repurposing cardiac glycosides as the hallmark of immunogenic modulators in cancer therapy. **2023**, 237-258 ○
- 46 m6A modification on the fate of colorectal cancer: functions and mechanisms of cell proliferation and tumorigenesis. 13, ○
- 45 Targeted blockade of interleukin-8 negates metastasis and chemoresistance via Akt/Erk-NF κ B axis in oral cancer. **2023**, 166, 156155 ○
- 44 BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia. ○
- 43 Telomerase deficiency and dysfunctional telomeres in the lung tumor microenvironment impair tumor progression in NSCLC mouse models and patient-derived xenografts. ○
- 42 Gut microbiome and cancer implications: Potential opportunities for fermented foods. **2023**, 188897 ○
- 41 MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer. **2023**, 24, 7608 ○

- 40 Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. **2023**, ○
- 39 Rottlerin and genistein inhibit neuroblastoma cell proliferation and invasion through EF2K suppression and related protein pathways. ○
- 38 Encapsulation for breast cancer treatment. **2023**, 661-720 ○
- 37 Potential prognostic and immunotherapeutic value of calponin 1: A pan-cancer analysis. 14, ○
- 36 Runt-related transcription factors in human carcinogenesis: a friend or foe?. ○
- 35 Drug targeting PIWI like protein-piRNA complex, a novel paradigm in the therapeutic framework of retinoblastoma. **2023**, 329-386 ○
- 34 The Potential of DHA as Cancer Therapy Strategies: A Narrative Review of In Vitro Cytotoxicity Trials. **2023**, 15, 2006 ○
- 33 Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia. **2023**, 11, ○
- 32 Cell-free RNA for the liquid biopsy of gastrointestinal cancer. ○
- 31 Analysis of differential gene immune infiltration and clinical characteristics of skin cutaneous melanoma based on systems biology and drug repositioning methods to identify drug candidates for skin cutaneous melanoma. ○
- 30 Colorectal mucinous adenocarcinoma indicates a meaningful subtype: A whole genome sequencing study. **2023**, 13, ○
- 29 In Vitro Approaches to Determine the Potential Carcinogenic Risk of Environmental Pollutants. **2023**, 24, 7851 ○
- 28 The Warburg effect: a signature of mitochondrial overload. **2023**, ○
- 27 Quantum evaluation and therapeutic activity of (E)-N-(4-methoxyphenyl)-2-(4-(3-oxo-3-phenylprop-1-en-1-yl) phenoxy)acetamide and its modified derivatives against EGFR and VEGFR-2 in the treatment of triple-negative cancer via in silico approach. **2023**, 23, ○
- 26 NEIL3 promotes the proliferation of ccRCC via the cyclin D1-Rb-E2F1 feedback loop regulation. ○
- 25 Role of heat shock proteins in oncogenesis and strategy for treating cancers using Drosophila model. ○
- 24 The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy. 14, ○
- 23 Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment. **2023**, 1-34 ○

- 22 Preoperative Ernährungsmangement in der großen Tumorchirurgie des Bauchraumes an deutschen Kliniken. Eine explorative Strukturanalyse. **2023**, 44, 275-286 ○
- 21 In situ supramolecular self-assembly for alleviating multidrug resistance in cancer. **2023**, 2, 100033 ○
- 20 Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring. **2023**, 12, 3127 ○
- 19 Apoptotic cell death in diseaseCurrent understanding of the NCCD 2023. **2023**, 30, 1097-1154 ○
- 18 Preparation and characterization of the farnesiferol C-loaded solid lipid nanoparticles decorated with folic acid-bound chitosan and evaluation of its in vitro anti-cancer and anti-angiogenic activities. **2023**, 382, 121908 ○
- 17 Gut microbiota, an emergent target to shape the efficiency of cancer therapy. 240-265 ○
- 16 Impact of microvessel patterns and immune status in NSCLC: a non-angiogenic vasculature is an independent negative prognostic factor in lung adenocarcinoma. 13, ○
- 15 Needlelike, short and thin multi-walled carbon nanotubes: comparison of effects on wild type and p53+/+at lungs. **2023**, 17, 270-288 ○
- 14 IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation. 13, ○
- 13 Stepwise activation of p63 and the MEK/ERK pathway induces the expression of ARL4C to promote oral squamous cell carcinoma cell proliferation. **2023**, 246, 154493 ○
- 12 Perivascular localized cells commit erythropoiesis in PDGF-B-expressing solid tumors. ○
- 11 Glia maturation factor- β s required for initiation and maintenance of hematopoietic stem and progenitor cells. **2023**, 14, ○
- 10 Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma. ○
- 9 USP7 - a crucial regulator of cancer hallmarks. **2023**, 1878, 188903 ○
- 8 A Novel Assessment of Metabolic Pathways in Peritoneal Metastases from Low-Grade Appendiceal Mucinous Neoplasms. ○
- 7 Prognostic significance of the immuno-peritoneal cancer index in peritoneal metastatic patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. **2023**, 408, ○
- 6 Dynamic Biophysical Cues Near the Tip Cell Microenvironment Provide Distinct Guidance Signals to Angiogenic Neovessels. ○
- 5 General aspects of cancer therapy. **2023**, 1-35 ○

- 4 Orchestration of miRNA patterns by testosterone and dietary tomato carotenoids during early prostate carcinogenesis in TRAMP mice.. **2023**,
- 3 Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor. **2023**, 91, 491-499
- 2 Danthron, an Anthraquinone Isolated from a Marine Fungus, Is a New Inhibitor of Angiogenesis Exhibiting Interesting Antitumor and Antioxidant Properties. **2023**, 12, 1101
- 1 Circadian clocks in health and disease: Dissecting the roles of the biological pacemaker in cancer. 12, 116